

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number  
WO 02/02597 A2

(51) International Patent Classification?: C07K 14/00

LTD. [GB/US]; 515 Galveston Drive, 94063 Redwood City (KY).

(21) International Application Number: PCT/DK01/00459

(72) Inventors: OKKELS, Jens, Sigurd; c/o Maxygen ApS, Agern Allé, DK-2970 Hørsholm (DK). JENSEN, Anne, Dam; c/o Maxygen ApS, Agern Allé 1, DK-2970 Hørsholm (DK). VAN DEN HAZEL, Bart; c/o Maxygen ApS, Agern Allé 1, DK-2970 Hørsholm (DK).

(22) International Filing Date: 29 June 2001 (29.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(74) Common Representative: MAXYGEN APS; Agern Allé 1, DK-2970 Hørsholm (DK).

(30) Priority Data:

PA 2000 01027 30 June 2000 (30.06.2000) DK

PA 2000 01092 14 July 2000 (14.07.2000) DK

PCT/DK00/00743

29 December 2000 (29.12.2000) DK

PCT/DK01/00090

9 February 2001 (09.02.2001) DK

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(71) Applicants: MAXYGEN APS [DK/DK]; Agern Allé 1, DK-2970 Hørsholm (DK). MAXYGEN HOLDINGS

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: PEPTIDE EXTENDED GLYCOSYLATED POLYPEPTIDES

## Pharmakokinetics - F008



(57) Abstract: Glycosylated polypeptides comprising the primary structure  $\text{NH}_2\text{-X-P}_2\text{-COOH}$  wherein X is a peptide addition comprising or contributing to a glycosylation site, and  $\text{P}_2$  is a polypeptide of interest or comprising the primary structure  $\text{NH}_2\text{-P}_1\text{-X-P}_2\text{-COOH}$ , wherein  $\text{P}_1$  is an N-terminal part of a polypeptide  $\text{P}_3$  of interest,  $\text{P}_2$  is a C-terminal part of said polypeptide  $\text{P}_3$ , and X is a peptide addition comprising or contributing to a glycosylation site. The glycosylated polypeptides having improved properties as compared to the polypeptide of interest.



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CR, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— without international search report and to be republished upon receipt of that report

## PEPTIDE EXTENDED GLYCOSYLATED POLYPEPTIDES

## FIELD OF THE INVENTION

5

The present invention relates to novel glycosylated polypeptides as well as means and methods for their preparation.

## BACKGROUND OF THE INVENTION

10

Polypeptides, including proteins, are used for a wide range of applications, including industrial uses and human or veterinary therapy.

One generally recognized drawback associated with polypeptides is that they do not have a sufficiently high stability, are immunogenic or allergenic, have a reduced serum half-life, are susceptible to clearance, are susceptible to proteolytic degradation, and the like.

One method for improving properties of polypeptides has been to attach non-peptide moieties to the polypeptide to improve properties thereof. For instance, polymer molecules such as PEG has been used for reducing immunogenicity and/or increasing serum half-life of therapeutic polypeptides and for reducing allergenicity of industrial enzymes. Glycosylation has been suggested as another convenient route for improving properties of polypeptides such as stability, half-life, etc.

Machamer and Rose, *J. Biol. Chem.*, 1988, 263, 5948-5954 and 5955-5960, disclose modified glycoprotein G of vesicular stomatitis virus that is glycosylated at additional N-glycosylation sites introduced in the polypeptide backbone.

25 US 5,218,092 discloses physiologically active polypeptides with at least one new or additional carbohydrate attached thereto. The additional carbohydrate molecule(s) is/are provided by adding one or more additional N-glycosylation sites to the polypeptide backbone, and expressing the polypeptide in a glycosylating host cell.

30 US 5,041,376 discloses a method of identifying or shielding epitopes of a transportable protein, in which method an N-glycosylation site is introduced on the exposed surface of the protein backbone (using oligonucleotide-directed mutagenesis of the nucleotide sequence encoding the protein), the resulting protein is expressed, glycosylated and assayed for protein activity and for shielded epitopes.

WO 00/26354 discloses a method of reducing the allergenicity of proteins by including an additional glycosylation site in the protein backbone and glycosylating the resulting protein variant.

Guan et al., Cell, 1985, Vol. 42, 489-496 disclose glycosylated fusion protein variants comprising a rat growth hormone backbone C-terminally extended with transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein, which growth hormone backbone has been modified to incorporate two additional N-glycosylation sites.

WO 97/04079 discloses lipolytic enzymes modified to by an N- or C-terminal peptide extension capable of conferring improved performance, in particular wash performance to the enzyme.

Matsuura et al., Nature Biotechnology, 1999, Vol. 17, 58-61 disclose the use of random elongation mutagenesis for improving thermostability of a non-glycosylated microbial catalase. The random elongation mutagenesis is conducted in the C-terminal end of the catalase.

US 5,338,835, entitled CTP extended forms of FSH, describe the use of the C-terminal portion of the CG beta subunit or a variant thereof for extension of the C-terminal of CG, FSH and LH. Said C-terminal portion may comprise O-glycosylation sites. It is speculated that a similar approach may be used for other proteins.

US 5,508,261 discloses alpha, beta-heterodimeric polypeptide having binding affinity to vertebrate luteinizing hormone (LH) receptors and vertebrate follicle stimulating hormone (FSH) receptors comprising a glycoprotein hormone alpha-subunit polypeptide and a specified non-naturally occurring beta-subunit polypeptide.

WO 95/05465 discloses EPO analogs which have one or more amino acids extending from the C-terminal end of EPO, the C-terminal extension having at least one additional carbohydrate site. The 28 amino acid C-terminal part of CG (having four O-glycosylation sites) is mentioned as an example.

WO 97/30161 discloses hybrid proteins comprising two coexpressed amino acid sequences forming a dimer, each comprising a) at least one amino acid sequence selected from a homomeric receptor, a chain of a heteromeric receptor, a ligand, and fragments thereof; and b) a subunit of a heterodimeric proteinaceous hormone or fragments thereof; in which a) and b) are bonded directly or through a peptide linker, and, in each couple, the two subunits (b) are different and capable of aggregating to form a dimer complex.

In none of the above reference it has been disclosed or indicated that a polypeptide of interest can be modified to include additional glycosylation sites by N-terminally extending

said polypeptide with a peptide sequence comprising one or more additional glycosylation sites. The present invention is based on this finding.

## 5 BRIEF DESCRIPTION OF THE INVENTION

Accordingly, in a first aspect the invention relates to a glycosylated polypeptide comprising the primary structure,

10  $\text{NH}_2\text{-X-Pp-COOH}$

wherein

X is a peptide addition comprising or contributing to a glycosylation site, and

15 Pp is a polypeptide of interest.

The introduction of additional glycosylation sites by means of a peptide addition is an elegant way of providing additional glycosylation sites in a polypeptide of interest. More specifically, the invention has the advantage that polypeptides with altered glycosylation pattern are more easily obtained, e.g. the variants can be designed without detailed knowledge  
20 or use of structural and/or functional properties of the polypeptide. Also, the utilization of glycosylation sites introduced by a peptide addition has been found to be improved relative to glycosylation sites introduced within a structural part of the polypeptide Pp. Also other properties of the peptide extended polypeptide, such as uptake in specific cells, may be improved relative to a polypeptide modified with glycosylation sites in a structural part (and  
25 not being subjected to peptide extension).

In a second aspect the invention relates to a glycosylated polypeptide comprising the primary structure  $\text{NH}_2\text{-P}_x\text{-X-P}_y\text{-COOH}$ , wherein

$\text{P}_x$  is an N-terminal part of a polypeptide Pp of interest,

30  $\text{P}_y$  is a C-terminal part of said polypeptide Pp, and

X is a peptide addition comprising or contributing to a glycosylation site.

In other aspects the invention relates to a nucleotide sequence encoding a polypeptide of the invention, an expression vector comprising said nucleotide sequence and methods of preparing a polypeptide of the invention.

In a further aspect the invention relates to a method of improving (a) selected property/ies of a polypeptide Pp of interest, which method comprises a) preparing a nucleotide sequence encoding a polypeptide comprising the primary structure



5 wherein

X is a peptide addition comprising or contributing to a glycosylation site, the peptide addition being capable of conferring the selected improved property/ies to the polypeptide Pp,

b) expressing the nucleotide sequence of a) in a suitable host cell under conditions ensuring attachment of an oligosaccharide moiety thereto, optionally

- 10 c) conjugating the expressed polypeptide of b) to a second non-peptide moiety, and  
d) recovering the polypeptide resulting from step c).

## DRAWINGS

- 15 Figure 1 is a dosis response curve for uptake of glucocerebrosidase wildtype and modified according to the invention into J774E macrophages. The activity is measured by the GCB activity assay.

Figure 2 illustrates the pharmacokinetics of a FSH polypeptide produced according to the

- 20 invention.

## DETAILED DISCLOSURE OF THE INVENTION

### 25 DEFINITIONS

In the context of the present application and invention the following definitions apply:

- The term "conjugate" is used about the covalent attachment of of one or more polypeptide(s) to one or more non-peptide moieties. The term covalent attachment means that  
30 the polypeptide and the non-peptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.

The term "non-peptide moiety" is intended to indicate a molecule, different from a peptide polymer composed of amino acid monomers and linked together by peptide bonds,

which molecule is capable of conjugating to an attachment group of the polypeptide of the invention. Preferred examples of such molecule include polymers, e.g. polyalkylene oxide moieties lipophilic groups, e.g. fatty acids and ceramides. The term "polymer molecule" is defined as a molecule formed by covalent linkage of two or more monomers and may be used interchangeably with "polymeric group". Except where the number of non-peptide moieties, such as polymeric groups, attached to the polypeptide is expressly indicated, every reference to "non-peptide moiety" referred to herein is intended as a reference to one or more non-peptide moieties attached to the polypeptide.

The term "oligosaccharide moiety" is intended to indicate a carbohydrate-containing molecule comprising one or more monosaccharide residues, capable of being attached to the polypeptide (to produce a glycosylated polypeptide) by way of *in vivo* or *in vitro* glycosylation. Except where the number of oligosaccharide moieties attached to the polypeptide is expressly indicated, every reference to "oligosaccharide moiety" referred to herein is intended as a reference to one or more such moieties attached to the polypeptide.

The term "*in vivo* glycosylation" is intended to mean any attachment of an oligosaccharide moiety occurring *in vivo*, i.e. during posttranslational processing in a glycosylating cell used for expression of the polypeptide, e.g. by way of N-linked and O-linked glycosylation. Usually, the N-glycosylated oligosaccharide moiety has a common basic core structure composed of five monosaccharide residues, namely two N-acetylglucosamine residues and three mannose residues. The exact oligosaccharide structure depends, to a large extent, on the glycosylating organism in question and on the specific polypeptide. Depending on the host cell in question the glycosylation is classified as a high mannose type, a complex type or a hybrid type. The term "*in vitro* glycosylation" is intended to refer to a synthetic glycosylation performed *in vitro*, normally involving covalently linking an oligosaccharide moiety to an attachment group of a polypeptide, optionally using a cross-linking agent. *In vivo* and *in vitro* glycosylation are discussed in detail further below.

An "N-glycosylation site" has the sequence N-X'-S/T/C-X'', wherein X' is any amino acid residue except proline, X'' any amino acid residue that may or may not be identical to X' and preferably is different from proline, N asparagine and S/T/C either serine, threonine or cysteine, preferably serine or threonine, and most preferably threonine. The oligosaccharide moiety is attached to the N-residue of such site. An "O-glycosylation site" is the OH-group of a serine or threonine residue. An "*in vitro* glycosylation site" is, e.g., selected from the group consisting of the N-terminal amino acid residue of the polypeptide, the C-terminal residue of the polypeptide, lysine, cysteine, arginine, glutamine, aspartic acid, glutamic acid, serine,

tyrosine, histidine, phenylalanine and tryptophan. Of particular interest is an *in vitro* glycosylation site that is an epsilon-amino group, in particular as part of a lysine residue.

The term "peptide addition" is intended to indicate one or more consecutive amino acid residues that are added to the amino acid sequence of the polypeptide Pp of interest. Normally, the peptide addition is linked to the amino acid sequence of the polypeptide Pp by a peptide linkage.

The term "attachment group" is intended to indicate a functional group of the polypeptide, in particular of an amino acid residue thereof or an oligosaccharide moiety attached to the polypeptide, capable of attaching a non-peptide moiety of interest. Useful attachment groups and their matching non-peptide moieties are apparent from the table below.

Attachment group	Amino acid	Examples of non-peptide moiety	Conjugation method/Activated PEG	Reference
-NH <sub>2</sub>	N-terminal, Lys	Polymer, e.g. PEG, with amide or imine group  Lipophilic substituent	mPEG-SPA Tresylated mPEG	Shearwater Inc. Delgado et al, critical reviews in Therapeutic Drug Carrier Systems 9(3,4):249-304 (1992) WO 97/31022
-COOH	C-term, Asp, Glu	Polymer, e.g. PEG, with ester or amide group	mPEG-Hz	Shearwater Inc
-SH	Cys	Polymer, e.g. PEG, with disulfide, maleimide or vinyl sulfone group	PEG-vinylsulphone PEG-maleimide	Shearwater Inc Delgado et al, critical reviews in Therapeutic Drug Carrier Systems 9(3,4):249-304 (1992)
-OH	Ser, Thr, OH-, Lys	PEG with ester, ether, carbamate, carbonate		
-CONH <sub>2</sub>		Polymer, e.g. PEG		
Aldehyde Ketone	Oxidized oligosaccharide	Polymer, e.g. PEG,	PEG-hydrazide	Andresz et al., 1978,



	de			Makromol. Chem. 179:301, WO 92/16555, WO 00/23114
--	----	--	--	---

The term "comprising an attachment group" is intended to mean that the attachment group is present on an amino acid residue of the relevant peptide or polypeptide or on an oligosaccharide moiety attached to said peptide or polypeptide.

The term "contributing to a glycosylation site" as used in connection with the peptide addition X is intended to cover the situation, where a glycosylation site is formed from more than one amino acid residue (as is the case with an N-glycosylation site), and where at least one such amino acid residue originates from the peptide X and at least one amino acid residue originates from the polypeptide Pp, whereby the glycosylation site can be considered to bridge X and Pp (or, where relevant, P<sub>x</sub> or P<sub>y</sub>).

The term "non-structural part" as used about a part of the polypeptide Pp of interest is intended to indicate a part of either the C- or N-terminal end of the folded polypeptide (e.g. protein) that is outside the first structural element, such as an  $\alpha$ -helix or a  $\beta$ -sheet structure. The non-structural part can easily be identified in a three-dimensional structure or model of the polypeptide. If no structure or model is available, a non-structural part typically comprises or consists of the first or last 1-20 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) amino acid residues, such as 1-10 amino acid residues of the amino acid sequence constituting the mature form of the polypeptide of interest.

Amino acid names and atom names (e.g. CA, CB, NZ, N, O, C, etc) are used as defined by the Protein DataBank (PDB) ([www.pdb.org](http://www.pdb.org)) which are based on the IUPAC nomenclature (IUPAC Nomenclature and Symbolism for Amino Acids and Peptides (residue names, atom names etc.), *Eur. J. Biochem.*, **138**, 9-37 (1984) together with their corrections in *Eur. J. Biochem.*, **152**, 1 (1985). The term "amino acid residue" is intended to indicate an amino acid residue contained in the group consisting of alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W), and tyrosine (Tyr or Y) residues. The terminology used for identifying amino acid

positions/mutations is illustrated as follows: A15 (indicates an alanine residue in position 15 of the polypeptide), A15T (indicates replacement of the alanine residue in position 15 with a threonine residue), A15[T/S] (indicates replacement of the alanine residue in position 15 with a threonine residue or a serine residue). Multiple substitutions are indicated with a "+", e.g. A15T+F57S means an amino acid sequence which comprises a substitution of the alanine residue in position 15 for a threonine residue and a substitution of the phenylalanine residue in position 57 for a serine residue.

The term "nucleotide sequence" is intended to indicate a consecutive stretch of two or more nucleotides. The nucleotide sequence can be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

"Cell", "host cell", "cell line" and "cell culture" are used interchangeably herein and all such terms should be understood to include progeny resulting from growth or culturing of a cell. "Transformation" and "transfection" are used interchangeably to refer to the process of introducing DNA into a cell.

"Operably linked" refers to the covalent joining of two or more nucleotide sequences in such a manner that the normal function of the sequences can be performed. For example, the nucleotide sequence encoding a presequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence.

"Introduction" or "removal" of a glycosylation site or an attachment group for a non-peptide moiety is normally achieved by introducing or removing an amino acid residue comprising or contributing to such site or group to/from the relevant amino acid sequence, conveniently by suitable modification of the encoding nucleotide sequence. For instance, when an N-glycosylation site is to be introduced/removed this can be done by introducing/removing a codon for the amino acid residue(s) required for a functional N-glycosylation site. When an attachment group for a PEG molecule is to be introduced/removed, it will be understood that this be done by introducing/removing a codon for an amino acid residue, e.g. a lysine residue, comprising such group to/from the encoding nucleotide sequence. The term "introduce" is primarily intended to include substitution of an existing amino acid residue, but can also mean insertion of additional amino acid residue. The term "remove" is primarily intended to include substitution of the amino acid residue to be removed for another amino acid residue, but can also mean deletion (without substitution) of the amino acid residue to be removed.

The term "epitope" is used in its conventional meaning to indicate one or more amino acid residue(s) displaying specific 3D and/or charge characteristics at the surface of the polypeptide, which is/are capable of giving rise to an immune response in a mammal and/or specifically binding to an antibody raised against said epitope or which is/are capable of giving rise to an allergic response.

The term "unshielded epitope" is intended to indicate that the epitope is not shielded and therefore has the above properties. The term "shielded epitope" is intended to indicate that the non-peptide moiety shields, and thus inactivates the epitope, whereby it is no longer capable of giving rise to any substantial immune response in a mammal, e.g. due to inappropriate processing and/or presentation in the antigen presenting cells, and/or of reacting with an antibody raised against the unshielded epitope. The shielding should thus be effective in both the naïve mammal and mammals that already produce antibodies reacting with the unshielded epitope.

The degree of shielding of epitopes can be determined as reduced immunogenicity and/or reduced antibody reactivity and/or reduced reactivity with monoclonal antibodies raised against the epitope(s) in question using methods known in the art. The degree of shielding of allergenic epitopes can be determined, e.g., as described in WO 00/26354.

The term "reduced" as used about an immunogenic or allergic response is intended to indicate that a given molecule gives rise to a measurably lower immune or allergic response than a reference molecule, when determined under comparable conditions. Preferably, the relevant response is reduced by at least 25%, such as at least 50%, such as preferably by at least 75%, such as by at least 90% or even at least 100%.

The term "serum half-life" is used in its normal meaning, i.e. the time in which half of the relevant molecules circulate in the plasma or bloodstream prior to being cleared. Alternatively used terms include "plasma half-life", "circulating half-life", "serum clearance", "plasma clearance" and "clearance half-life". The term "functional *in vivo* half-life" is the time in which 50% of a given function (such as biological activity) of the relevant molecule is retained, when tested *in vivo* (such as the time at which 50% of the biological activity of the molecule is still present in the body/target organ, or the time at which the activity of the polypeptide is 50% of the initial value). The molecule is normally cleared by the action of one or more of the reticuloendothelial systems (RES), kidney (e.g. by glomerular filtration), spleen or liver, or receptor-mediated elimination, or degraded by specific or unspecific proteolysis. Normally, clearance depends on size or hydrodynamic volume (relative to the cut-off for glomerular filtration), shape/rigidity, charge, attached carbohydrate chains, and the presence of

cellular receptors for the molecule. The term "increased" as used about serum half-life or functional *in vivo* half-life is used to indicate that the relevant half-life of the relevant molecule is statistically significantly increased relative to that of the reference molecule as determined under comparable conditions. For instance, the relevant half-life is increased by at least 25%,  
5 such as by at least 50%, by at least 100% or by at least 1000%.

The term "function" is intended to indicate one or more specific functions of the polypeptide of interest and is to be understood qualitatively (i.e. having a similar function as the polypeptide of interest) and not necessarily quantitatively (i.e. the magnitude of the function is not necessarily similar). Typically, a given polypeptide has many different  
10 functions, examples of which are given further below in the section entitled "Screening for or measurement of function". For therapeutically useful polypeptides an important "function" is biological activity, e.g. *in vitro* or *in vivo* bioactivity. For enzymes, an important function is biological activity such as catalytic activity.

The interchangeably used terms "measurable function" and "functional" are intended to  
15 indicate that the relevant function (preferably reflecting the intended use) of a polypeptide of the invention is above detection limit when measured by standard methods known in the art, e.g. as an *in vitro* bioactivity and/or *in vivo* bioactivity. For instance, if the polypeptide is a hormone and the function of interest is the hormone's affinity towards a specific receptor a measurable function is defined to be a detectable affinity between the hormone modified in  
20 accordance with the invention and the receptor as determined by the normal methods used for measuring such affinity. If the polypeptide is an enzyme and a function of interest is the catalytic activity a measurable function is the enzyme's ability to catalyze a reaction involving the normal substrates for the enzyme as measured by the normal methods for determining the enzyme activity in question. Typically, if not otherwise stated herein, a measurable function is  
25 at least 2%, such as at least 5% of that of the unmodified polypeptide Pp, as determined under comparable conditions, e.g. in the range of 2-1000%, such as 2-500% or 2-100%, such as 5-100% of that of the unmodified polypeptide.

The term "functional site" is intended to indicate one or more amino acid residues which is/are essential for or otherwise involved in the function or performance of the  
30 polypeptide, i.e. the amino acid residue(s) that mediate(s) a desired biological activity of the polypeptide Pp. Such amino acid residues are "located at" the functional site. For instance, the functional site can be a binding site (e.g. a receptor-binding site of a hormone or growth factor or a ligand-binding site of a receptor), a catalytic site (e.g. of an enzyme), an antigen-binding site (e.g. of an antibody), a regulatory site (e.g. of a polypeptide subject to regulation), or an

interaction site (e.g. for a regulatory protein or an inhibitor). The functional site can be determined by methods known in the art and is conveniently identified by analysing a three-dimensional or model structure of the polypeptide complexed to a relevant ligand.

The term "polypeptide" is intended to indicate any structural form (e.g. the primary, secondary or tertiary form (i.e. protein form)) of an amino acid sequence comprising more than 5 amino acid residues, which may or may not be post-translationally modified (e.g. acetylated, carboxylated, phosphorylated, lipidated, or acylated). The interchangeably used terms "native" and "wild-type" are used about a polypeptide which has an amino acid sequence that is identical to one found in nature. The native polypeptide is typically isolated from a naturally occurring source, in particular a mammalian or microbial source, such as a human source, or is produced recombinantly by use of a nucleotide sequence encoding the naturally occurring amino acid sequence. The term "native" is intended to encompass allelic variants of the polypeptide in question. A "variant" is a polypeptide, which has an amino acid sequence that differs from that of a native polypeptide in one or more amino acid residues. The variant is typically prepared by modification of a nucleotide sequence encoding the native polypeptide (e.g. to result in substitution, deletion or truncation of one or more amino acid residues of the polypeptide or by introduction (by addition or insertion) of one or more amino acid residues into the polypeptide) so as to modify the amino acid sequence constituting said native polypeptide. A "fragment" is a part of a parent native or variant polypeptide, typically differing from such parent in one or more removed C-terminal or N-terminal amino acid residues or removal of both types of such residues. Normally, the variant or fragment has retained at least one of the functions of the corresponding parent polypeptide (e.g. a biological function such as enzyme activity or receptor binding capability). Normally, the polypeptide Pp is a full length protein or a variant or fragment thereof.

The term "antibody" includes single monoclonal antibodies (including agonist and antagonist antibodies) and antibody compositions with polypeptidic specificity (also termed polyclonal antibodies).


The term "monoclonal antibody" is used in its conventional meaning to indicate a population of substantially homogeneous antibodies. The individual antibodies comprised in the population have identical binding affinities and vary structurally only to a limited extent. Monoclonal antibodies are highly specific, being directed against a single epitope. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different epitopes, each monoclonal antibody is

directed against a single epitope on the antigen. The antibody to be modified is preferably a human or humanized monoclonal antibody.

"Antibody fragment" is defined as a portion of an intact antibody comprising the antigen binding site or the entire or part of the variable region of the intact antibody, wherein the portion is free of the constant heavy chain domains (i.e. CH2, CH3, and CH4, depending on antibody isotype) of the Fc regions of the intact antibody. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')<sub>2</sub>, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (which may also be termed a single chain antibody fragment or a single chain polypeptide).

#### Polypeptide of the invention

In its first aspect the invention relates to a glycosylated polypeptide comprising the primary structure,



wherein

X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest.

In one embodiment the polypeptide consists essentially of or consists of a polypeptide with the primary structure  $\text{NH}_2\text{-X-Pp-COOH}$ .

The peptide addition according to this aspect is preferably one, which has less than 90% identity to a native full length protein. The identity is determined on the basis of an alignment of the peptide addition to the entire amino acid sequence of the full length native protein, the alignment being made to ensure the highest possible degree of identity between amino acid residues. For instance, the program CLUSTALW version 1.74 using default parameters (Thompson et al., 1994, CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Research, 22:4673-4680) can be used.

Usually, the peptide addition is fused to the N-terminal end of the polypeptide Pp as reflected in the above shown structure so as to provide an N-terminal elongation of the polypeptide Pp. However, it is also possible to insert the peptide addition within the amino acid sequence of the polypeptide Pp. This is reflected in the polypeptide according to the second

aspect of the invention, wherein the polypeptide comprises the primary structure  $\text{NH}_2\text{-P}_x\text{-X-P}_y\text{-COOH}$ , wherein

$\text{P}_x$  is an N-terminal part of a polypeptide Pp of interest,

$\text{P}_y$  is a C-terminal part of said polypeptide Pp, and

- 5 X is a peptide addition comprising or contributing to a glycosylation site.

In one embodiment the polypeptide consists essentially of or consists of a polypeptide with the primary structure  $\text{NH}_2\text{-P}_x\text{-X-P}_y\text{-COOH}$ .

- In order to minimize structural changes effected by the insertion of the peptide addition within the sequence of the polypeptide Pp, it is desirable that it be inserted in a non-structural  
10 part thereof. For instance,  $\text{P}_x$  is a non-structural N-terminal part of a mature polypeptide Pp, and  $\text{P}_y$  is a structural C-terminal part of said mature polypeptide, or  $\text{P}_x$  is a structural N-terminal part of a mature polypeptide Pp, and  $\text{P}_y$  is a non-structural C-terminal part of said mature polypeptide. Preferably, when the glycosylation site to be introduced is an N-glycosylation site,  $\text{P}_x$  is a non-structural N-terminal part since, in general, the best N-glycosylation is obtained in  
15 the N-terminal part of a polypeptide.

- When the peptide addition comprises only few amino acid residues, e.g. 1-5 such as 1-3 amino acid residues, and in particular 1 amino acid residue, the peptide addition can be inserted into a loop structure of the polypeptide Pp and thereby elongate said loop. When the peptide addition is constituted by one amino acid residue it will be understood that this is selected so as  
20 to ensure that a functional glycosylation site is introduced.

- Polypeptides of the invention are glycosylated polypeptides. Normally, the peptide addition part of the polypeptide of the invention has attached at least one oligosaccharide moiety. The polypeptide Pp part of the polypeptide may or may not have attached at least one oligosaccharide moiety. Glycosylation can be achieved as described in the section entitled  
25 "Glycosylation"

- Preferably, the polypeptide of the invention has properties such as size, charge, molecular weight and/or hydrodynamic volume that are sufficient to reduce or escape clearance by any of the clearance mechanisms disclosed herein, in particular renal clearance. Such properties are, e.g., determinable by the nature and number of oligosaccharide and second non-  
30 peptide moieties attached thereto. In one embodiment, the polypeptide of the invention has a molecular weight of at least 67 kDa, in particular at least 70 kDa as measured by SDS-PAGE according to Laemmli, U.K., Nature Vol 227 (1970), p680-85. This is of particular relevance when the polypeptide of interest is a therapeutically useful protein, the functional *in vivo* half-life of which is to be prolonged. A molecular weight of at least 67 kDa is obtainable by

introduction of a sufficient number of glycosylation sites to obtain a glycosylated polypeptide with such Mw, or by conjugating the glycosylated polypeptide to a sufficient number and type of a second non-peptide moiety to obtain such Mw. For instance, for a glycosylated polypeptide of interest having a molecular weight of at least 25 kDa linked to a peptide  
5 addition of 2 kDa, the combined extended polypeptide having at least two PEG-attachment groups, conjugation to two or more PEG molecules each having a molecular weight of 20 kDa results in a total molecular weight of at least 67 kDa.

Preferably, the polypeptide of the invention has at least one of the following properties relative to the polypeptide Pp, the properties being measured under comparable conditions:  
10 *in vitro* bioactivity which is at least 25%, such as at least 30% or at least 45% of that of the polypeptide Pp as measured under comparable conditions, increased affinity for a mannose receptor, a mannose-6-phosphate receptor or other carbohydrate receptors, increased serum half-life, increased functional *in vivo* half-life, reduced renal clearance, reduced immunogenicity, increased resistance to proteolytic cleavage, improved targeting to lysosomes,  
15 macrophages and/or other subpopulations of human cells, improved stability in production, improved shelf life, improved formulation, e.g. liquid formulation, improved purification, improved solubility, and/or improved expression.

Improved properties are determined by conventional methods known in the art for determining such properties. The improvement is of a magnitude that is within detection limits.

20

Improved affinity for or uptake by the mannose receptor is expected to result in increased uptake in phagocytic cells, preferably monocytes, macrophages (e.g. Kupffer cells, glia/mikroglia, alveolar phagocytes, reticulum cells, or other peripheral macrophages) or macrophage like cells (for instance osteoclasts, dendritic cells, or astrocytes) in increased  
25 uptake of the polypeptide in phagocytic cells (e.g. macrophages). This is of particular relevance when the polypeptide of interest is one for which such uptake is required for the polypeptide to exert its biological activity. Such polypeptide is e.g. an antigen intended for use for vaccine purposes or a lysosomal enzyme.

### 30 *Polypeptide of interest*

The present invention can be applied broadly. Thus, the polypeptide of interest can have any function and be of any origin. Accordingly, the polypeptide can be a protein, in particular a mature protein or a precursor form thereof or a functional fragment thereof that essentially has retained a biological activity of the mature protein. Furthermore, the polypeptide can be an



oligopeptide that contains in the range of 30 to 4500 amino acids, preferably in the range of 40 to 3000 amino acids.

The polypeptide can be a native polypeptide or a variant thereof. For instance, the polypeptide is a variant that comprises at least one introduced and/or at least one removed glycosylation site as compared to the corresponding native polypeptide. The variant has retained at least one function of the corresponding native polypeptide, in particular a biological activity thereof.

The polypeptide can be a therapeutic polypeptide useful in human or veterinary therapy, i.e. a polypeptide that is physiologically active when introduced into the circulatory system of or otherwise administered to a human or an animal; a diagnostic polypeptide useful in diagnosis; or an industrial polypeptide useful for industrial purposes, such as in the manufacture of goods wherein the polypeptide constitutes a functional ingredient or wherein the polypeptide is used for processing or other modification of raw ingredients during the manufacturing process.

The polypeptide can be of mammalian origin, e.g. of human, porcine, ovine, urcine, murine, rabbit, donkey, or bat origin, of microbial origin, e.g. of fungal, yeast or bacterial origin, or can be derived from other sources such as venom, leech, frog or mosquito origin. Preferably, the industrial polypeptide of interest is of microbial origin and the therapeutic polypeptide of human origin.

Specific examples of groups of polypeptides to be modified according to the invention include: an antibody or antibody fragment, an immunoglobulin or immunoglobulin fragment, a plasma protein, an erythrocyte or thrombocyte protein, a cytokine, a growth factor, a profibrinolytic protein, a binding protein, a protease inhibitor, an antigen, an enzyme, a ligand, a receptor, or a hormone. Of particular interest is a polypeptide that mediates its biological effect by binding to a cellular receptor, when administered to a patient. The antibody can be a polyclonal or monoclonal antibody, and can be of any origin including human, rabbit and murine origin. Preferably, the antibody is a human or humanized monoclonal antibody. Immunoglobulins of interest include IgG, IgE, IgM, IgA, and IgD and fragments thereof, e.g. Fab fragments. Specific antibodies and fragments thereof are those reactive with any of the proteins mentioned immediately below.

The non-antibody polypeptide of interest can be i) a plasma protein, e.g. a factor from the coagulation system, such as Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, thrombin, protein C, antithrombin III or heparin co-factor II, Tissue factor inhibitor (e.g. 1 or 2), endothelial cell surface protein C receptor, a factor from the fibrinolytic system such as pro-

- urokinase, urokinase, tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1) or plasminogen activator inhibitor 2 (PAI-2), the Von Willebrand factor, or an  $\alpha$ -1-proteinase inhibitor, ii) a erythrocyte or thrombocyte protein, e.g. hemoglobin, thrombospondin or platelet factor 4, iii) a cytokine, e.g. an interleukin such as IL-1 (e.g. IL-1 $\alpha$  or IL-1 $\beta$ ), IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, a cytokine-related polypeptide, such as IL-1Ra, an interferon such as interferon- $\alpha$ , interferon- $\beta$  or interferon- $\gamma$ , a colony-stimulating factor such as GM-CSF or G-CSF, stem cell factor (SCF), a binding protein, a member of the tumor necrosis factor family (e.g. TNF- $\alpha$ , lymphotoxin- $\alpha$ , lymphotoxin- $\beta$ , FasL, CD40L, CD30L, CD27L, OX40L, 4-1BBL, RANKL, TRAIL, TWEAK, LIGHT, TRANCE, APRIL, THANK or TALL-1), iv) a growth factor, e.g. platelet-derived growth factor (PDGF), transforming growth factor  $\alpha$  (TGF- $\alpha$ ), transforming growth factor  $\beta$  (TGF- $\beta$ ), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), somatotropin (growth hormone), a somatomedin such as insulin-like growth factor I (IGF-I) or insulin-like growth factor II (IGF-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, v) a profibrinolytic protein, e.g. staphylokinase or streptokinase, vi) a protease inhibitor, e.g. aprotinin or C1-2A, vii) an enzyme, e.g. superoxide dismutase, catalase, uricase, bilirubin oxidase, trypsin, papain, asparaginase, arginase, arginine deiminase, adenosin deaminase, ribonuclease, alkaline phosphatase,  $\beta$ -glucuronidase, purine nucleoside phosphorylase or batroxobin, viii) an opioid, e.g. endorphins, enkephalins or non-natural opioids, ix) a hormone or neuropeptide, e.g. insulin, calcitonin, glucagons, adrenocorticotrophic hormone (ACTH), somatostatin, gastrins, cholecystokinins, parathyroid hormone (PTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), gonadotropin-releasing hormone, chorionic gonadotropin, corticotropin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), prolactin, neuropeptide Y, peptide YY, pancreatic polypeptide, leptin, orexin, CART (cocaine and amphetamine regulated transcript), a CART-related peptide, melanocortins (melanocyte-stimulating hormones), melanin-concentrating hormone, natriuretic peptides, adrenomedullin, endothelin, exendin, secretin, amylin (IAPP; islet amyloid polypeptide precursor), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), agouti and agouti-related peptides or somatotropin-releasing hormones, or x) another type of protein or peptide such as thymosin, bombesin, bombesin-like peptides, heparin-binding protein, soluble CD4,

pigmentary hormones, hypothalamic releasing factor, melanotons, phospholipase activating protein, a detoxifying enzyme such as acyloxyacyl hydrolase, or an antimicrobial peptide.

One group of polypeptides of particular interest in the present invention is selected from the group of lysosomal enzymes (as defined in US 5,929,304) such as those responsible for or otherwise involved in a lysosomal storage disease, i.e. enzymes that have a therapeutical effect on patients with a lysosomal storage disease. Such enzymes, e.g. include glucocerebrosidase,  $\alpha$ -L-iduronidase, acid  $\alpha$ -glucosidase,  $\alpha$ -galactosidase, acid sphingomyelinase, galactocerebrosidase, arylsulphatase A, sialidase, and hexosaminidase. Also, other proteins involved in lysosomal storage diseases such as Saposin A, B, C or D (Nakano et al., J. Biochem. (Tokyo) 105, 152-154, 1989; Gavrieli-Rorman and Grabowski, Genomics 5, 486-492, 1989) can be modified as described herein. Preferably, these polypeptides are of human origin.

The present inventors have shown that providing such enzymes with additional N-linked oligosaccharide moieties considerably improve properties thereof, such as stability, targeting, expression, and *in vivo* activity and targeting. Accordingly, in one embodiment the polypeptide of the invention is a glycosylated lysosomal enzyme comprising a peptide addition comprising or contributing to a glycosylation site.

The industrial polypeptide is typically an enzyme, in particular a microbial enzyme, and can be used in products or in the manufacture of products such as detergents, household articles, personal care products, agrochemicals, textile, food products, in particular bakery products, feed products, or in industrial processes such as hard surface cleaning. The industrial polypeptide is normally not intended for internal administration to humans or animals. Specific examples include hydrolases, such as proteases, lipases or cutinases, oxidoreductases, such as laccase and peroxidase, transferases such as transglutaminases, isomerases, such as protein disulphide isomerase and glucose isomerase, cell wall degrading enzymes such as cellulases, xylanases, pectinases, mannanases, etc., amylolytic enzymes such as endoamylases, e.g. alpha-amylases, or exo-amylases, e.g. beta-amylases or amyloglucosidases, etc. Further specific examples are those listed in WO 00/26354, the contents of which are incorporated herein by reference. Normally, an enzyme modified according to the present invention has one or more improved properties selected from the group consisting of increased stability (in particular against proteolytic degradation or thermal degradation) leading to, e.g., improved shelf life and improved performance in use; improved production, e.g. in terms of improved expression (e.g. as a consequence of improved secretion and/or increased stability of the expressed enzyme)

and improved purification, decreased allergenicity, increased activity in the relevant industrial process in which it is used, and improved properties with respect to immobilization.

When the polypeptide Pp is an industrial enzyme the N-terminal peptide addition may comprise or contribute to a glycosylation site. However, it is also within the scope of the present invention to provide a polypeptide comprising an industrial enzyme and a C-terminal or N-terminal peptide addition comprising an attachment group for a second non-peptide moiety being a polymer, e.g. PEG. The peptide addition may or may not comprise a glycosylation site. The peptide addition is preferably as described herein. For instance, such attachment group can be provided by a lysine or cysteine residue.

10 In one embodiment the polypeptide of the invention comprises a personal care enzyme (i.e. an enzyme useful for personal care applications), which polypeptide is incapable of passing the mucous membrane of a mammal in particular a human exposed to the polypeptide. Thereby, allergenicity can be reduced or avoided. Furthermore, stability of such enzyme can be increased. The polypeptide according to this embodiment comprises an N-terminal or C-  
15 terminal peptide addition comprising or contributing to a glycosylation site and/or an attachment group for a second non-peptide moiety, e.g. a polymer such as PEG.

In another embodiment the polypeptide comprises a lipase as disclosed in WO 97/04079, in particular a *Humicola lanuginosa* lipase, wherein the N- or C-terminal peptide addition comprises a glycosylation site and/or at least one attachment group for a second non-peptide moiety, e.g. a polymer such as PEG. Thereby, the N- or C-terminal peptide addition is shielded from degradation and/or increased expression, including secretion, of the enzyme is likely to be obtained. In connection with this embodiment the N-terminal peptide addition can comprise any of the peptide additions disclosed in WO 97/04079.

In yet another embodiment the polypeptide Pp is an amyloglucosidase and the N- or C-  
25 terminal peptide addition comprises or contributes to a glycosylation site and/or an attachment group for a second non-peptide moiety, e.g. a polymer such as PEG. When the peptide addition is N-terminal the modification of such enzyme is contemplated to result in reduced or no degradation of the N-terminus of said enzyme (an otherwise well known problem associated with the recombinant production of amyloglucosidase). In other words the N-terminus of the  
30 enzyme is protected by the non-peptide moiety attached to the N-terminal peptide addition of the amyloglucosidase.

In yet another embodiment the polypeptide Pp is an antigen, in particular an antigen intended for use in eliciting an immune response (for vaccine purposes). It is contemplated to be advantageous to add N-terminal glycosylation site(s) to antigens in accordance with the

invention in that the risk of changing antigenicity is thereby reduced. Antigens are recognized by a wide range of target cells, including antigen presenting cells (APC), and taken up by those cells for efficient intracellular processing and presentation to other cells of the immune system, such as, e.g., T cells, to induce or elicit desired immune responses. Antigens (and fragments thereof, e.g., antigen peptides) can be modified by a peptide addition and non-peptide moieties according to the invention. Such modifications facilitate and/or optimize uptake and/or targeting to processing compartment of the antigen by such target cells. For example, N-terminally extended antigen polypeptides of the invention are taken up by the target cells more efficiently and/or at an enhanced or improved rate (when the non-peptide moiety is one involved in such uptake). Such efficient, improved, or enhanced uptake of modified antigens by the target cells increases the kinetics and potency of the immune response to the immunizing antigen. These modifications to antigens also improve the affinity of the antigens for particular cellular receptors on target cells, including, e.g., mannose receptors and other carbohydrate receptors (in particular when the non-peptide moiety is an oligosaccharide moiety).

Antigen polypeptides of the invention include, but are not limited to those, for which an improved, enhanced or altered uptake of antigens in the following type of target cells is desired: antigen-presenting and antigen-processing cells, such as monocytes, B cells, antigen-presenting macrophages, marginal zone macrophages, follicular dendritic cells, dendritic cells, Langerhans cells, keratinocytes, M-cells (e.g., M-cells of the gut), myocytes for intramuscular immunization or epithelial cells for mucosal immunization, Kupffer cells in the liver, and the like. A number of other cells, including capillary endothelium and some endocrine cells, can present antigen in some circumstances; the cells develop MHC class II molecules that confer antigen-presenting function. Furthermore, MHC class I molecules are expressed on the surface of most nucleated cells, including, for example, muscle cells, and therefore these cells can also present antigens to CD8+ T cells. Activated T cells, which release IFN-gamma actively induce expression of MHC molecules on some tissue cells. Such cells are also of use with the novel polypeptides of the invention. Preferably, such cells are of mammalian origin, in particular human (for use in immunization of a human) or animal (for veterinary purposes).

A wide range of antigens can be modified according to the invention. Examples are as follows:

#### *Cancer antigens*

Examples of cancer antigens that can be modified according to the invention include, but are not limited to: bullous pemphigoid antigen 2, prostate mucin antigen (PMA) (Beckett

- and Wright (1995) *Int. J. Cancer* 62: 703-710), tumor associated Thomsen-Friedenreich antigen (Dahlenborg *et al.* (1997) *Int. J. Cancer* 70: 63-71), prostate-specific antigen (PSA) (Dannull and Belldgrun (1997) *Br. J. Urol.* 1: 97-103), EpCam/KSA antigen, luminal epithelial antigen (LEA.135) of breast carcinoma and bladder transitional cell carcinoma (TCC) (Jones *et al.* (1997) *Anticancer Res.* 17: 685-687), cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) (Kierkegaard *et al.* (1995) *Gynecol. Oncol.* 59: 251-254), the epithelial glycoprotein 40 (EGP40) (Kievit *et al.* (1997) *Int. J. Cancer* 71: 237-245), squamous cell carcinoma antigen (SCC) (Lozza *et al.* (1997) *Anticancer Res.* 17: 525-529), cathepsin E (Mota *et al.* (1997) *Am. J. Pathol.* 150: 1223-1229), tyrosinase in melanoma (Fishman *et al.* (1997) *Cancer* 79: 1461-1464), cell nuclear antigen (PCNA) of cerebral cavernomas (Notelet *et al.* (1997) *Surg. Neurol.* 47: 364-370), DF3/MUC1 breast cancer antigen (Apostolopoulos *et al.* (1996) *Immunol. Cell. Biol.* 74: 457-464; Pandey *et al.* (1995) *Cancer Res.* 55: 4000-4003), carcinoembryonic antigen (Paone *et al.* (1996) *J. Cancer Res. Clin. Oncol.* 122: 499-503; Schlom *et al.* (1996) *Breast Cancer Res. Treat.* 38: 27-39), tumor-associated antigen CA 19-9 (Tolliver and O'Brien (1997) *South Med. J.* 90: 89-90; Tsuruta *et al.* (1997) *Urol. Int.* 58: 20-24), human melanoma antigens MART-1/Melan-A27-35 and gp100 (Kawakami and Rosenberg (1997) *Int. Rev. Immunol.* 14: 173-192; Zajac *et al.* (1997) *Int. J. Cancer* 71: 491-496), the T and Tn pancarcinoma (CA) glycopeptide epitopes (Springer (1995) *Crit. Rev. Oncog.* 6: 57-85), a 35 kD tumor-associated autoantigen in papillary thyroid carcinoma (Lucas *et al.* (1996) *Anticancer Res.* 16: 2493-2496), KH-1 adenocarcinoma antigen (Deshpande and Danishefsky (1997) *Nature* 387: 164-166), the A60 mycobacterial antigen (Maes *et al.* (1996) *J. Cancer Res. Clin. Oncol.* 122: 296-300), heat shock proteins (HSPs) (Blachere and Srivastava (1995) *Semin. Cancer Biol.* 6: 349-355), and MAGE, tyrosinase, melan-A and gp75 and mutant oncogene products (*e.g.*, p53, ras, and HER-2/neu (Bueler and Mulligan (1996) *Mol. Med.* 2: 545-555; Lewis and Houghton (1995) *Semin. Cancer Biol.* 6: 321-327; Theobald *et al.* (1995) *Proc. Nat'l. Acad. Sci. USA* 92: 11993-11997); TAG-72, a mucin ag expressed in most human adenocarcinomas (McGuinness *et al.* (1999) *Hum Gene Ther* 10:165-73).

### 30 Bacterial antigens

Bacterial antigens that can be modified according to the invention include, but are not limited to, *Helicobacter pylori* antigens CagA and VacA (Blaser (1996) *Aliment. Pharmacol. Ther.* 1: 73-7; Blaser and Crabtree (1996) *Am. J. Clin. Pathol.* 106: 565-7; Censini *et al.* (1996) *Proc. Nat'l. Acad. Sci. USA* 93: 14648-14643). Other suitable *H. pylori* antigens include, for

- example, four immunoreactive proteins of 45-65 kDa as reported by Chatha *et al.* (1997) *Indian J. Med. Res.* 105: 170-175 and the *H. pylori* GroES homologue (HspA) (Kansau *et al.* (1996) *Mol. Microbiol.* 22: 1013-1023. Other suitable bacterial antigens include, but are not limited to, the 43-kDa and the fimbriin (41 kDa) proteins of *P. gingivalis* (Boutsl *et al.* (1996) *Oral Microbiol. Immunol.* 11: 236-241); pneumococcal surface protein A (Briles *et al.* (1996) *Ann. NY Acad. Sci.* 797: 118-126); *Chlamydia psittaci* antigens, 80-90 kDa protein and 110 kDa protein (Buendia *et al.* (1997) *FEMS Microbiol. Lett.* 150: 113-9); the chlamydial exoglycolipid antigen (GLXA) (Whittum-Hudson *et al.* (1996) *Nature Med.* 2: 1116-1121); *Chlamydia pneumoniae* species-specific antigens in the molecular weight ranges 92-98, 51-55, 43-46 and 31.5-33 kDa and genus-specific antigens in the ranges 12, 26 and 65-70 kDa (Halme *et al.* (1997) *Scand. J. Immunol.* 45: 378-84); *Neisseria gonorrhoeae* (GC) or *Escherichia coli* phase-variable opacity (Opa) proteins (Chen and Gotschlich (1996) *Proc. Nat'l. Acad. Sci. USA* 93: 14851-14856), any of the twelve immunodominant proteins of *Schistosoma mansoni* (ranging in molecular weight from 14 to 208 kDa) as described by Cutts and Wilson (1997) *Parasitology* 114: 245-55; the 17-kDa protein antigen of *Brucella abortus* (De Mot *et al.* (1996) *Curr. Microbiol.* 33: 26-30); a gene homolog of the 17-kDa protein antigen of the Gram-negative pathogen *Brucella abortus* identified in the nocardioform actinomycete *Rhodococcus* sp. NI86/21 (De Mot *et al.* (1996) *Curr. Microbiol.* 33: 26-30); the staphylococcal enterotoxins (SEs) (Wood *et al.* (1997) *FEMS Immunol. Med. Microbiol.* 17: 1-10), a 42-kDa *M. hyopneumoniae* NrdF ribonucleotide reductase R2 protein or 15-kDa subunit protein of *M. hyopneumoniae* (Fagan *et al.* (1997) *Infect. Immun.* 65: 2502-2507), the meningococcal antigen PorA protein (Feavers *et al.* (1997) *Clin. Diagn. Lab. Immunol.* 3: 444-50); pneumococcal surface protein A (PspA) (McDaniel *et al.* (1997) *Gene Ther.* 4: 375-377); *F. tularensis* outer membrane protein FopA (Fulop *et al.* (1996) *FEMS Immunol. Med. Microbiol.* 13: 245-247); the major outer membrane protein within strains of the genus *Actinobacillus* (Hartmann *et al.* (1996) *Zentralbl. Bakteriol.* 284: 255-262); p60 or listeriolysin (Hly) antigen of *Listeria monocytogenes* (Hess *et al.* (1996) *Proc. Nat'l. Acad. Sci. USA* 93: 1458-1463); flagellar (G) antigens observed on *Salmonella enteritidis* and *S. pullorum* (Holt and Chaubal (1997) *J. Clin. Microbiol.* 35: 1016-1020); *Bacillus anthracis* protective antigen (PA) (Ivins *et al.* (1995) *Vaccine* 13: 1779-1784); *Echinococcus granulosus* antigen 5 (Jones *et al.* (1996) *Parasitology* 113: 213-222); the *rol* genes of *Shigella dysenteriae* 1 and *Escherichia coli* K-12 (Klee *et al.* (1997) *J. Bacteriol.* 179: 2421-2425); cell surface proteins Rib and alpha of group B streptococcus (Larsson *et al.* (1996) *Infect. Immun.* 64: 3518-3523); the 37 kDa secreted polypeptide encoded on the 70 kb virulence plasmid of pathogenic *Yersinia* spp.

- (Leary *et al.* (1995) *Contrib. Microbiol. Immunol.* 13: 216-217 and Roggenkamp *et al.* (1997) *Infect. Immun.* 65: 446-51); the OspA (outer surface protein A) of the Lyme disease spirochete *Borrelia burgdorferi* (Li *et al.* (1997) *Proc. Nat'l. Acad. Sci. USA* 94: 3584-3589, Padilla *et al.* (1996) *J. Infect. Dis.* 174: 739-746, and Wallich *et al.* (1996) *Infection* 24: 396-397); the
- 5 *Brucella melitensis* group 3 antigen gene encoding Omp28 (Lindler *et al.* (1996) *Infect. Immun.* 64: 2490-2499); the Pac antigen of *Streptococcus mutans* (Murakami *et al.* (1997) *Infect. Immun.* 65: 794-797); pneumolysin, Pneumococcal neuraminidases, autolysin, hyaluronidase, and the 37 kDa pneumococcal surface adhesin A (Paton *et al.* (1997) *Microb. Drug Resist.* 3: 1-10); 29-32, 41-45, 63-71 x 10(3) MW antigens of *Salmonella typhi* (Perez *et al.* (1996) *Immunology* 89: 262-267); K-antigen as a marker of *Klebsiella pneumoniae*
- 10 (Priamukhina and Morozova (1996) *Klin. Lab. Diagn.* 47-9); nocardial antigens of molecular mass approximately 60, 40, 20 and 15-10 kDa (Prokesova *et al.* (1996) *Int. J. Immunopharmacol.* 18: 661-668); *Staphylococcus aureus* antigen ORF-2 (Rieneck *et al.* (1997) *Biochim Biophys Acta* 1350: 128-132); GlpQ antigen of *Borrelia hermsii* (Schwan *et al.* (1996) *J. Clin. Microbiol.* 34: 2483-2492); cholera protective antigen (CPA) (Sciortino (1996)
- 15 *J. Diarrhoeal Dis. Res.* 14: 16-26); a 190-kDa protein antigen of *Streptococcus mutans* (Sempuku *et al.* (1996) *Oral Microbiol. Immunol.* 11: 121-128); Anthrax toxin protective antigen (PA) (Sharma *et al.* (1996) *Protein Expr. Purif.* 7: 33-38); *Clostridium perfringens* antigens and toxoid (Strom *et al.* (1995) *Br. J. Rheumatol.* 34: 1095-1096); the SEF14 fimbrial
- 20 antigen of *Salmonella enteritidis* (Thorns *et al.* (1996) *Microb. Pathog.* 20: 235-246); the *Yersinia pestis* capsular antigen (F1 antigen) (Titball *et al.* (1997) *Infect. Immun.* 65: 1926-1930); a 35-kilodalton protein of *Mycobacterium leprae* (Triccas *et al.* (1996) *Infect. Immun.* 64: 5171-5177); the major outer membrane protein, CD, extracted from *Moraxella* (Branhamella) catarrhalis (Yang *et al.* (1997) *FEMS Immunol. Med. Microbiol.* 17: 187-199);
- 25 pH6 antigen (PsaA protein) of *Yersinia pestis* (Zav'yalov *et al.* (1996) *FEMS Immunol. Med. Microbiol.* 14: 53-57); a major surface glycoprotein, gp63, of *Leishmania major* (Xu and Liew (1994) *Vaccine* 12: 1534-1536; Xu and Liew (1995) *Immunology* 84: 173-176); mycobacterial heat shock protein 65, mycobacterial antigen (*Mycobacterium leprae* hsp65) (Lowrie *et al.* (1994) *Vaccine* 12: 1537-1540; Ragno *et al.* (1997) *Arthritis Rheum.* 40: 277-283; Silva (1995)
- 30 *Braz. J. Med. Biol. Res.* 28: 843-851); *Mycobacterium tuberculosis* antigen 85 (Ag85) (Huygen *et al.* (1996) *Nat. Med.* 2: 893-898); the 45/47 kDa antigen complex (APA) of *Mycobacterium tuberculosis*, *M. bovis* and BCG (Horn *et al.* (1996) *J. Immunol. Methods* 197: 151-159); the mycobacterial antigen, 65-kDa heat shock protein, hsp65 (Tascon *et al.* (1996) *Nat. Med.* 2: 888-892); the mycobacterial antigens MPB64, MPB70, MPB57 and alpha antigen (Yamada *et*



- al.* (1995) *Kekkaku* 70: 639-644); the *M. tuberculosis* 38 kDa protein (Vordermeier *et al.* (1995) *Vaccine* 13: 1576-1582); the MPT63, MPT64 and MPT-59 antigens from *Mycobacterium tuberculosis* (Manca *et al.* (1997) *Infect. Immun.* 65: 16-23; Oettinger *et al.* (1997) *Scand. J. Immunol.* 45: 499-503; Wilcke *et al.* (1996) *Tuber. Lung Dis.* 77: 250-256);
- 5 the 35-kilodalton protein of *Mycobacterium leprae* (Triccas *et al.* (1996) *Infect. Immun.* 64: 5171-5177); the ESAT-6 antigen of virulent mycobacteria (Brandt *et al.* (1996) *J. Immunol.* 157: 3527-3533; Pollock and Andersen (1997) *J. Infect. Dis.* 175: 1251-1254); *Mycobacterium tuberculosis* 16-kDa antigen (Hsp16.3) (Chang *et al.* (1996) *J. Biol. Chem.* 271: 7218-7223); and the 18-kilodalton protein of *Mycobacterium leprae* (Baumgart *et al.* (1996) *Infect. Immun.* 64: 2274-2281); protective antigen (PA) of *B. anthracis*; V antigen from *Yersinia pestis*, *Y. enterocolitica*, and *Y. pseudotuberculosis*; antigens against bacterium *Vibrio cholerae*, cholera toxin B subunit, and heat-labile enterotoxins (LT) from enterotoxigenic *E. coli* strains.

### *Viral pathogens*

- 15 Polypeptides or proteins corresponding to or associated with various viral pathogens, including, but not limited to, e.g., hanta virus (e.g., hanta virus glycoproteins), flaviviruses, such as, e.g., Dengue viruses (e.g., envelope proteins), Japanese, St. Louis and Murray Valley encephalitis viruses, tick-borne encephalitis viruses can be modified according to the invention.
- Viral antigens that can be modified according to the invention include, but are not
- 20 limited to, influenza A virus N2 neuraminidase (Kilbourne *et al.* (1995) *Vaccine* 13: 1799-1803); Dengue virus envelope (E) and premembrane (prM) antigens (Feighny *et al.* (1994) *Am. J. Trop. Med. Hyg.* 50: 322-328; Putnak *et al.* (1996) *Am. J. Trop. Med. Hyg.* 55: 504-10); HIV antigens Gag, Pol, Vif and Nef (Vogt *et al.* (1995) *Vaccine* 13: 202-208); HIV antigens gp120 and gp160 (Achour *et al.* (1995) *Cell. Mol. Biol.* 41: 395-400; Hone *et al.* (1994) *Dev. Biol.* 25 *Stand.* 82: 159-162); gp41 epitope of human immunodeficiency virus (Eckhart *et al.* (1996) *J. Gen. Virol.* 77: 2001-2008); rotavirus antigen VP4 (Mattion *et al.* (1995) *J. Virol.* 69: 5132-5137); the rotavirus protein VP7 or VP7sc (Bmslie *et al.* (1995) *J. Virol.* 69: 1747-1754; Xu *et al.* (1995) *J. Gen. Virol.* 76: 1971-1980); herpes simplex virus (HSV) glycoproteins gB, gC, gD, gE, gG, gH, and gI (Fleck *et al.* (1994) *Med. Microbiol. Immunol. (Berl)* 183: 87-94
- 30 [Mattion, 1995]; Ghiasi *et al.* (1995) *Invest. Ophthalmol. Vis. Sci.* 36: 1352-1360; McLean *et al.* (1994) *J. Infect. Dis.* 170: 1100-1109); immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) (Banks *et al.* (1994) *Virology* 200: 236-245); immediate-early (IE) proteins ICP27, ICP0, and ICP4 of herpes simplex virus (Manickan *et al.* (1995) *J. Virol.* 69: 4711-4716); influenza virus nucleoprotein and hemagglutinin (Deck *et al.* (1997) *Vaccine* 15:

- 71-78; Fu *et al.* (1997) *J. Virol.* 71: 2715-2721); B19 parvovirus capsid proteins VP1 (Kawase *et al.* (1995) *Virology* 211: 359-366) or VP2 (Brown *et al.* (1994) *Virology* 198: 477-488); Hepatitis B virus core and e antigen and capsid protein (Schodel *et al.* (1996) *Intervirology* 39: 104-106); hepatitis B surface antigen (Shiau and Murray (1997) *J. Med. Virol.* 51: 159-166);
- 5 hepatitis B surface antigen fused to the core antigen of the virus (Id.); Hepatitis B virus core-preS2 particles (Nemeckova *et al.* (1996) *Acta Virol.* 40: 273-279); HBV preS2-S protein (Kutinova *et al.* (1996) *Vaccine* 14: 1045-1052); VZV glycoprotein I (Kutinova *et al.* (1996) *Vaccine* 14: 1045-1052); rabies virus glycoproteins (Xiang *et al.* (1994) *Virology* 199: 132-140; Xuan *et al.* (1995) *Virus Res.* 36: 151-161) or ribonucleocapsid (Hooper *et al.* (1994)
- 10 *Proc. Nat'l. Acad. Sci. USA* 91: 10908-10912); human cytomegalovirus (HCMV) glycoprotein B (UL55) (Britt *et al.* (1995) *J. Infect. Dis.* 171: 18-25); the hepatitis C virus (HCV) nucleocapsid protein in a secreted or a nonsecreted form, or as a fusion protein with the middle (pre-S2 and S) or major (S) surface antigens of hepatitis B virus (HBV) (Inchauspe *et al.* (1997) *DNA Cell Biol.* 16: 185-195; Major *et al.* (1995) *J. Virol.* 69: 5798-5805); the hepatitis
- 15 C virus antigens: the core protein (pC); E1 (pE1) and E2 (pE2) alone or as fusion proteins (Saito *et al.* (1997) *Gastroenterology* 112: 1321-1330); the gene encoding respiratory syncytial virus fusion protein (FPF-2) (Falsey and Walsh (1996) *Vaccine* 14: 1214-1218; Piedra *et al.* (1996) *Pediatr. Infect. Dis. J.* 15: 23-31); the VP6 and VP7 genes of rotaviruses (Choi *et al.* (1997) *Virology* 232: 129-138; Jin *et al.* (1996) *Arch. Virol.* 141: 2057-2076); the E1, E2, E3,
- 20 E4, E5, E6 and E7 proteins of human papillomavirus (Brown *et al.* (1994) *Virology* 201: 46-54; Dillner *et al.* (1995) *Cancer Detect. Prev.* 19: 381-393; Krul *et al.* (1996) *Cancer Immunol. Immunother.* 43: 44-48; Nakagawa *et al.* (1997) *J. Infect. Dis.* 175: 927-931); a human T-lymphotropic virus type I gag protein (Porter *et al.* (1995) *J. Med. Virol.* 45: 469-474); Epstein-Barr virus (EBV) gp340 (Mackett *et al.* (1996) *J. Med. Virol.* 50: 263-271); the Epstein-Barr
- 25 virus (EBV) latent membrane protein LMP2 (Lee *et al.* (1996) *Eur. J. Immunol.* 26: 1875-1883); Epstein-Barr virus nuclear antigens 1 and 2 (Chen and Cooper (1996) *J. Virol.* 70: 4849-4853; Khanna *et al.* (1995) *Virology* 214: 633-637); the measles virus nucleoprotein (N) (Fooks *et al.* (1995) *Virology* 210: 456-465); and cytomegalovirus glycoprotein gB (Marshall *et al.* (1994) *J. Med. Virol.* 43: 77-83) or glycoprotein gH (Rasmussen *et al.* (1994) *J. Infect.*
- 30 *Dis.* 170: 673-677).

### Parasites

Antigens from parasites can also be modified according to the invention. These include, but are not limited to, the schistosome gut-associated antigens CAA (circulating

anodic antigen) and CCA (circulating cathodic antigen) in *Schistosoma mansoni*, *S. haematobium* or *S. japonicum* (Deelder *et al.* (1996) *Parasitology* 112: 21-35); a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite *Schistosoma mansoni* (Ferru *et al.* (1997) *Parasite Immunol.* 19: 1-11); *Leishmania* parasite surface molecules (Lezama-Davila (1997) *Arch. Med. Res.* 28: 47-53); third-stage larval (L3) antigens of *L. loa* (Akue *et al.* (1997) *J. Infect. Dis.* 175: 158-63); the genes, Tams1-1 and Tams1-2, encoding the 30- and 32-kDa major merozoite surface antigens of *Theileria annulata* (Ta) (d'Oliveira *et al.* (1996) *Gene* 172: 33-39); *Plasmodium falciparum* merozoite surface antigen 1 or 2 (al-Yaman *et al.* (1995) *Trans. R. Soc. Trop. Med. Hyg.* 89: 555-559; Beck *et al.* (1997) *J. Infect. Dis.* 175: 921-926; Rzepczyk *et al.* (1997) *Infect. Immun.* 65: 1098-1100); circumsporozoite (CS) protein-based B-epitopes from *Plasmodium berghei*, (PPPNPND)<sub>2</sub> and *Plasmodium yoelii*, (QGPGAP)<sub>3</sub>QG, along with a *P. berghei* T-helper epitope KQIRDSITEEWS (Reed *et al.* (1997) *Vaccine* 15: 482-488); NYVAC-Pf7 encoded *Plasmodium falciparum* antigens derived from the sporozoite (circumsporozoite protein and sporozoite surface protein 2), liver (liver stage antigen 1), blood (merozoite surface protein 1, serine repeat antigen, and apical membrane antigen 1), and sexual (25-kDa sexual-stage antigen) stages of the parasite life cycle were inserted into a single NYVAC genome to generate NYVAC-Pf7 (Tine *et al.* (1996) *Infect. Immun.* 64: 3833-3844); *Plasmodium falciparum* antigen Pfs230 (Williamson *et al.* (1996) *Mol. Biochem. Parasitol.* 78: 161-169); *Plasmodium falciparum* apical membrane antigen (AMA-1) (Lal *et al.* (1996) *Infect. Immun.* 64: 1054-1059); *Plasmodium falciparum* proteins Pfs28 and Pfs25 (Duffy and Kaslow (1997) *Infect. Immun.* 65: 1109-1113); *Plasmodium falciparum* merozoite surface protein, MSP1 (Hui *et al.* (1996) *Infect. Immun.* 64: 1502-1509); the malaria antigen Pf332 (Ahlborg *et al.* (1996) *Immunology* 88: 630-635); *Plasmodium falciparum* erythrocyte membrane protein 1 (Baruch *et al.* (1995) *Proc. Nat'l. Acad. Sci. USA* 93: 3497-3502; Baruch *et al.* (1995) *Cell* 82: 77-87); *Plasmodium falciparum* merozoite surface antigen, PfMSP-1 (Egan *et al.* (1996) *J. Infect. Dis.* 173: 765-769); *Plasmodium falciparum* antigens SERA, EBA-175, RAP1 and RAP2 (Riley (1997) *J. Pharm. Pharmacol.* 49: 21-27); *Schistosoma japonicum* paramyosin (Sj97) or fragments thereof (Yang *et al.* (1995) *Biochem. Biophys. Res. Commun.* 212: 1029-1039); and Hsp70 in parasites (Maresca and Kobayashi (1994) *Experientia* 50: 1067-1074).

#### Allergen antigens

Allergen antigens that can be modified according to the invention, include, but are not limited to those of animals, including the mite (*e.g.*, *Dermatophagoides pteronyssinus*,

- Dermatophagoides farinae*, *Blomia tropicalis*), such as the allergens der p1 (Scobie *et al.* (1994) *Biochem. Soc. Trans.* 22: 448S; Yssel *et al.* (1992) *J. Immunol.* 148: 738-745), der p2 (Chua *et al.* (1996) *Clin. Exp. Allergy* 26: 829-837), der p3 (Smith and Thomas (1996) *Clin. Exp. Allergy* 26: 571-579), der p5, der p V (Lin *et al.* (1994) *J. Allergy Clin. Immunol.* 94: 989-996), der p6 (Bennett and Thomas (1996) *Clin. Exp. Allergy* 26: 1150-1154), der p 7 (Shen *et al.* (1995) *Clin. Exp. Allergy* 25: 416-422), der f2 (Yuuki *et al.* (1997) *Int. Arch. Allergy Immunol.* 112: 44-48), der f3 (Nishiyama *et al.* (1995) *FEBS Lett.* 377: 62-66), der f7 (Shen *et al.* (1995) *Clin. Exp. Allergy* 25: 1000-1006); Mag 3 (Fujikawa *et al.* (1996) *Mol. Immunol.* 33: 311-319). Also of interest as antigens are the house dust mite allergens Tyr p2 (Eriksson *et al.* (1998) *Eur. J. Biochem.* 251: 443-447), Lep d1 (Schmidt *et al.* (1995) *FEBS Lett.* 370: 11-14), and glutathione S-transferase (O'Neill *et al.* (1995) *Immunol Lett.* 48: 103-107); the 25,589 Da, 219 amino acid polypeptide with homology with glutathione S-transferases (O'Neill *et al.* (1994) *Biochim. Biophys. Acta.* 1219: 521-528); Blo t 5 (Arruda *et al.* (1995) *Int. Arch. Allergy Immunol.* 107: 456-457); bee venom phospholipase A2 (Carballido *et al.* (1994) *J. Allergy Clin. Immunol.* 93: 758-767; Jutel *et al.* (1995) *J. Immunol.* 154: 4187-4194); bovine dermal/dander antigens BDA 11 (Rautiainen *et al.* (1995) *J. Invest. Dermatol.* 105: 660-663) and BDA20 (Mantylarvi *et al.* (1996) *J. Allergy Clin. Immunol.* 97: 1297-1303); the major horse allergen Equ c1 (Gregoire *et al.* (1996) *J. Biol. Chem.* 271: 32951-32959); Jumper ant *M. pilosula* allergen Myr p I and its homologous allergenic polypeptides Myr p2 (Donovan *et al.* (1996) *Biochem. Mol. Biol. Int.* 39: 877-885); 1-13, 14, 16 kD allergens of the mite *Blomia tropicalis* (Caraballo *et al.* (1996) *J. Allergy Clin. Immunol.* 98: 573-579); the cockroach allergens Bla g Bd90K (Helm *et al.* (1996) *J. Allergy Clin. Immunol.* 98: 172-80) and Bla g 2 (Arruda *et al.* (1995) *J. Biol. Chem.* 270: 19563-19568); the cockroach Cr-Pf allergens (Wu *et al.* (1996) *J. Biol. Chem.* 271: 17937-17943); fire ant venom allergen, Sol i 2 (Schmidt *et al.* (1996) *J. Allergy Clin. Immunol.* 98: 82-88); the insect *Chironomus thummi* major allergen Chi t 1-9 (Kipp *et al.* (1996) *Int. Arch. Allergy Immunol.* 110: 348-353); dog allergen Can f 1 or cat allergen Fel d 1 (Ingram *et al.* (1995) *J. Allergy Clin. Immunol.* 96: 449-456); albumin, derived, for example, from horse, dog or cat (Goubran Botros *et al.* (1996) *Immunology* 88: 340-347); deer allergens with the molecular mass of 22 kD, 25 kD or 60 kD (Spitzauer *et al.* (1997) *Clin. Exp. Allergy* 27: 196-200); and the 20 kd major allergen of cow (Ylonen *et al.* (1994) *J. Allergy Clin. Immunol.* 93: 851-858).

Pollen and grass allergens can also be modified according to the invention. Such allergens include, for example, Hor v9 (Astwood and Hill (1996) *Gene* 182: 53-62, Lig v1 (Batanero *et al.* (1996) *Clin. Exp. Allergy* 26: 1401-1410); Lol p 1 (Muller *et al.* (1996) *Int.*

- Arch. Allergy Immunol.* 109: 352-355), Lol p II (Tamborini *et al.* (1995) *Mol. Immunol.* 32: 505-513), Lol p VA, Lol p VB (Ong *et al.* (1995) *Mol. Immunol.* 32: 295-302), Lol p 9 (Blaher *et al.* (1996) *J. Allergy Clin. Immunol.* 98: 124-132); Par J I (Costa *et al.* (1994) *FEBS Lett.* 341: 182-186; Sallusto *et al.* (1996) *J. Allergy Clin. Immunol.* 97: 627-637), Par j 2.0101
- 5 (Duro *et al.* (1996) *FEBS Lett.* 399: 295-298); Bet v1 (Faber *et al.* (1996) *J. Biol. Chem.* 271: 19243-19250), Bet v2 (Rihs *et al.* (1994) *Int. Arch. Allergy Immunol.* 105: 190-194); Dac g3 (Guerin-Marchand *et al.* (1996) *Mol. Immunol.* 33: 797-806); Phl p 1 (Petersen *et al.* (1995) *J. Allergy Clin. Immunol.* 95: 987-994), Phl p 5 (Muller *et al.* (1996) *Int. Arch. Allergy Immunol.* 109: 352-355), Phl p 6 (Petersen *et al.* (1995) *Int. Arch. Allergy Immunol.* 108: 55-59); Cry j I
- 10 (Sone *et al.* (1994) *Biochem. Biophys. Res. Commun.* 199: 619-625), Cry j II (Namba *et al.* (1994) *FEBS Lett.* 353: 124-128); Cor a 1 (Schenk *et al.* (1994) *Eur. J. Biochem.* 224: 717-722); cyn d1 (Smith *et al.* (1996) *J. Allergy Clin. Immunol.* 98: 331-343), cyn d7 (Suphioglu *et al.* (1997) *FEBS Lett.* 402: 167-172); Pha a 1 and isoforms of Pha a 5 (Suphioglu and Singh (1995) *Clin. Exp. Allergy* 25: 853-865); Cha o 1 (Suzuki *et al.* (1996) *Mol. Immunol.* 33: 451-
- 15 460); profilin derived, e.g., from timothy grass or birch pollen (Valenta *et al.* (1994) *Biochem. Biophys. Res. Commun.* 199: 106-118); P0149 (Wu *et al.* (1996) *Plant Mol. Biol.* 32: 1037-1042); Ory s1 (Xu *et al.* (1995) *Gene* 164: 255-259); and Amb a V and Amb t 5 (Kim *et al.* (1996) *Mol. Immunol.* 33: 873-880; Zhu *et al.* (1995) *J. Immunol.* 155: 5064-5073).

- Food allergens that can be modified according to the invention include, for example,
- 20 profilin (Rihs *et al.* (1994) *Int. Arch. Allergy Immunol.* 105: 190-194); rice allergenic cDNAs belonging to the alpha-amylase/trypsin inhibitor gene family (Alvarez *et al.* (1995) *Biochim Biophys Acta* 1251: 201-204); the main olive allergen, Ole e I (Lombardero *et al.* (1994) *Clin Exp Allergy* 24: 765-770); Sin a 1, the major allergen from mustard (Gonzalez De La Peña *et al.* (1996) *Eur J Biochem.* 237: 827-832); parvalbumin, the major allergen of salmon
- 25 (Lindstrom *et al.* (1996) *Scand. J. Immunol.* 44: 335-344); apple allergens, such as the major allergen Mal d 1 (Vanek-Krebitz *et al.* (1995) *Biochem. Biophys. Res. Commun.* 214: 538-551); and peanut allergens, such as Ara h I (Burks *et al.* (1995) *J. Clin. Invest.* 96: 1715-1721).

- Fungal allergens that can be modified according to the invention include, but are not limited to, the allergen, Cla h III, of *Cladosporium herbarum* (Zhang *et al.* (1995) *J. Immunol.*
- 30 154: 710-717); the allergen Psi c 2, a fungal cyclophilin, from the basidiomycete *Psilocybe cubensis* (Horner *et al.* (1995) *Int. Arch. Allergy Immunol.* 107: 298-300); hsp 70 cloned from a cDNA library of *Cladosporium herbarum* (Zhang *et al.* (1996) *Clin Exp Allergy* 26: 88-95); the 68 kD allergen of *Penicillium notatum* (Shen *et al.* (1995) *Clin. Exp. Allergy* 26: 350-356); aldehyde dehydrogenase (ALDH) (Achatz *et al.* (1995) *Mol Immunol.* 32: 213-227); enolase

(Achatz *et al.* (1995) *Mol. Immunol.* 32: 213-227); YCP4 (Id.); acidic ribosomal protein P2 (Id.).

- Other allergens that can be modified include latex allergens, such as a major allergen (Hev b 5) from natural rubber latex (Akasawa *et al.* (1996) *J. Biol. Chem.* 271: 25389-25393);
- 5 Slater *et al.* (1996) *J. Biol. Chem.* 271: 25394-25399).

*Antigens associated with autoimmune diseases and inflammatory conditions*

- Autoantigens that can be modified according to the invention include, but are not limited to, myelin basic protein (Stinissen *et al.* (1996) *J. Neurosci. Res.* 45: 500-511) or a
- 10 fusion protein of myelin basic protein and proteolipid protein (Elliott *et al.* (1996) *J. Clin. Invest.* 98: 1602-1612), proteolipid protein (PLP) (Rosener *et al.* (1997) *J. Neuroimmunol.* 75: 28-34), 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) (Rosener *et al.* (1997) *J. Neuroimmunol.* 75: 28-34), the Epstein Barr virus nuclear antigen-1 (EBNA-1) (Vaughan *et al.* (1996) *J. Neuroimmunol.* 69: 95-102), HSP70 (Salvetti *et al.* (1996) *J. Neuroimmunol.* 65: 143-
- 15 53; Feldmann *et al.* (1996) *Cell* 85: 307).

- Antigens that can be modified according to the invention and used to treat scleroderma, systemic sclerosis, and systemic lupus erythematosus include, for example, (-2-GPI, 50 kDa glycoprotein (Blank *et al.* (1994) *J. Autoimmun.* 7: 441-455), Ku (p70/p80) autoantigen, or its 80-kd subunit protein (Hong *et al.* (1994) *Invest. Ophthalmol. Vis. Sci.* 35: 4023-4030; Wang *et al.* (1994) *J. Cell Sci.* 107: 3223-3233), the nuclear autoantigens La (SS-B) and Ro (SS-A)
- 20 (Huang *et al.* (1997) *J. Clin. Immunol.* 17: 212-219; Igarashi *et al.* (1995) *Autoimmunity* 22: 33-42; Keech *et al.* (1996) *Clin. Exp. Immunol.* 104: 255-263; Manoussakis *et al.* (1995) *J. Autoimmun.* 8: 959-969; Topfer *et al.* (1995) *Proc. Nat'l. Acad. Sci. USA* 92: 875-879), proteasome (-type subunit C9 (Feist *et al.* (1996) *J. Exp. Med.* 184: 1313-1318), Scleroderma
- 25 antigens Rpp 30, Rpp 38 or Scl-70 (Eder *et al.* (1997) *Proc. Nat'l. Acad. Sci. USA* 94: 1101-1106; Hietarinta *et al.* (1994) *Br. J. Rheumatol.* 33: 323-326), the centrosome autoantigen PCM-1 (Bao *et al.* (1995) *Autoimmunity* 22: 219-228), polymyositis-scleroderma autoantigen (PM-Scl) (Kho *et al.* (1997) *J. Biol. Chem.* 272: 13426-13431), scleroderma (and other systemic autoimmune disease) autoantigen CENP-A (Muro *et al.* (1996) *Clin. Immunol.*
- 30 *Immunopathol.* 78: 86-89), U5, a small nuclear ribonucleoprotein (snRNP) (Okano *et al.* (1996) *Clin. Immunol. Immunopathol.* 81: 41-47), the 100-kd protein of PM-Scl autoantigen (Ge *et al.* (1996) *Arthritis Rheum.* 39: 1588-1595), the nucleolar U3- and Th(7-2) ribonucleoproteins (Verheijen *et al.* (1994) *J. Immunol. Methods* 169: 173-182), the ribosomal protein L7 (Neu *et al.* (1995) *Clin. Exp. Immunol.* 100: 198-204), hPop1 (Lygerou *et al.* (1996)

*EMBO J.* 15: 5936-5948), and a 36-kD protein from nuclear matrix antigen (Deng *et al.* (1996) *Arthritis Rheum.* 39: 1300-1307).

Antigens useful in treatment of hepatic autoimmune disorders can also be modified; these include the cytochromes P450 and UDP-glucuronosyl-transferases (Obermayer-Straub and Manns (1996) *Baillieres Clin. Gastroenterol.* 10: 501-532), the cytochromes P450 2C9 and P450 1A2 (Bourdi *et al.* (1996) *Chem. Res. Toxicol.* 9: 1159-1166; Clemente *et al.* (1997) *J. Clin. Endocrinol. Metab.* 82: 1353-1361), LC-1 antigen (Klein *et al.* (1996) *J. Pediatr. Gastroenterol. Nutr.* 23: 461-465), and a 230-kDa Golgi-associated protein (Funaki *et al.* (1996) *Cell Struct. Funct.* 21: 63-72).

Antigens useful for treatment of autoimmune disorders of the skin that can be modified according to the invention include, but are not limited to, the 450 kD human epidermal autoantigen (Fujiwara *et al.* (1996) *J. Invest. Dermatol.* 106: 1125-1130), the 230 kD and 180 kD bullous pemphigoid antigens (Hashimoto (1995) *Keio J. Med.* 44: 115-123; Murakami *et al.* (1996) *J. Dermatol. Sci.* 13: 112-117), pemphigus foliaceus antigen (desmoglein 1), pemphigus vulgaris antigen (desmoglein 3), BPAG2, BPAG1, and type VII collagen (Batteux *et al.* (1997) *J. Clin. Immunol.* 17: 228-233; Hashimoto *et al.* (1996) *J. Dermatol. Sci.* 12: 10-17), a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid (Ghohestani *et al.* (1996) *J. Invest. Dermatol.* 107: 136-139), and a 218-kD nuclear protein (218-kD Mi-2) (Seelig *et al.* (1995) *Arthritis Rheum.* 38: 1389-1399).

Antigens for treating insulin dependent diabetes mellitus can also be modified; these, include, but are not limited to, insulin, proinsulin, GAD65 and GAD67, heat-shock protein 65 (hsp65), and islet-cell antigen 69 (ICA69) (French *et al.* (1997) *Diabetes* 46: 34-39; Roep (1996) *Diabetes* 45: 1147-1156; Schloot *et al.* (1997) *Diabetologia* 40: 332-338), viral proteins homologous to GAD65 (Jones and Crosby (1996) *Diabetologia* 39: 1318-1324), islet cell antigen-related protein-tyrosine phosphatase (PTP) (Cui *et al.* (1996) *J. Biol. Chem.* 271: 24817-24823), GM2-1 ganglioside (Cavallo *et al.* (1996) *J. Endocrinol.* 150: 113-120; Dotta *et al.* (1996) *Diabetes* 45: 1193-1196), glutamic acid decarboxylase (GAD) (Nepom (1995) *Curr. Opin. Immunol.* 7: 825-830; Panina-Bordignon *et al.* (1995) *J. Exp. Med.* 181: 1923-1927), an islet cell antigen (ICA69) (Karges *et al.* (1997) *Biochim. Biophys. Acta* 1360: 97-101; Roep *et al.* (1996) *Eur. J. Immunol.* 26: 1285-1289), Tep69, the single T cell epitope recognized by T cells from diabetes patients (Karges *et al.* (1997) *Biochim. Biophys. Acta* 1360: 97-101), ICA 512, an autoantigen of type I diabetes (Solimena *et al.* (1996) *EMBO J.* 15: 2102-2114), an islet-cell protein tyrosine phosphatase and the 37-kDa autoantigen derived from it in type 1 diabetes (including IA-2, IA-2) (La Gasse *et al.* (1997) *Mol. Med.* 3: 163-173), the 64 kDa

protein from In-111 cells or human thyroid follicular cells that is immunoprecipitated with sera from patients with islet cell surface antibodies (ICSA) (Igawa *et al.* (1996) *Endocr. J.* 43: 299-306), phogrin, a homologue of the human transmembrane protein tyrosine phosphatase, an autoantigen of type 1 diabetes (Kawasaki *et al.* (1996) *Biochem. Biophys. Res. Commun.* 227: 440-447), the 40 kDa and 37 kDa tryptic fragments and their precursors IA-2 and IA-2 in IDDM (Lampasona *et al.* (1996) *J. Immunol.* 157: 2707-2711; Notkins *et al.* (1996) *J. Autoimmun.* 9: 677-682), insulin or a cholera toxoid-insulin polypeptide (Bergerot *et al.* (1997) *Proc. Nat'l. Acad. Sci. USA* 94: 4610-4614), carboxypeptidase H, the human homologue of gp330, which is a renal epithelial glycoprotein involved in inducing Heymann nephritis in rats, and the 38-kDa islet mitochondrial autoantigen (Arden *et al.* (1996) *J. Clin. Invest.* 97: 551-561).

Useful antigens for rheumatoid arthritis treatment that can be modified according to the invention include, but are not limited to, the 45 kDa DEK nuclear antigen, in particular onset juvenile rheumatoid arthritis and iridocyclitis (Murray *et al.* (1997) *J. Rheumatol.* 24: 560-567), human cartilage glycoprotein-39, an autoantigen in rheumatoid arthritis (Verheijden *et al.* (1997) *Arthritis Rheum.* 40: 1115-1125), a 68k autoantigen in rheumatoid arthritis (Blass *et al.* (1997) *Ann. Rheum. Dis.* 56: 317-322), collagen (Rosloniec *et al.* (1995) *J. Immunol.* 155: 4504-4511), collagen type II (Cook *et al.* (1996) *Arthritis Rheum.* 39: 1720-1727; Trentham (1996) *Ann. N. Y. Acad. Sci.* 778: 306-314), cartilage link protein (Guerassimov *et al.* (1997) *J. Rheumatol.* 24: 959-964), ezrin, radixin and moesin, which are auto-immune antigens in rheumatoid arthritis (Wagatsuma *et al.* (1996) *Mol. Immunol.* 33: 1171-1176), and mycobacterial heat shock protein 65 (Ragno *et al.* (1997) *Arthritis Rheum.* 40: 277-283).

Antigens useful for treatment are autoimmune thyroid disorders that can be modified include, for example, thyroid peroxidase and the thyroid stimulating hormone receptor (Tandon and Weetman (1994) *J. R. Coll. Physicians Lond.* 28: 10-18), thyroid peroxidase from human Graves' thyroid tissue (Gardas *et al.* (1997) *Biochem. Biophys. Res. Commun.* 234: 366-370; Zimmer *et al.* (1997) *Histochem. Cell. Biol.* 107: 115-120), a 64-kDa antigen associated with thyroid-associated ophthalmopathy (Zhang *et al.* (1996) *Clin. Immunol. Immunopathol.* 80: 236-244), the human TSH receptor (Nicholson *et al.* (1996) *J. Mol. Endocrinol.* 16: 159-170), and the 64 kDa protein from In-111 cells or human thyroid follicular cells that is immunoprecipitated with sera from patients with islet cell surface antibodies (ICSA) (Igawa *et al.* (1996) *Endocr. J.* 43: 299-306).

Other associated antigens that can be modified include, but are not limited to, Sjogren's syndrome (-fodrin; Haneji *et al.* (1997) *Science* 276: 604-607), myasthenia gravis (the human M2 acetylcholine receptor or fragments thereof, specifically the second extracellular loop of



- the human M2 acetylcholine receptor; Fu *et al.* (1996) *Clin. Immunol. Immunopathol.* 78: 203-207), vitiligo (tyrosinase; Fishman *et al.* (1997) *Cancer* 79: 1461-1464), a 450 kD human epidermal autoantigen recognized by serum from individual with blistering skin disease, and ulcerative colitis (chromosomal proteins HMG1 and HMG2; Sobajima *et al.* (1997) *Clin. Exp. Immunol.* 107: 135-140).

### *Sperm Antigens*

- Sperm antigens which can be used in the genetic vaccines include, for example, lactate dehydrogenase (LDH-C4), galactosyltransferase (GT), SP-10, rabbit sperm autoantigen (RSA), guinea pig (g)PH-20, cleavage signal protein (CS-1), HSA-63, human (h)PH-20, and AgX-1 (Zhu and Naz (1994) *Arch. Androl.* 33: 141-144), the synthetic sperm peptide, P10G (O'Rand *et al.* (1993) *J. Reprod. Immunol.* 25: 89-102), the 135kD, 95kD, 65kD, 47kD, 41kD and 23kD proteins of sperm, and the FA-1 antigen (Naz *et al.* (1995) *Arch. Androl.* 35: 225-231), and the 35 kD fragment of cytokeratin 1 (Lucas *et al.* (1996) *Anticancer Res.* 16: 2493-2496).
- Also, examples of antigens are set forth in Punnonen *et al.* (1999) WO 99/41369; Punnonen *et al.* (1999) WO 99/41383; Punnonen *et al.* (1999) WO 99/41368; and Punnonen *et al.* (1999) WO 99/41402), the contents of all of which are incorporated herein by reference in their entirety for all purposes. Other useful antigens have been described in the literature or can be discovered using genomics approaches.

### *Peptide addition*

- In principle the peptide addition X can be any stretch of amino acid residues ranging from a single amino acid residue to a large protein, e.g. a mature protein. Usually, the peptide addition X comprises 1-500 amino acid residues, such as 2-500, normally 2-50 or 3-50 amino acid residues, such as 3-20 amino acid residues. The length of the peptide addition to be used for modification of a given polypeptide is dependent of or determined on the basis of a number of factors including the type of polypeptide of interest and the desired effect to be achieved by the modification. Normally, the peptide addition has less than 90% identity to the amino acid sequence of a native full length polypeptide, in particular less than 80% identity, such as less than 70% identity or even lower degree of identity to a full length protein. In one embodiment the peptide addition may constitute a part of a full length protein (e.g. 1-50 amino acid residues thereof).

The peptide addition may be designed by a site-specific or random approach, e.g. as outlined in further detail in the Methods section below. This section also comprises a set of

guidelines useful for preparing a peptide addition for use in the present invention are described. It will be understood that those guidelines are intended for illustration purposes only and that a person skilled in the art will be aware of alternative useful routes for design of peptide addition. Thus, the method of designing a peptide addition for use herein should not be considered limited to that described in the Materials section.

The number of glycosylation sites should be sufficient to provide the desired effect. Typically, the peptide addition X comprises 1-20, such as 1-10 glycosylation sites. For instance, the peptide addition X comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 glycosylation sites. It is well known that one frequently occurring consequence of modifying an amino acid sequence of, e.g., a human protein is that new epitopes are created by such modification. In order to shield any new epitopes created by the peptide addition, it is desirable that sufficient glycosylation sites are present to enable shielding of all epitopes introduced into the sequence. This is e.g. achieved when the peptide addition X comprises at least one glycosylation site within a stretch of 30 contiguous amino acid residues, such as at least one glycosylation site within 20 amino acid residues or at least one glycosylation site within 10 amino acid residues, in particular 1-3 glycosylation sites within a stretch of 10 contiguous amino acid residues in the peptide addition X.

Thus, in one embodiment the peptide addition X comprises at least two glycosylation sites, wherein two of said sites are separated by at most 10 amino acid residues, none of which comprises a glycosylation site. Furthermore, the polypeptide Pp can comprise at least one introduced glycosylation site, in particular 1-5 introduced glycosylation sites. Analogously, the polypeptide Pp can comprise at least one removed glycosylation site, in particular 1-5 removed glycosylation sites.

The glycosylation site of the peptide addition may be an *in vivo* or *in vitro* glycosylation site. Preferably, the glycosylation site is an *in vivo* glycosylation site, in particular an N-glycosylation site since glycosylation of such site is more easy to control than to an O-glycosylation site. Accordingly, in a preferred embodiment the peptide addition X comprises at least one N-glycosylation site, typically at least two N-glycosylation sites. For instance, the peptide addition X has the structure  $X_1-N-X_2-[T/S]/C-Z$ , wherein  $X_1$  is a peptide comprising at least one amino acid residue or is absent,  $X_2$  is any amino acid residue different from Pro, and Z is absent or a peptide comprising at least one amino acid residue. For instance,  $X_1$  is absent,  $X_2$  is an amino acid residue selected from the group consisting of I, A, G, V and S (all relatively small amino acid residues), and Z comprises at least 1 amino acid residue.

For instance, Z can be a peptide comprising 1-50 amino acid residues and, e.g., 1-10 glycosylation sites.

In another polypeptide of the invention  $X_1$  comprises at least one amino acid residue, e.g. 1-50 amino acid residues,  $X_2$  is an amino acid residue selected from the group consisting of I, A, G, V and S, and Z is absent. For instance,  $X_1$  comprises 1-10 glycosylation sites. For instance, the peptide addition for use in the present invention can comprise a peptide sequence selected from the group consisting of INA[T/S], GNI[T/S], VNI[T/S], SNI[T/S], ASNI[T/S], NI[T/S], SPINA[T/S], ASPINA[T/S], ANI[T/S]ANI[T/S]ANI, ANI[T/S]GSNI[T/S]GSNI[T/S], FNI[T/S]VNI[T/S]V, YNI[T/S]VNI[T/S]V, AFNI[T/S]VNI[T/S]V, AYNI[T/S]VNI[T/S]V, APND[T/S]VNI[T/S]V, ANI[T/S], ASNS[T/S]NNG[T/S]LNA[T/S], ANH[T/S]NE[T/S]NA[T/S], GSPINA[T/S], ASPINA[T/S]SPINA[T/S], ANN[T/S]NY[T/S]NW[T/S], ATNI[T/S]LNY[T/S]AN[T/S]JT, AANS[T/S]GNI[T/S]ING[T/S], AVNW[T/S]SND[T/S]SNS[T/S], GNA[T/S], AVNW[T/S]SND[T/S]SNS[T/S], ANN[T/S]NY[T/S]NS[T/S], ANNINYTNWT, ANI[T/S]VNI[T/S]V, ND[T/S]VNF[T/S] and NI[T/S]VNI[T/S]V wherein [T/S] is either a T or an S residue, preferably a T residue. Other non-limiting examples include a peptide addition comprising the sequence NSTQNATA, which corresponds to positions 231 to 238 of the human calcium activated channel 2 precursor (to add two N-glycosylation sites), or the sequence ANLTVRNLTRNVTV, which corresponds to positions 538 to 551 of the human G protein coupled receptor 64 (to add three N-glycosylation sites).

The peptide addition can comprise one or more of these peptide sequences, i.e. at least two of said sequences either directly linked together or separated by one or more amino acid residues, or can contain two or more copies of any of these peptide sequence. It will be understood that the above specific sequences are given for illustrative purposes and thus do not constitute an exclusive list of peptide sequences of use in the present invention.

In a more specific embodiment the peptide addition X is selected from the group consisting of INA[T/S], GNI[T/S], VNI[T/S], SNI[T/S], ASNI[T/S], NI[T/S], SPINA[T/S], ASPINA[T/S], ANI[T/S]ANI[T/S]ANI, and ANI[T/S]GSNI[T/S]GSNI[T/S], wherein [T/S] is either a T or an S residue, preferably a T residue.

As stated further above the polypeptide Pp can be a native polypeptide that may or may not comprise one or more glycosylation sites. In order to further modify the glycosylation of the polypeptide Pp of interest (in terms of the number of oligosaccharide moieties attached to the polypeptide), the polypeptide Pp can be a variant of a native polypeptide that differs from said polypeptide in at least one introduced or at least one removed glycosylation site.

For instance, the polypeptide Pp comprises at least one introduced glycosylation site, in particular 1-5 introduced glycosylation sites, such as 2-5 introduced glycosylation sites.

In order to affect the total glycosylation of the polypeptide of interest the glycosylation site is introduced so that the N residue of said glycosylation site is exposed at the surface of the polypeptide, when folded in its active form. Likewise, a glycosylation site to be removed is selected from those having an N residue exposed at the surface of the polypeptide.

In one embodiment, the peptide addition X has an N residue in position -2 or -1, and the polypeptide Pp or P<sub>x</sub> has a T or an S residue in position +1 or +2, respectively, the residue numbering being made relative to the N-terminal amino acid residue of Pp or P<sub>x</sub>, whereby an N-glycosylation site is formed.

#### *Glycosylation*

The polypeptide of the invention is glycosylated (i.e. comprises an *in vivo* attached N- or O-linked oligosaccharide moiety or *in vitro* attached oligosaccharide moiety) and furthermore has an altered glycosylation profile as compared to that of the polypeptide Pp. For instance, the altered glycosylation profile is a consequence of an altered, normally increased, number of attached oligosaccharide moieties and/or an altered type or distribution of attached oligosaccharide moieties.

Furthermore, for polypeptides intended for therapeutic or veterinary uses or to which a human or animal is otherwise exposed, the type of oligosaccharide moiety to be attached should normally be one that does not lead to increased immunogenicity of the polypeptide as compared to that of the polypeptide Pp. The coupling of an oligosaccharide moiety may take place *in vivo* or *in vitro*. In order to achieve *in vivo* glycosylation of a nucleotide sequence encoding the polypeptide should be inserted in a glycosylating, eucaryotic expression host. The expression host cell may be selected from fungal (filamentous fungal or yeast), insect, mammalian cells or transgenic plant cells as disclosed in further detail in the section entitled "Methods of preparing a polypeptide of the invention". Also, the glycosylation may be achieved in the human body when using a nucleotide sequence encoding the polypeptide of the invention in gene therapy.

*In vitro* glycosylation can be achieved by attaching chemically synthesized oligosaccharide structures to the polypeptide using a variety of different chemistries e.g. the chemistries employed for attachment of PEG to proteins, wherein the oligosaccharide is linked to a functional group, optionally via a short spacer (see the section entitled Conjugation to a Non-Oligosaccharide Macromolecular Moiety). The *in vitro* glycosylation can be carried out

in a suitable buffer at pH 4-7 in protein concentrations of 0.5-2 mg/ml and a volume of 0.02-2 ml. The activated mannose compound is present in 2-200 fold molar excess, and reactions are incubated at 4-25°C for periods of 0.1-3 hours. *In vitro* glycosylated GCB polypeptides are purified by dialysis and standard chromatographic techniques.

5 Other *in vitro* glycosylation methods are described, for example in WO 87/05330, by Aplin et al., CRC Crit Rev. Biochem., pp. 259-306, 1981, by Lundblad and Noyes, Chemical Reagents for Protein Modification, CRC Press Inc. Boca Raton, FL, by Yan and Wold, Biochemistry, 1984, Jul. 31: 23(16): 3759-65, and by Doeber et al., J. Biol. Chem., 257, pp2193-2199, 1982.

10 Furthermore, *in vitro* glycosylation to protein- and peptide-bound Gln-residues can be carried out by transglutaminases (TGases). Transglutaminases catalyse the transfer of donor amine-groups to protein- and peptide-bound Gln-residues in a so-called cross-linking reaction. The donor-amine groups can be protein- or peptide-bound e.g. as the  $\epsilon$ -amino-group in Lys-residues or it can be part of a small or large organic molecule. An example of a small organic  
15 molecule functioning as amino-donor in TGase-catalysed cross-linking is putrescine (1,4-diaminobutane). An example of a larger organic molecule functioning as amino-donor in TGase-catalysed cross-linking is an amine-containing PEG (Sato et al., Biochemistry 35, 1996, 13072-13080).

TGases, in general, are highly specific enzymes, and not every Gln-residues exposed on  
20 the surface of a protein is accessible to TGase-catalysed cross-linking to amino-containing substances. In order to render a protein susceptible to TGase-catalysed cross-linking reactions stretches of amino acid sequence known to function very well as TGase substrates are inserted at convenient positions in the amino acid sequence encoding a GCB polypeptide. Several amino acid sequences are known to be or to contain excellent natural TGase substrates e.g.  
25 substance P, elafin, fibrinogen, fibronectin,  $\alpha_2$ -plasmin inhibitor,  $\alpha$ -caseins, and  $\beta$ -caseins and may thus be inserted into and thereby constitute part of the amino acid sequence of a polypeptide of the invention.

The nature and number of oligosaccharide moieties of a glycosylated polypeptide of the invention may be determined by a number of different methods known in the art e.g. by lectin  
30 binding studies (Reddy et al., 1985, Biochem. Med. 33: 200-210; Cummings, 1994, Meth. Enzymol. 230: 66-86; Protein Protocols (Walker ed.), 1998, chapter 9); by reagent array analysis method (RAAM) sequencing of released oligosaccharides (Edge et al., 1992, Proc. Natl. Acad. Sci. USA 89: 6338-6342; Prime et al., 1996, J. Chrom. A 720: 263-274); by RAAM sequencing of released oligosaccharides in combination with mass spectrometry

- (Klausen, et al., 1998, Molecular Biotechnology 9: 195-204); or by combining proteolytic degradation, glycopeptide purification by HPLC, exoglycosidase degradations and mass spectrometry (Krogh et al, 1997, Eur. J. Biochem. 244: 334-342). Specific methods for determining the glycosylation profile is described in the examples section hereinafter.
- 5 Normally, the glycosylated polypeptide of the invention comprises 1-15 oligosaccharide moieties, such as 1-10 or 1-6 oligosaccharide moieties. Usually, at least one of these is attached to the peptide addition and further oligosaccharide structures are attached to the peptide addition or the polypeptide Pp.

10 *Polypeptide of the invention conjugated to a second non-peptide moiety*

- It can be advantageous that the glycosylated polypeptide of the invention further comprises at least one second non-peptide moiety. The term "second non-peptide moiety" is intended to indicate a non-peptide moiety different from an oligosaccharide moiety, e.g. a polymer
- 15 molecule, a lipophilic compound and an organic derivatizing agent.

For this purpose the polypeptide must comprise at least one attachment group for the second non-peptide moiety. The attachment group can be one present on an amino acid residue, e.g., selected from the group consisting of the N-terminal or C-terminal amino acid residue of the polypeptide of the invention, lysine, cysteine, arginine, glutamine, aspartic acid, glutamic

20 acid, serine, tyrosine, histidine, phenylalanine and tryptophan, or on an oligosaccharide moiety attached to the polypeptide. For instance, the attachment group for the non-peptide moiety is an epsilon-amino group.

It will be understood that an attachment group for the second non-peptide moiety may be provided by the N-terminal peptide addition, within the polypeptide Pp, and/or as a C-

25 terminal peptide addition (having similar properties to those described above for the peptide addition X). In one embodiment, the peptide addition X comprising or contributing to an attachment site further comprises an attachment group for a second non-peptide moiety. For instance, the peptide addition may comprise 1-20, such as 1-10 attachment groups for a second non-peptide moiety. Such attachment groups may be distributed in a similar manner as that

30 described immediately above for glycosylation sites. Also, the peptide addition X can comprise at least two attachment groups for the second non-peptide moiety.

Also, the polypeptide Pp can be a variant of a native polypeptide, which as compared to said native polypeptide, comprises at least one introduced and/or at least one removed attachment group for the second non-peptide moiety. For instance, the polypeptide Pp

comprises at least one introduced attachment group, in particular 1-5 introduced attachment groups, such as 2-5 introduced attachment groups.

The attachment group is preferably located in a position that is exposed at the surface of the folded protein and thus accessible for conjugation to the polymer molecule. For instance, attachment to one or more polymer molecules increases the molecular weight of the polypeptide and can further serve to shield one or more epitopes thereof. The polymer molecule may be any of the molecules mentioned in the section entitled "Conjugation to a polymer molecule", but is preferably selected from the group consisting of linear or branched polyethylene glycol or polyalkylene oxide. Most preferably, the polymer molecule is mPEG-SPA, mPEG-SCM, mPEG-BTC from Shearwater Polymers, Inc, SC-PEG from Enzon, Inc., tresylated mPEG (US 5,880,255) or oxycarbonyl-oxy-N-dicarboxyimide PEG (US 5,122,614) (and the relevant attachment group is one present on a lysine or N-terminal residue). Alternatively, the polymer molecule is an activated PEG molecule reactive with a cysteine residue, e.g. VS-PEG from Shearwater Polymers.

Especially, when the polypeptide Pp is an industrial enzyme, the second non-peptide moiety may be one which is capable of cross-linking and thereby of being immobilized on a suitable solid support. Such cross-linking polymers are available from Shearwater Polymers, Inc. It will be understood that the peptide addition of the polypeptide according to this embodiment comprises an attachment group for the cross-linking polymer in question. In connection with this embodiment the polypeptide Pp is preferably an amyloglucosidase, an alpha-amylase, a glucose isomerase, an amidase, or a lipolytic enzyme.

In the following sections "Conjugation to a lipophilic compound", "Conjugation to a polymer molecule", and "Conjugation to an organic derivatizing agent" conjugation to specific types of non-peptide moieties is described.

It will be understood that a conjugation step of any method of the invention only finds relevance when a non-polypeptide moiety other than an *in vivo* attached oligosaccharide moiety is to be conjugated to the polypeptide, since *in vivo* glycosylation takes place during the expression step when using an appropriate glycosylating host cell as expression host. Accordingly, whenever a conjugation step occurs in the present invention this is intended to be conjugation to a non-polypeptide moiety other than an oligosaccharide moiety attached by *in vivo* glycosylation during expression in a glycosylating organism. *In vitro* glycosylation methods are described in the section entitled "glycosylation".

*Conjugation to a lipophilic compound*

The polypeptide and the lipophilic compound can be conjugated to each other, either directly or by use of a linker. The lipophilic compound can be a natural compound such as a saturated or unsaturated fatty acid, a fatty acid diketone, a terpene, a prostaglandin, a vitamin, a carotenoid or sterol, or a synthetic compound such as a carbon acid, an alcohol, an amine and sulphonic acid with one or more alkyl-, aryl-, alkenyl- or other multiple unsaturated compounds. Furthermore, the lipophilic compound may be any of the lipophilic substituents disclosed in WO 97/31022, the contents of which are incorporated herein by reference. The conjugation between the polypeptide and the lipophilic compound, optionally through a linker can be done according to methods known in the art, e.g. as described by Bodanszky in Peptide Synthesis, John Wiley, New York, 1976 and in WO 96/12505 and further as described in WO 97/31022.

#### *Conjugation to a polymer molecule*

The polymer molecule to be coupled to the polypeptide of the invention can be any suitable polymer molecule, such as a natural or synthetic homo-polymer or heteropolymer, typically with a molecular weight in the range of 300-100,000 Da, such as 300-20,000 Da, more preferably in the range of 500-10,000 Da, even more preferably in the range of 500-5000 Da.

Examples of homo-polymers include a polyol (i.e. poly-OH), a polyamine (i.e. poly-NH<sub>2</sub>) and a polycarboxylic acid (i.e. poly-COOH). A hetero-polymer is a polymer that comprises different coupling groups, such as a hydroxyl group and an amine group.

Examples of suitable polymer molecules include polymer molecules selected from the group consisting of polyalkylene oxide (PAO), including polyalkylene glycol (PAG), such as polyethylene glycol (PEG) and polypropylene glycol (PPG), branched PEGs, poly-vinyl alcohol (PVA), poly-carboxylate, poly-(vinylpyrrolidone), polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, dextran, including carboxymethyl-dextran, or any other biopolymer suitable for the intended purpose, such as for reducing immunogenicity and/or increasing functional *in vivo* half-life and/or serum half-life, or for providing immobilization properties to the polypeptide (as discussed in the section entitled "Polypeptide of interest"). Another example of a polymer molecule is human albumin or another abundant plasma protein. Generally, polyalkylene glycol-derived polymers are biocompatible, non-toxic, non-antigenic, non-immunogenic, have various water solubility properties, and are easily excreted from living organisms.

PEG is the preferred polymer molecule for reducing immunogenicity, allergenicity and/or increasing half-life, since it has only few reactive groups capable of cross-linking



compared, e.g., to polysaccharides such as dextran, and the like. In particular, monofunctional PEG, e.g. methoxypolyethylene glycol (mPEG), is of interest since its coupling chemistry is relatively simple (only one reactive group is available for conjugating with attachment groups on the polypeptide). Consequently, the risk of cross-linking is eliminated, the resulting polypeptide conjugates are more homogeneous and the reaction of the polymer molecules with the polypeptide is easier to control.

To effect covalent attachment of the polymer molecule(s) to the polypeptide, the hydroxyl end groups of the polymer molecule must be provided in activated form, i.e. with reactive functional groups. Suitable activated polymer molecules are commercially available, e.g. from Shearwater Polymers, Inc., Huntsville, AL, USA. Alternatively, the polymer molecules can be activated by conventional methods known in the art, e.g. as disclosed in WO 90/13540. Specific examples of activated linear or branched polymer molecules for use in the present invention are described in the Shearwater Polymers, Inc. 1997 and 2000 Catalogs (Functionalized Biocompatible Polymers for Research and pharmaceuticals, Polyethylene Glycol and Derivatives, incorporated herein by reference). Specific examples of activated PEG polymers include the following linear PEGs: NHS-PEG (e.g. SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM-PEG), and NOR-PEG), BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs such as PEG2-NHS and those disclosed in US 5,932,462 and US 5,643,575, both of which are incorporated herein by reference. Furthermore, the following publications, incorporated herein by reference, disclose useful polymer molecules and/or PEGylation chemistries: US 5,824,778, US 5,476,653, WO 97/32607, EP 229,108, EP 402,378, US 4,902,502, US 5,281,698, US 5,122,614, US 5,219,564, WO 92/16555, WO 94/04193, WO 94/14758, WO 94/17039, WO 94/18247, WO 94/28024, WO 95/00162, WO 95/11924, WO95/13090, WO 95/33490, WO 96/00080, WO 97/18832, WO 98/41562, WO 98/48837, WO 99/32134, WO 99/32139, WO 99/32140, WO 96/40791, WO 98/32466, WO 95/06058, EP 439 508, WO 97/03106, WO 96/21469, WO 95/13312, EP 921 131, US 5,736,625, WO 98/05363, EP 809 996, US 5,629,384, WO 96/41813, WO 96/07670, US 5,473,034, US 5,516,673, EP 605 963, US 5,382,657, EP 510 356, EP 400 472, EP 183 503 and EP 154 316.

The conjugation of the polypeptide and the activated polymer molecules is conducted by use of any conventional method, e.g. as described in the following references (which also describe suitable methods for activation of polymer molecules): R.F. Taylor, (1991), "Protein immobilisation. Fundamental and applications", Marcel Dekker, N.Y.; S.S. Wong, (1992),

"Chemistry of Protein Conjugation and Crosslinking", CRC Press, Boca Raton; G.T. Hermanson et al., (1993), "Immobilized Affinity Ligand Techniques", Academic Press, N.Y.). The skilled person will be aware that the activation method and/or conjugation chemistry to be used depends on the attachment group(s) of the polypeptide (examples of which are given further above), as well as the functional groups of the polymer (e.g. being amine, hydroxyl, carboxyl, aldehyde, sulfhydryl, succinimidyl, maleimide, vinylsulfone or haloacetate). The PEGylation can be directed towards conjugation to all available attachment groups on the polypeptide (i.e. such attachment groups that are exposed at the surface of the polypeptide) or can be directed towards one or more specific attachment groups, e.g. the N-terminal amino group (US 5,985,265). Furthermore, the conjugation can be achieved in one step or in a stepwise manner (e.g. as described in WO 99/55377).

It will be understood that the PEGylation is designed so as to produce the optimal molecule with respect to the number of PEG molecules attached, the size and form of such molecules (e.g. whether they are linear or branched), and where in the polypeptide such molecules are attached. For instance, the molecular weight of the polymer to be used can be chosen on the basis of the desired effect to be achieved. For instance, if the primary purpose of the conjugation is to achieve a polypeptide having a high molecular weight (e.g. to reduce renal clearance) it is usually desirable to conjugate as few high Mw polymer molecules as possible to obtain the desired molecular weight. When a high degree of epitope shielding is desirable this can be obtained by use of a sufficiently high number of low molecular weight polymer molecules (e.g. with a molecular weight of about 5,000 Da) to effectively shield all or most epitopes of the polypeptide. For instance, 2-8, such as 3-6 such polymers can be used.

In connection with conjugation to only a single attachment group on the protein (as described in US 5,985,265), it can be advantageous that the polymer molecule, which can be linear or branched, has a high molecular weight, e.g. about 20 kDa.

Normally, the polymer conjugation is performed under conditions aiming at reacting all available polymer attachment groups with polymer molecules. Typically, the molar ratio of activated polymer molecules to polypeptide is up to about 1000-1, in particular 200-1, preferably 100-1, such as 10-1 or 5-1, but also equimolar ratios can be used in order to obtain optimal reaction.

It is also contemplated according to the invention to couple the polymer molecules to the polypeptide through a linker. Suitable linkers are well known to the skilled person. A preferred example is cyanuric chloride (Abuchowski et al., (1977), J. Biol. Chem., 252, 3578-3581; US 4,179,337; Shafer et al., (1986), J. Polym. Sci. Polym. Chem. Ed., 24, 375-378.

Subsequent to the conjugation residual activated polymer molecules are blocked according to methods known in the art, e.g. by addition of primary amine to the reaction mixture, and the resulting inactivated polymer molecules are removed by a suitable method.

In a specific embodiment, the polypeptide of the invention is one that comprises one or  
5 more PEG molecules attached to the peptide addition, but not to the polypeptide P. For instance, the PEG molecule is attached to one or more cysteine residues present in the peptide addition X and, if necessary, one or more cysteine residues have been removed from the polypeptide P of interest in order to avoid conjugation thereto.

In another specific embodiment, the polypeptide of the invention comprises at least one  
10 PEG molecule attached to a lysine residue of the peptide addition X, in particular a linear or branched PEG molecule with a molecular weight of at least 5kDa.

#### *Methods of preparing a polypeptide of the invention*

The invention further comprises a method of producing the polypeptide of the invention, which  
15 method comprises culturing a host cell transformed or transfected with a nucleotide sequence encoding the polypeptide under conditions permitting the expression of the polypeptide, and recovering the polypeptide from the culture.

Apart from recombinant production, polypeptides of the invention may be produced, albeit less efficiently, by chemical synthesis or a combination of chemical synthesis and  
20 recombinant DNA technology.

The nucleotide sequence of the invention encoding a polypeptide of the invention may be constructed by isolating or synthesizing a nucleotide sequence encoding the parent polypeptide and fusing a nucleotide sequence encoding the relevant peptide addition in accordance with established technologies. To the extent amino acid modifications are to be  
25 made in the parent polypeptide, these are conveniently done by mutagenesis, e.g. using site-directed mutagenesis in accordance with well-known methods, e.g. as described in Nelson and Long, Analytical Biochemistry 180, 147-151, 1989, random mutagenesis or shuffling.

The nucleotide sequence may be prepared by chemical synthesis, e.g. by using an oligonucleotide synthesizer, wherein oligonucleotides are designed based on the amino acid  
30 sequence of the desired polypeptide, and preferably selecting those codons that are favoured in the host cell in which the recombinant polypeptide will be produced. For example, several small oligonucleotides coding for portions of the desired polypeptide may be synthesized and assembled by polymerase chain reaction (PCR), ligation or ligation chain reaction (LCR). The individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.

Once assembled (by synthesis, site-directed mutagenesis or another method), the nucleotide sequence encoding the polypeptide may be inserted into a recombinant vector and operably linked to control sequences necessary for expression of thereof in the desired transformed host cell.

It should of course be understood that not all vectors and expression control sequences function equally well to express the nucleotide sequence encoding the polypeptide part of the invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation. For example, in selecting a vector, the host must be considered because the vector must replicate in it or be able to integrate into the chromosome. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered. In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleotide sequence encoding the polypeptide, particularly as regards potential secondary structures. Hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleotide sequence, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification of the products coded for by the nucleotide sequence.

The recombinant vector may be an autonomously replicating vector, i.e. a vector existing as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector is one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector, in which the nucleotide sequence encoding the polypeptide of the invention is operably linked to additional segments required for transcription of the nucleotide sequence. The vector is typically derived from plasmid or viral DNA. A number of suitable expression vectors for expression in the host cells mentioned herein are commercially available or described in the literature. Useful expression vectors for eukaryotic hosts, include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus and cytomegalovirus. Specific vectors are, e.g., pCDNA3.1(+)(Hyg (Invitrogen, Carlsbad, CA, USA) and pCI-neo (Stratagene, La Jolla, CA, USA). Useful expression vectors for yeast cells include the 2 $\mu$  plasmid and derivatives thereof,

the POT1 vector (US 4,931,373), the pISO37 vector described in (Okkels, Ann. New York Acad. Sci. 782, 202-207, 1996) and pPICZ A, B or C (Invitrogen, Carlsbad, CA, USA). Useful vectors for insect cells include pVL941, pBG311 (Cate et al., "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance And Expression of the Human Gene In Animal Cells", Cell, 45, pp. 685-98 (1986), pBluebac 4.5 and pMelbac (both available from Invitrogen, Carlsbad, CA, USA).

Other vectors for use in this invention include those that allow the nucleotide sequence encoding the polypeptide of the invention to be amplified in copy number. Such amplifiable vectors are well known in the art. They include, for example, vectors able to be amplified by DHFR amplification (see, e.g., Kaufman, U.S. Pat. No. 4,470,461, Kaufman and Sharp, "Construction Of A Modular Dihydrofolate Reductase cDNA Gene: Analysis Of Signals Utilized For Efficient Expression", Mol. Cell. Biol., 2, pp. 1304-19 (1982)) and glutamine synthetase ("GS") amplification (see, e.g., US 5,122,464 and EP 338,841).

The recombinant vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An example of such a sequence (when the host cell is a mammalian cell) is the SV40 origin of replication. When the host cell is a yeast cell, suitable sequences enabling the vector to replicate are the yeast plasmid 2 $\mu$  replication genes REP 1-3 and origin of replication.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or the Schizosaccharomyces pombe TPI gene (described by P.R. Russell, Gene 40, 1985, pp. 125-130), or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate. For filamentous fungi, selectable markers include amdS, pyrG, arcB, niaD, sC.

The term "control sequences" is defined herein to include all components, which are necessary or advantageous for the expression of the polypeptide of the invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, enhancer or upstream activating sequence, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter operably linked to the nucleotide sequence encoding the polypeptide.

"Operably linked" refers to the covalent joining of two or more nucleotide sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one another such that the normal function of the sequences can be performed. For example, the nucleotide

sequence encoding a presequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the nucleotide sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used, in conjunction with standard recombinant DNA methods.

10 A wide variety of expression control sequences may be used in the present invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors as well as any sequence known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

15 Examples of suitable control sequences for directing transcription in mammalian cells include the early and late promoters of SV40 and adenovirus, e.g. the adenovirus 2 major late promoter, the MT-1 (metallothionein gene) promoter, the human cytomegalovirus immediate-early gene promoter (CMV), the human elongation factor 1 $\alpha$  (EF-1 $\alpha$ ) promoter, the *Drosophila* minimal heat shock protein 70 promoter, the Rous Sarcoma Virus (RSV) promoter, the human ubiquitin C (UbC) promoter, the human growth hormone terminator, SV40 or  
20 adenovirus Elb region polyadenylation signals and the Kozak consensus sequence (Kozak, M. *J Mol Biol* 1987 Aug 20;196(4):947-50).

In order to improve expression in mammalian cells a synthetic intron may be inserted in the 5' untranslated region of the nucleotide sequence encoding the polypeptide of the  
25 invention. An example of a synthetic intron is the synthetic intron from the plasmid pCI-Neo (available from Promega Corporation, WI, USA).

Examples of suitable control sequences for directing transcription in insect cells include the polyhedrin promoter, the P10 promoter, the *Autographa californica* polyhedrosis virus basic protein promoter, the baculovirus immediate early gene 1 promoter and the baculovirus  
30 39K delayed-early gene promoter, and the SV40 polyadenylation sequence.

Examples of suitable control sequences for use in yeast host cells include the promoters of the yeast  $\alpha$ -mating system, the yeast triose phosphate isomerase (TPI) promoter, promoters from yeast glycolytic genes or alcohol dehydrogenase genes, the ADH2-4c promoter and the inducible GAL promoter.

Examples of suitable control sequences for use in filamentous fungal host cells include the ADH3 promoter and terminator, a promoter derived from the genes encoding *Aspergillus oryzae* TAKA amylase triose phosphate isomerase or alkaline protease, an *A. niger*  $\alpha$ -amylase, *A. niger* or *A. nidulans* glucoamylase, *A. nidulans* acetamidase, *Rhizomucor miehei* aspartic  
5 proteinase or lipase, the TPI1 terminator and the ADH3 terminator.

The nucleotide sequence of the invention may or may not also include a nucleotide sequence that encode a signal peptide. The signal peptide is present when the polypeptide is to be secreted from the cells in which it is expressed. Such signal peptide, if present, should be one recognized by the cell chosen for expression of the polypeptide. The signal peptide may be  
10 homologous (e.g. be that normally associated with the parent polypeptide in question) or heterologous (i.e. originating from another source than the parent polypeptide) to the polypeptide or may be homologous or heterologous to the host cell, i.e. be a signal peptide normally expressed from the host cell or one which is not normally expressed from the host cell. Accordingly, the signal peptide may be prokaryotic, e.g. derived from a bacterium, or  
15 eukaryotic, e.g. derived from a mammalian, or insect, filamentous fungal or yeast cell.

The presence or absence of a signal peptide will, e.g., depend on the expression host cell used for the production of the polypeptide, the protein to be expressed (whether it is an intracellular or extracellular protein) and whether it is desirable to obtain secretion. For use in filamentous fungi, the signal peptide may conveniently be derived from a gene encoding an  
20 *Aspergillus* sp. amylase or glucoamylase, a gene encoding a *Rhizomucor miehei* lipase or protease or a *Humicola lanuginosa* lipase. The signal peptide is preferably derived from a gene encoding *A. oryzae* TAKA amylase, *A. niger* neutral  $\alpha$ -amylase, *A. niger* acid-stable amylase, or *A. niger* glucoamylase. For use in insect cells, the signal peptide may conveniently be derived from an insect gene (cf. WO 90/05783), such as the lepidopteran *Manduca sexta*  
25 adipokinetic hormone precursor, (cf. US 5,023,328), the honeybee melittin (Invitrogen, Carlsbad, CA, USA), ecdysteroid UDPglucosyltransferase (egt) (Murphy et al., Protein Expression and Purification 4, 349-357 (1993) or human pancreatic lipase (hpl) (Methods in Enzymology 284, pp. 262-272, 1997).

Specific examples of signal peptides for use in mammalian cells include that of human  
30 glucocerebrosidase apparent from the examples hereinafter or the murine Ig kappa light chain signal peptide (Coloma, M (1992) J. Imm. Methods 152:89-104). For use in yeast cells suitable signal peptides have been found to be the  $\alpha$ -factor signal peptide from *S. cerevisiae*, (cf. US 4,870,008), the signal peptide of mouse salivary amylase (cf. O. Hagenbueche et al., Nature 289, 1981, pp. 643-646), a modified carboxypeptidase signal peptide (cf. L.A.

Valls et al., Cell 48, 1987, pp. 887-897), the yeast BAR1 signal peptide (cf. WO 87/02670), and the yeast aspartic protease 3 (YAP3) signal peptide (cf. M. Egel-Mitani et al., Yeast 6, 1990, pp. 127-137).

Any suitable host may be used to produce the polypeptide of the invention, including  
5 bacteria, fungi (including yeasts), plant, insect, mammal, or other appropriate animal cells or cell lines, as well as transgenic animals or plants. When a non-glycosylating organism such as *E. coli* is used, and the polypeptide is to be a glycosylated polypeptide, the expression in *E. coli* is preferably followed by suitable *in vitro* glycosylation.

Examples of bacterial host cells include grampositive bacteria such as strains of  
10 *Bacillus*, e.g. *B. brevis* or *B. subtilis*, *Pseudomonas* or *Streptomyces*, or gramnegative bacteria, such as strains of *E. coli*. The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971,  
15 *Journal of Molecular Biology* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

Examples of suitable filamentous fungal host cells include strains of *Aspergillus*, e.g. *A. oryzae*, *A. niger*, or *A. nidulans*, *Fusarium* or *Trichoderma*. Fungal cells may be transformed  
20 by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and US 5,679,543. Suitable methods for transforming *Fusarium* species are described by Malardier et al., 1989, *Gene* 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and  
25 Guarente, In Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, *Journal of Bacteriology* 153: 163; and Hininen et al., 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

When the polypeptide of the invention is to be *in vivo* glycosylated, the host cell is  
30 selected from a group of host cells capable of generating the desired glycosylation of the polypeptide. Thus, the host cell may advantageously be selected from a yeast cell, insect cell, or mammalian cell.

Examples of suitable yeast host cells include strains of *Saccharomyces*, e.g. *S. cerevisiae*, *Schizosaccharomyces*, *Kluyveromyces*, *Pichia*, such as *P. pastoris* or *P. methanolica*,



- Hansenula*, such as *H. polymorpha* or *yarrowia*. Of particular interest are yeast glycosylation mutant cells, e.g. derived from *S. cerevisiae*, *P. pastoris* or *Hansenula* spp. (e.g. the *S. cerevisiae* glycosylation mutants och1, och1 mm1 or och1 mm1 alg3 described by Nagasu et al. Yeast 8, 535-547, 1992 and Nakanisho-Shindo et al. J. Biol. Chem. 268, 26338-26345, 1993). Methods for transforming yeast cells with heterologous DNA and producing heterologous polypeptides therefrom are disclosed by Clontech Laboratories, Inc, Palo Alto, CA, USA (in the product protocol for the Yeastmaker™ Yeast Transformation System Kit), and by Reeves et al., FEMS Microbiology Letters 99 (1992) 193-198, Manivasakam and Schiestl, Nucleic Acids Research, 1993, Vol. 21, No. 18, pp. 4414-4415 and Ganeva et al., FEMS Microbiology Letters 121 (1994) 159-164.
- Examples of suitable insect host cells include a *Lepidoptera* cell line, such as *Spodoptera frugiperda* (Sf9 or Sf21) or *Trichoplusia ni* cells (High Five) (US 5,077,214). Transformation of insect cells and production of heterologous polypeptides therein may be performed as described by Invitrogen, Carlsbad, CA, USA.
- Examples of suitable mammalian host cells include Chinese hamster ovary (CHO) cell lines, (e.g. CHO-K1; ATCC CCL-61), Green Monkey cell lines (COS) (e.g. COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cells (e.g. NS/O), Baby Hamster Kidney (BHK) cell lines (e.g. ATCC CRL-1632 or ATCC CCL-10), and human cells (e.g. HEK 293 (ATCC CRL-1573)), as well as plant cells in tissue culture. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. Of interest for the present purpose are a mammalian glycosylation mutant cell line, such as CHO-LEC1, CHOL-LEC2 or CHO-LEC18 (CHO-LEC1: Stanley et al. Proc. Natl. Acad. USA 72, 3323-3327, 1975 and Grossmann et al., J. Biol. Chem. 270, 29378-29385, 1995, CHO-LEC18: Raju et al. J. Biol. Chem. 270, 30294-30302, 1995).
- Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection, electroporation, DEAE-dextran mediated transfection, liposome-mediated transfection, viral vectors and the transfection method described by Life Technologies Ltd, Paisley, UK using Lipofectamin 2000. These methods are well known in the art and e.g. described by Ausbel et al. (eds.), 1996, Current Protocols in Molecular Biology, John Wiley & Sons, New York, USA. The cultivation of mammalian cells are conducted according to established methods, e.g. as disclosed in (Animal Cell Biotechnology, Methods and Protocols, Edited by Nigel Jenkins, 1999, Human Press Inc, Totowa, New Jersey, USA and Harrison MA and Rae IF, General Techniques of Cell Culture, Cambridge University Press 1997).

In the production methods of the present invention, cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, cells are cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermenters performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation.

The polypeptides may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., *Protein Purification*, J-C Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

#### *Other methods of the invention*

- In accordance with a specific aspect a nucleotide sequence encoding the polypeptide of the invention is prepared by a method comprising
- a) subjecting a nucleotide sequence encoding the polypeptide Pp to elongation mutagenesis,
  - b) expressing the mutated nucleotide sequence obtained in step a) in a suitable host cell, optionally
  - c) conjugating polypeptides expressed in step b) to a second non-peptide moiety,
  - d) selecting polypeptides of step b) or c) which comprises at least one oligosaccharide moiety and optionally second non-peptide moiety attached to the peptide addition part of the polypeptide, and
  - e) isolating a nucleotide sequence encoding the polypeptide selected in step d).

In the present context the term "elongation mutagenesis" is intended to indicate any manner in which the nucleotide sequence encoding the parent polypeptide Pp can be extended to further encode the peptide addition. For instance, a nucleotide sequence encoding a peptide addition of a suitable length may be synthesized and fused to a nucleotide sequence encoding the polypeptide Pp. The resulting fused nucleotide sequence may then be subjected to further modification by any suitable method, e.g. one which involves gene shuffling, other recombination between nucleotide sequences, random mutagenesis, random elongation mutagenesis or any combination of these methods. Such methods are further described in the Methods section herein.

10 The expression and optional conjugation steps are conducted as described in further detail elsewhere in the present application, and the selection step d) using any suitable method available in the art.

In one embodiment the above method further comprises screening polypeptides resulting from step b) or c) for at least one improved property, in particular any of those improved properties listed herein, prior to the selection step, and wherein the selection step d) further comprises selecting polypeptides having such improved property.

Furthermore, in the above method the elongation mutagenesis can be conducted so as to enrich for codons encoding a glycosylation site and/or an amino acid residue comprising an attachment group for a second non-peptide moiety, in particular an *in vivo* glycosylation site.

20 Still further, the above method can comprise subjecting the part of the nucleotide sequence encoding the polypeptide Pp of interest to mutagenesis to remove and/or introduce glycosylation site(s) and/or amino acid residue(s) comprising an attachment group for the second non-peptide moiety. The nucleotide sequence may be subjected to any type of mutagenesis, e.g. any of those described herein. The mutagenesis of the nucleotide sequence encoding the polypeptide Pp of interest can be conducted prior to assembling the sequence with that encoding the peptide addition, concomitantly with or after any mutagenesis of the peptide addition part of the assembled nucleotide sequence.

In a further aspect, the invention relates to a method of producing a glycosylated polypeptide encoded by a nucleotide sequence of the invention prepared by the above method, wherein the nucleotide sequence encoding the polypeptide selected in step c) is expressed in a glycosylating host cell and the resulting glycosylated expressed polypeptide is recovered.

In a still further aspect the invention relates to a method of improving one or more selected properties of a polypeptide Pp of interest, which method comprises

a) preparing a nucleotide sequence encoding a polypeptide comprising or consisting essentially of the primary structure

$\text{NH}_2\text{-X-Pp-COOH}$ ,

5

wherein

X is a peptide addition comprising or contributing to a glycosylation site and/or an attachment group for a second non-peptide moiety that is capable of conferring the selected improved property/ies to the polypeptide Pp,

- 10 b) expressing the nucleotide sequence of a) in an suitable host cell, optionally  
c) conjugating the expressed polypeptide of b) to a second non-peptide moiety, and  
d) recovering the polypeptide resulting from step b) or c).

For instance, the polypeptide is any of those described herein. For instance the nucleotide sequence of step a) is prepared by subjecting a nucleotide sequence encoding the polypeptide Pp to elongation mutagenesis, e.g. to enrich for codons encoding an amino acid residue comprising or contributing to a glycosylation site and/or an attachment group for a second non-peptide moiety, in particular an *in vivo* glycosylation site. Also, in the preparation of the nucleotide sequence of a), the part of the nucleotide sequence encoding the polypeptide Pp can be subjected to mutagenesis to remove and/or introduce glycosylation site(s) and/or attachment group(s) for a second non-peptide moiety.

20 The method according to this aspect can further comprise a screening step (after step c)), wherein the polypeptide resulting from step b) or c) is screened for one or more improved properties, in particular any of those improved properties which are described hereinabove.

Usually, when a polypeptide has been selected in a screening step of a method of the invention the nucleotide sequence encoding the polypeptide is isolated and used for expression of larger amounts of the polypeptide. The amino acid sequence of the resulting polypeptide is determined and the polypeptide may be subjected to conjugation in a larger scale. Subsequently, the polypeptide is assayed with respect to the property to be improved.

#### 30 Uses of a polypeptide of the invention

It will be understood that polypeptides of the invention can be used for a variety of purposes, depending on the type and nature of polypeptide. For instance, it is contemplated that a polypeptide of the invention prepared from a therapeutic polypeptide is useful for the same

therapeutic purposes as the parent polypeptide, i.e. for the treatment of a particular disease. Accordingly, the polypeptide of the invention may be formulated into a pharmaceutical composition. Also, when the polypeptide of the invention is an *in vivo* glycosylated polypeptide which does not comprise any other type of non-peptide moiety, a nucleotide sequence encoding the polypeptide can be used in gene therapy in accordance with established principles. When the polypeptide Pp is an antigen the polypeptide of the invention may be provided in the form of a vaccine.

## METHODS

10

### *Nucleotide sequence modification methods*

For example, a peptide addition may be constructed from two or more nucleotide sequences encoding a polypeptide of interest with a peptide addition, the sequences being sufficiently homologous to allow recombination between the sequences, in particular in the part thereof encoding the peptide addition. The combination of nucleotide sequences or sequence parts is conveniently conducted by methods known in the art, for instance methods which involve homologous cross-over such as disclosed in US 5,093,257, or methods which involve gene shuffling, i.e., recombination between two or more homologous nucleotide sequences resulting in new nucleotide sequences having a number of nucleotide alterations when compared to the starting nucleotide sequences. In order for homology based nucleic acid shuffling to take place the relevant parts of the nucleotide sequences are preferably at least 50% identical, such as at least 60% identical, more preferably at least 70% identical, such as at least 80% identical. The recombination can be performed in vitro or in vivo. Examples of suitable in vitro gene shuffling methods are disclosed by Stemmer et al (1994), Proc. Natl. Acad. Sci. USA; vol. 91, pp. 10747-10751; Stemmer (1994), Nature, vol. 370, pp. 389-391; Smith (1994), Nature vol. 370, pp. 324-325; Zhao et al., Nat. Biotechnol. 1998, Mar; 16(3): 258-61; Zhao H. and Arnold, FB, Nucleic Acids Research, 1997, Vol. 25. No. 6 pp. 1307-1308; Shao et al., Nucleic Acids Research 1998, Jan 15; 26(2): pp. 681-83; and WO 95/17413. Example of a suitable in vivo shuffling method is disclosed in WO 97/07205.

Furthermore, a peptide addition can be constructed by preparing a randomly mutagenized library, conveniently prepared by subjecting a nucleotide sequence encoding the polypeptide of the invention or the peptide addition to random mutagenesis to create a large

number of mutated nucleotide sequences. While the random mutagenesis can be entirely random, both with respect to where in the nucleotide sequence the mutagenesis occurs and with respect to the nature of mutagenesis, it is preferably conducted so as to randomly mutate only the part of the sequence that encode the peptide addition. Also, the random mutagenesis can be  
5 directed towards introducing certain types of amino acid residues, in particular amino acid residues containing an attachment group, at random into the polypeptide molecule or at random into peptide addition part thereof. Besides substitutions, random mutagenesis can also cover random introduction of insertions or deletions. Preferably, the insertions are made in reading frame, e.g., by performing multiple introduction of three nucleotides as described by Hallet et  
10 al., *Nucleic Acids Res.* 1997, 25(9):1866-7 and Sondek and Shrotle, *Proc Natl. Acad. Sci USA* 1992, 89(8):3581-5.

The random mutagenesis (either of the whole nucleotide sequence or more preferably the part thereof encoding the peptide addition) can be performed by any suitable method. For example, the random mutagenesis is performed using a suitable physical or chemical  
15 mutagenizing agent, a suitable oligonucleotide, PCR generated mutagenesis or any combination of these mutagenizing agents and/or other methods according to state of the art technology, e.g. as disclosed in WO 97/07202.

Error prone PCR generated mutagenesis, e.g. as described by J.O. Deshler (1992), *GATA* 9(4): 103-106 and Leung et al., *Technique* (1989) Vol. 1, No. 1, pp. 11-15, is  
20 particularly useful for mutagenesis of longer peptide stretches (corresponding to nucleotide sequences containing more than 100 bp) or entire genes, and are preferably performed under conditions that increase the misincorporation of nucleotides.

Random mutagenesis based on doped or spiked oligonucleotides or by specific sequence oligonucleotides, is of particular use for mutagenesis of the part of the nucleotide  
25 sequence encoding the peptide addition.

Random mutagenesis of the part of the nucleotide sequence encoding the peptide addition can be performed using PCR generated mutagenesis, in which one or more suitable oligonucleotide primers flanking the area to be mutagenized are used. In addition, doping or spiking with oligonucleotides can be used to introduce mutations so as to remove or introduce  
30 attachment groups for the relevant non-peptide moiety. State of the art knowledge and computer programs (e.g. as described by Siderovski DP and Mak TW, *Comput. Biol. Med.* (1993) Vol. 23, No. 6, pp. 463-474 and Jensen et al. *Nucleic Acids Research*, 1998, Vol. 26, No. 3) can be used for calculating the most optimal nucleotide mixture for a given amino acid preference. The oligonucleotides can be incorporated into the nucleotide sequence encoding the

peptide addition by any published technique using e.g. PCR, LCR or any DNA polymerase or ligase.

According to a convenient PCR method the nucleotide sequence encoding the polypeptide of the invention and in particular the peptide addition thereof is used as a template and, e.g., doped or specific oligonucleotides are used as primers. In addition, cloning primers localized outside the targetted region can be used. The resulting PCR product can either directly be cloned into an appropriate expression vector or gel purified and amplified in a second PCR reaction using the cloning primers and cloned into an appropriate expression vector.

10 In addition to the random mutagenesis methods described herein, it is occasionally useful to employ site specific mutagenesis techniques to modify one or more selected amino acids in the peptide addition, in particular to optimise the peptide addition with respect to the number of attachment groups.

Furthermore, random elongation mutagenesis as described by Matsuura et al, *op cit* can be used to construct a nucleotide sequence encoding a polypeptide having a C-terminal peptide addition. Construction of a nucleotide sequence encoding the polypeptide of the invention having an N-terminal peptide addition can be constructed in an analogous way.


Also, the methods disclosed in WO 97/04079, the contents of which are incorporated herein by reference, can be used for constructing a nucleotide sequence encoding the polypeptide of the invention.

20 The nucleotide sequence(s) or nucleotide sequence region(s) to be mutagenized is typically present on a suitable vector such as a plasmid or a bacteriophage, which as such is incubated with or otherwise exposed to the mutagenizing agent. The nucleotide sequence(s) to be mutagenized can also be present in a host cell either by being integrated into the genome of said cell or by being present on a vector harboured in the cell. Alternatively, the nucleotide sequence to be mutagenized is in isolated form. The nucleotide sequence is preferably a DNA sequence such as a cDNA, genomic DNA or synthetic DNA sequence.

Subsequent to the incubation with or exposure to the mutagenizing agent, the mutated nucleotide sequence, normally in amplified form, is expressed by culturing a suitable host cell carrying the nucleotide sequence under conditions allowing expression to take place. The host cell used for this purpose is one, which has been transformed with the mutated nucleotide sequence(s), optionally present on a vector, or one which carried the nucleotide sequence during the mutagenesis, or any kind of gene library.

*Design of peptide addition*


One example of a useful guide for designing an N-terminal peptide addition containing N-glycosylation sites is characterized by the following formula:



- 5 wherein each of  $X_1$ ,  $X_3$  and  $X_4$  independently is absent or 1, 2, 3 or 4 amino acid residues of any type,  $X_2$  a single amino acid residue of any type except for proline,  $n$  any integer between 0 and 6,  $[T/S]$  a threonine or serine residue, preferably a threonine residue, and  $N$  and  $Pp$  has the meaning defined elsewhere herein. It has been found that sometimes the nature of the amino acid residue occupying position -1 to -4 relative to the N-residue of an N-glycosylation site  
10 may be important for the degree to which said N-glycosylation site is used. Accordingly,  $X_1$ ,  $X_3$ , and  $X_4$  may be chosen so as to obtain an increased utilization of the relevant site (as determined by a trial and error type of experiment). In a first step about 10 different muteins are made that has the above formula. For instance, the about 10 muteins are designed on the basis that each of  $X_1$ ,  $X_3$  and  $X_4$  independently is 1 or 2 alanine residues or is absent,  $Z$  any  
15 integer between 0 and 5,  $[T/S]$  threonine, and Alanine. Based on, e.g., *in vitro* bioactivity and half-life results obtained with these muteins (or any other relevant property), optimal number(s) of amino acids and glycosylation(s) can be determined and new muteins can be constructed based on this information. The process is repeated until an optimal glycosylated polypeptide is obtained.

- 20 Alternatively, random mutagenesis may be used for creating N-terminally extended polypeptides. For instance, a random mutagenized library is made on the basis of the above formula. Doped oligonucleotides are synthesized coding for one amino acid residue in position B (the amino acid residue being different from proline), each of  $X_1$ ,  $X_3$ , and  $X_4$  independently is 0, 1 or 2 amino acid residues of any type,  $n$  is 2 and  $T$  is threonine and used for constructing  
25 the random mutagenized library.

One example of a useful guide for designing an N-terminal peptide addition containing a PEGylation attachment group is characterized by the following formula using a lysine residue as an example of a PEGylation site. It will be understood that peptide additions with other attachment groups can be designed in an analogous way.



wherein each of  $Y^1$ ,  $Y^2$  and  $Y^3$  independently is 0, 1, 2, 3 or 4 amino acid residues of any type except lysine,  $n$  an integer between 0 and 6,  $K$  lysine, and  $Pp$  is as defined elsewhere herein.



In a first step about 10 different muteins are made that has the above formula. For instance, the about 10 muteins are designed on the basis that each of  $Y^1$ ,  $Y^2$  and  $Y^3$  independently is 1 or 2 alanine residues or is absent,  $n$  any integer between 0 and 5. The muteins are then PEGylated with 10 kDa PEG (e.g. using mPEG-SPA). Based on, e.g., *in vitro* bioactivity and half-life results obtained with these muteins (or any other relevant property), optimal number(s) of amino acids and PEGylation sites can be determined and new muteins can be constructed based on this information. The process is repeated until an optimal PEGylated polypeptide is obtained.

Alternatively, random mutagenesis may be performed by making a random mutagenized library based on the above formula. Doped oligonucleotides are synthesized coding for one amino acid residue in position  $Y^1$ ,  $Y^2$  and/or  $Y^3$  independently is 0, 1 or 2 amino acid residues of any type, and  $n$  is 2 and used for constructing the random mutagenized library.

15 *Glucocerebrosidase (GCB) Activity Assay using PNP-glucopyranoside substrate*

The enzymatic activity of recombinant GCB is measured using p-nitrophenyl- $\beta$ -D-glucopyranoside (PNP-Glu) as a substrate. Hydrolysis of the PNP-Glu substrate generates p-nitrophenyl, which can be quantified by measuring absorption at 405 nm using a spectrophotometer, as previously described (Friedmann et al., 1999, Blood 93; 2807-2816).

20 The assay is carried out under conditions which partially inhibit non-GCB glucosidase activities, such conditions being achieved by using a phosphate/citrate buffer pH=5.5, 0.25 % Triton X-100 and 0.25 % taurocholate.

The assay is run in a final volume of 200  $\mu$ l, containing GCB Activity Assay Buffer and 4 mM PNP-Glu. The enzymatic hydrolysis is initiated by adding GCB and the reaction is allowed to proceed for 1 hour at 37°C before being stopped by adding 50  $\mu$ l 1 M NaOH and measuring absorption at 405 nm. A reference standard curve of p-nitrophenyl, assayed in parallel, is used to quantify concentrations of GCB in samples to be tested.

*In vitro uptake and stability of GCB polypeptide in macrophages*

30 The murine monocyte/macrophage cells line, J774E (Mukhopadhyay and Stahl, *Arch Biochem Biophys* 1995 Dec 1;324(1):78-84 and Diment et al., *J Leukoc Biol* 1987 Nov;42(5):485-90) is used to study the uptake and stability of GCB polypeptides. Cells are grown in  $\alpha$ -MEM (supplemented with 10 % fetal calf serum, 1X Pen/Strep, and 60  $\mu$ M 6-

thioguanine), seeded (200,000 cells pr. well) in the above-mentioned media containing 10  $\mu$ M conditol B epoxide, CBE (an irreversible GCB inhibitor) and incubated for 24 hr at 37°C.

Before starting the uptake assay, cells are washed in 0.5 ml HBSS (Hanks balanced salt solution). The uptake is done in a 200  $\mu$ l volume, containing the appropriate concentration of GCB polypeptide (a dose response curve is made with GCB concentrations in the range of 25-400 mU/ml). As a control, yeast mannan (final concentration 1.4 mg/ml) is added to inhibit the uptake through the macrophage mannose receptor. The cells are incubated for 1 hr at 37°C and washed three times with 0.5 ml cold HBSS.

To measure the amount of GCB taken up by the J774E cells, cells are lysed in 200  $\mu$ l GCB Activity Assay Buffer with 4 mM PMP-Glu and incubated for 1 hr at 37°C. Then, the hydrolysis is stopped by addition of 50  $\mu$ l 1M NaOH and OD405 is measured. The data are analysed by non-linear regression using GraphPad Prism 2.0 (GraphPad Software, San Diego, CA)

To study the stability of GCB polypeptides in J774E cells, CBE treated cells are incubated with 400 mU/ml GCB for 1 hr at 37°C. Then, cells are washed 3 times in HBSS to remove extracellular GCB and incubated in HBSS. A time-course study is done by lysing the cells after 30 min, 1 hr, 2 hr, 3hr, 4 hr, and 5 hr in 200  $\mu$ l GCB Activity Assay Buffer with 4mM PNP-Glu and incubating the samples for 1 hr at 37°C before stopping the hydrolysis with 50  $\mu$ l 1 M NaOH and measuring OD405. The data are analysed by non-linear regression using GraphPad Prism 2.0 (GraphPad Software, San Diego, CA).

#### Site-directed mutagenesis

Constructions of site-directed mutations were performed using PCR with oligonucleotides containing the desired amino acid exchanges or additions (e.g. to introduce glycosylation sites). The resulting PCR fragment was cloned into the GCB expression vector using appropriate restriction enzymes and subsequently DNA sequenced in order to confirm that the construct contained the desired exchanges.

#### 30 MATERIALS

##### *GCB Activity Assay Buffer:*

120 mM phosphate/citrate buffer, pH=5.5, 1 mM EDTA, pH=8.0, 0.25 % Triton X-100, 0.25 % taurocholate, 4 mM  $\beta$ -mercaptoethanol

*pGC-12 vector*

- 5 pVL1392 (Pharmingen, USA) with GCB wt cDNA sequence (SEQ ID NO 2) inserted between EcoRV and XbaI.

*Table 1*

- Sequence of primers used for cloning the wt GCB coding region and inserting signal peptides  
10 into the pGCBmat plasmid as described in Example 1.

- SO49 (WT-sp-BglII): 5'-CGCAGATCTGATGGCTGGCAGCCTCACAGGATTGC-3'  
SO50 (WT-stop-EcoRI): 5'-CCGGAATTCCCATCACTGGCGACGCCACAGGTAGGTG-3'  
SO51 (WT-mature-SacI): 5'-ACGCGAGCTGCCCCCTGCATCCCTAAAAGCTTCGG-3'  
15 SO52 (SPegt-NheI/SacI-as): 5'-  
GCGTTGACGGCAGTCAGAGTTGACAGAAGGGCCAGCCAGCAAAGGATAGTCATG-  
3'  
SO53 (SPegt-NheI/SacI-s): 5'-  
CTAGCATGACTATCCTTTGCTGGCTGGCCCTTCTGTCAACTCTGACTGCCGTCAACG  
20 CAGCT-3'  
SO54 (SPegt-NheI/SacI-as): 5'-  
CCTGCTACTGCTCCAGCAGCAGTGAAAGAGTCCAAAGTGGCAGCATG-3'  
SO55 (SPegt-NheI/SacI-s): 5'-  
CTAGCATGCTGCCACTTTGGACTCTTTCACTGCTGCTGGGAGCAGTAGCAGGAGCT  
25 -3'

*Cerezyme* was kindly provided by Dr. E. Beutler, Scripps Institute, CA, USA.

- J774E* was kindly provided by G. Grabowski, Cincinnati, Ohio, US  
30

EXAMPLE 1

## PRODUCTION OF WT GCB

Cloning and Expression in Insect Cells

A human fibroblast cDNA library was obtained from Clontech (Human fibroblast skin cDNA  
5 cloned in lambda-gt11, cat# HL1052b). Lambda DNA was prepared from the library by  
standard methods and used as a template in a PCR reaction with either SO49 and SO50 as  
primer (amplifies the GCB coding region with the human signal peptide from the second ATG)  
or SO50 and SO51 as primer (amplifies the mature part of the GCB coding region) (see Table  
1 in the Materials section).

10 The PCR products were reamplified with the same primers and agarose gel purified.  
Subsequently the SO49/50 PCR product was digested with BglII and EcoRI and cloned into  
the pBlueBac 4.5 vector (InVitrogenInvitrogen, Carlsbad, CA, USA, Carlsbad, CA, USA)  
digested with BamHI and EcoRI. Sequencing confirmed that the insert is identical to the  
wtGCB sequence as given in SEQ ID NO 2. The resulting plasmid was used for infection of  
15 insect cells with the GCB being partly secreted from the cells due to the human signal sequence  
as described in Martin et al., DNA 7, pp. 99-106, 1988. The SO50/51 PCR product was  
digested with SacI and EcoRI and cloned into the pBlueBac 4.5 vector (InVitrogenInvitrogen,  
Carlsbad, CA, USA) digested with the same enzymes resulting in the pGCBmat plasmid. Two  
different signal sequences were inserted upstream of the mature GCB codons in order to  
20 increase the secreted amount of enzyme. The baculovirus ecdysteroid UDPglucosyltransferase  
(egt) signal sequence (Murphy et al., Protein Expression and Purification 4, 349-357, 1993)  
was inserted by annealing SO52 and SO53 (Table 1) and the human pancreatic lipase signal  
sequence (Lowe et al., J. Biol. Chem. 264, 20042, 1989) was inserted by annealing SO54 and  
SO55 (Table 1) and cloning them into the NheI and SacI digested pGCBmat plasmid. Infection  
25 of *Spodoptera frugiperda* (Sf9) cells of the resulting plasmid was done according to the  
protocols from InVitrogenInvitrogen, Carlsbad, CA, USA.

*Purification of GCB polypeptides produced in insect cells*

Polypeptides with GCB activity were purified as described in US 5,236,838, with some  
30 modifications. Cells were removed from the culture medium by centrifugation (10 min at 4000  
rpm in a Sorvall RC5C centrifuge) and the supernatant microfiltered using a 0.22 µm filter  
prior to purification. DTT was added to 1 mM and the culture supernatant was ultrafiltered to  
approximately 1/10 of the starting volume using a Vivaflow 200 system (Vivascience). The  
concentrated media was centrifuged to remove possible aggregates before application on a

Toyopearl Butyl650C resin (TosoHaas) previously equilibrated in 50 mM sodium citrate, 20 % (v/v) ethylene glycol, 1 mM DTT, pH 5.0. This chromatographic step was performed at room temperature. The resin was washed with at least 3 column volumes of 50 mM sodium citrate, 20 % (v/v) ethylene glycol, 1 mM DTT, pH 5.0 (until the absorbance at 280 nm reaches baseline level) and GCB was eluted with a linear gradient from 0% to 100% 50 mM sodium citrate, 80% (v/v) ethylene glycol, 1 mM DTT, pH 5.0. Fractions were collected and assayed for GCB activity using the GCB Activity Assay. Usually, wt GCB starts to elute at approx. 70% (v/v) ethylene glycol.

The subsequent purification was done by either of the following two methods. #2 method results in GCB of a higher purity.

#### Method #1

GCB enriched fractions from the first process step were pooled and diluted approx. 4 times with a buffer containing 50 mM sodium citrate, 5 mM DTT, pH 5.0 to reduce the ethylene glycol content to 20% (or lower). In the second HIC purification step the diluted and partially purified GCB was applied on a Toyopearl phenyl resin (TosoHaas) equilibrated in 50 mM sodium citrate, 1 mM DTT, pH 5.0 (Buffer A) before use. After application, the resin was washed with at least 3 column volumes of 50 mM sodium citrate, pH 5 (until the absorbance at 280 nm reaches baseline level) and GCB was then eluted with a linear ethanol gradient from 0% to 100% buffer B (50 mM sodium citrate, 50% (v/v) ethanol, 1 mM DTT, pH 5.0). Highly purified fractions of GCB (wildtype  $\geq 95\%$  pure), identified using the GCB Activity Assay, start to elute at approx. 40% ethanol. The purified GCB bulk product was dialyzed against 50 mM sodium citrate, 0.2 M mannitol, 0.09% tween80, pH 6.1 to retain the GCB activity upon subsequent storage at 4–8°C or at -80°C.

#### Method #2

GCB enriched fractions eluted from the Toyopearl butyl650C resin were pooled and applied at 4°C on a SP sepharose resin (Amersham Pharmacia Biotech) previously equilibrated in 25 mM sodium citrate, 1 mM DTT, 10% ethylene glycol, pH 5.0. After application, the resin was washed with 25 mM sodium citrate, 1 mM DTT, 10% ethylene glycol, pH 5.0 (until absorption at 280 nm reached baseline level) and GCB was then eluted with a linear gradient from 0 to 100% 0.25 M sodium citrate, 1 mM DTT, 10% ethylene glycol, pH 5.0. GCB begins to elute around 0.15 M sodium citrate. Fractions containing GCB were pooled and applied at room temperature onto a Phenyl sepharose High Performance (Pharmacia Biotech) previously

equilibrated in 25 mM sodium citrate 1 mM DTT, pH 5.0. After application, the resin was washed with 25 mM sodium citrate 1 mM DTT, pH 5.0 until absorption at 280 nm reached baseline level, and GCB was then eluted with a linear ethanol gradient from 0 to 100% 25 mM sodium citrate 1 mM DTT 50 % ethanol pH 5.0. GCB typically elutes around 35 % ethanol.

- 5 The purified GCB bulk product was dialyzed against either 50 mM sodium citrate, 1 mM DTT, pH 5.0 or 50 mM sodium citrate, 0.2 M mannitol, 1 mM DTT, pH 6.1 to retain the GCB activity upon subsequent storage. The purified GCB was concentrated and sterile filtered before storage at 4 – 8°C or at –80°C. Typically, GCB purified by this method is >95% pure.

10

## EXAMPLE 2

*Preparation of GCB with N-terminal peptide additions using a site-directed or random mutagenesis approach*

15

Nucleotide sequences encoding the following N-terminal peptide additions were added to the nucleotide sequence shown in SEQ ID NO 2 encoding wtGCB: (A-4)+(N-3)+(I-2)+(T-1) (representing an extension to the N-terminal of the amino acid sequence shown in SEQ ID NO 1 with the amino acid residues ANIT), and (A-7)+(S-6)+(P-5)+(I-4)+(N-3)+(A-2)+(T-1) 20 (ASPINAT).

A nucleotide sequence encoding the N-terminal peptide addition (A-4)+(N-3)+(I-2)+(T-1) was prepared by PCR using the following conditions:

PCR 1:

Template: 10 ng pBlueBac5 with wt GCB cDNA sequence

- 25 primer SO60: 5'-CAGCTGGCCATGGGTACCCGG-3' and

primer SO85:

5'-TGGGCATCAGGTGCCAACATTACAGCCCGCCCTGCATCCCTAAAAGC-3'

BIO-X-ACT™ DNA polymerase (Bioline, London, U.K.)

1xOptiBuffer™ (Bioline, London, U.K.)

- 30 30 cycles of 96°C 30s, 55°C 30s, 72°C 1 min

PCR 2:

Template: 10 ng pBlueBac5 with wt GCB,

Baculo virus forward primer: 5'-TTTACTGTTTTCGTAACAGTTTG-3' and

PrimerSO86:

5'-GCAGGGGCGGGCTGTAATGTTGGCACCTGATGCCCCACGACACTGCCTG-3'

BIO-X-ACT™ DNA polymerase (Bioline, London, U.K.)

1xOptiBuffer™ (Bioline, London, U.K.)

30 cycles of 96°C 30s, 55°C 30s, 72°C 1 min

5 PCR 3:

3 µl of agarose gel purified PCR1 and PCR2 products (app. 10 ng)

Baculo virus forward primer: 5'-TTTACTGTTTTCGTAACAGTTTITG-3' and primer SO60.

BIO-X-ACT™ DNA polymerase (Bioline, London, U.K.)

1xOptiBuffer™ (Bioline, London, U.K.)

10 30 cycles of 96°C 30s, 55°C 30s, 72°C 1 min

PCR 3 was agarose gel purified and digested with NheI and NcoI and cloned into pBluebac4.5+wtGCB digested with NheI and NcoI.

After confirmation of the correct mutations by DNA sequencing the plasmid was transfected into insect cells using the Bac-N-Blue™ transfection kit from Invitrogen, Carlsbad, CA, USA. Expression of the muteins was tested by western blotting and by activity measurement of the muteins using the GCB Activity Assay.

Enzymatic activity of wtGCB (SEQ ID NO 1) expressed in the expression vector pVL1392 in insect cells (Sf9) using an analogous method to that described in Example 1 gave 13 units/L, while the N-terminal peptide addition ASPINAT gave 28.5 units/L.

20

Construction of libraries of GCB with N-terminal peptide addition

Using random mutagenesis two different libraries were constructed on the basis of GCB polypeptides with an N-terminal extension - library A with an N-terminal extension encoding the following amino acid sequence AXNXTXNXTXNXT, and library B with an N-terminal extension encoding ANXTNXTNXT.

25

Primers for library A were designed:

SO167: 5'-

GTGTCGTGGGCATCAGGTGCCNN(G/C)AA(C/T)(T/A/G)N(G/C)AC(A/T/C)(T/A/G)N(G/C)AA(C/T)(T/A/G)N(G/C)AC(A/T/C)(T/A/G)N(G/C)AA(C/T)(T/A/G)N(G/C)AC(A/T/C)GC

30

CCGCCCTGCATCCCTAAAAGC

SO168: 5'-GGCACCTGATGCCCCACGACACTGCCTG

Primers for library B were designed using trinucleotides in the random positions.

X is a mixture of trinucleotide codons for all natural amino acid residues, except proline. The trinucleotide codons used were the same as described by Kayushin et al., Nucleic Acids Research, 24, 3748-3755, 1996.

5 SO165: 5'-

CGTGGGCATCAGGTGCCAAC(X)AC(A/T/C)AA(C/T)(X)AC(A/T/C)AA(C/T)(X)AC(A/T/C)GCCCCGCCCTGCATCCCTAAAAAGC

SO166 : 5'- GTTGGCACCTGATGCCCACGACACTGCCTG

10 For both libraries:

SO60 and pBR10: 5'- TTT ACT GTT TTC GTA ACA GTT TTG

In all PCR reactions BIO-X-ACT™ DNA polymerase (Bioline, London, U.K.) and 1\*Optibuffer™ (Bioline, London, U.K.) were used. The PCR conditions were 30 cycles of 15 94°C 30s, 55°C 1 min, and 72°C 1 min.

Templates and primers used for preparing a nucleotide sequence encoding the N-terminal extension by the above PCR were as follows:

PCR 1A:

20 Template: pGC12

Primers: SO60 + SO167

PCR 1B:

Template: pGC12

25 Primers: SO60 + SO165

PCR 2A:

Template: pGC12

Primers: SO168 + pBR10

30

PCR 2B:

Template: pGC12

Primers: SO166 + pBR10

PCR 3A:



Template: 1  $\mu$ l of agarose gel purified PCR 1A and 2A products

Primers: SO60 + pBR10

PCR 3B:

5 Template: 1  $\mu$ l of agarose gel purified PCR 1B and 2B products

Primers: SO60 + pBR10

PCR 3A and 3B were agarose gel purified and digested with NheI and NcoI and ligated into pGC-12 digested with NheI and NcoI. The ligation mixture is transformed into competent *E. coli*. The diversity of the library was examined by DNA sequencing of different *E. coli* clones and gave rise to the following amino acid sequences:

Library A:

- 1: AFNXTLNKTWN(F/L)T
- 15 2: TMNNTWNWTWNWT
- 3: -EXT wt
- 4: ALNSTGNLTVDGT
- 5: ASNSTFNLTENLT
- 6: TRNVIINCTUNST
- 20 7: -EXT wt
- 8: ALNWTYNGTIKNVT
- 9: AANWTVNFTGNFT
- 10: -EXT wt
- 11: AXNXTVNSTUNVT
- 25 12: ANNFIFNGLTNLNLT
- 13: AGNWTANVTNVNVT
- 14: AGNSTSNVTGNWT
- 15: AVNSTMNIHAIPP (1 deletion - nonsens)
- 16: AGNGTVNGTINGT
- 30 17: AVNSTGNXTGNWT
- 18: AGNGTFUNGTSNLT
- 19: -EXT wt
- 20: AMNSTKNSTLNTI
- 21: AFNYTSKNST

- 22: -EXT wt  
23: AVNATM~~N~~WTANGT  
24: ASNSTNGTILNAT  
25: ARNKT~~K~~NFTINLT  
5 26: APNITUNDIVNMT  
27: AQNK~~T~~FNFTMNCT  
28: ALNVTW~~N~~CTILNLT  
29: ALNTI~~T~~WNLTL
- 10 Library B:
- 1: AN~~T~~TNFTNET  
2: ANWTN~~R~~TNCT  
3: ANWTNFTNWT  
4: PTGLIG~~T~~NFT  
15 5: ANWTN~~K~~TNFT  
6: ANNTNL~~T~~NAT  
7: ANYTNW~~T~~NFT  
8: ANT~~T~~NQTNDT  
9: -EXT wt  
20 10: ANRTNWTNTT  
11: PTATNH~~T~~NST  
12: -EXT wt  
13: ANWINQT~~N~~QT  
14: ANWINWTNAT  
25 15: ANFTN~~K~~TNMT  
16: ANHTNETNAT  
17: AN(C/W)TNFTNET  
18: ANLDK~~L~~H~~K~~UH (insertion - nonsens)  
19: ANCFTNQT~~N~~FT  
30 20: ANWTNWTNEW~~T~~  
21: ANCTNWTNCT  
22: -EXT wt  
23: -EXT wt  
24: CHPYNWTNWT

- 25: ANETNYTNET  
26: ANWTNWT  
27: AKPYKSYKFY (insertion - nonsense)  
28: ANITNKTNWT  
5 29: ANWTNMINIT  
30: ANNTNRTNET  
31: ANWINWINWT  
32: ANWRTNHINKT  
33: - EXT wt  
10 34: ANQTNITNWT

Library B was transfected into insect cells using the Bac-N-Blue™ transfection kit from Invitrogen, Carlsbad, CA, USA. First, 96 plaques from Library B were picked and tested by activity measurement (GCB Activity Assay). Plaques were selected as follows: 3 with high  
15 activity, 3 with medium activity and 3 with low or no activity, and virus was purified for DNA sequencing resulting in the following amino acid sequences:

High activity:

1-1: Mixed sequence

1-2: ANFTNVATNQT

20 1-3: (A)(N)ITXLTN(K)T

Medium activity:

2-1: ANKTN(S/C)TNIT

2-2: Mixed sequence

25 2-3: ANWINCTN(I)T

Low activity:

3-1: ANWTN(F/L)TNWT

3-2: CQLDURSTNET

30 3-3: No sequence

From both libraries 96 plaques were picked and tested by activity measurement (GCB Activity Assay). From each library 6 plaques with high activity were selected and virus were purified for DNA sequencing. The amino acid sequence encoded by the different clones were:

## Library A:

- 1: Mixed sequence
- 2: Mixed sequence
- 5 3: Mixed sequence
- 4: WT
- 5: ANNTNYTNWT
- 6: ANNTNYTNWT

## 10 Library B:

- 1: AANDTUNWTVNCT
- 2: ATNIIILNYTANTT
- 3: WT
- 4: AANSTGNITINGT
- 15 5: AVNWTSNDTSNST

GCB polypeptides of the invention were tested for various properties, including GCB activity, stability in J774E cells and uptake in J774E cells. Unless otherwise stated the properties were tested by use of the methods described in the Methods section herein.

- 20 In the below table the GCB activity of various GCB polypeptides of the invention is listed together with the activity of the positives from Library A and B after plaque purification.

Table 2

Plasmid	Vector	Mutations	Activity after	
			# Glycosylation sites introduced	Plaque Isolation (U/L)
pGC-1	PBlueBac4.5	Wt	0	6
pGC-6	pBlueBac4.5	N-termANIT	1	3
pGC-12	pVL1392	Wt	0	13
pGC-13	pVL1392	N-termASPINAT	1	29
pGC-36	pVL1392	N-term: ASPINATSPINAT	2	16
pGC-38	pVL1392	N-term: ASPINAT,K194N, K321N	3	16
pGC-40	pVL1392	N-term: ASPINAT,T132N, K293N, V295T	3	3.5
pGC-47	pVL1392	N-term: AGNGTVNGTINGT	3	30
pGC-48	pVL1392	N-term: ASNSTNNGTILNAT	3	36

pGC-56 pVL1392	N-term: ASPINATSPINAT, K194N, K321N	4	24
pGC-57 pVL1392	N-term: ASPINAT, T132N, K194N, K321N	4	20
pGC-58 pVL1392	N-term: ASPINAT, T132N, K194N	3	10
pGC-60 pVL1392	N-term: ANNTNYINWT	3	P2: 14
pGC-61 pVL1392	N-term: ATNITLNYTANIT	3	P2: 38
pGC-62 pVL1392	N-term: AANSTGNITNGT	3	P2: 35
pGC-63 pVL1392	N-term: AVNWTSDNITSNST	3	P2: 66
pGC-68 pVL1392	AN N-term extension + R2T	1	37

Table 2: The plasmid column shows the number of the GCB polypeptide. The vector column shows the plasmid vector used for expression of the polypeptide. The mutation column shows the amino acid exchanges of the GCB polypeptide. N-terminal extensions are described as N-term followed by the amino acid residues that makes up the extension. The Activity column gives the units per liter of GCB activity measured by the GCB Activity Assay on the supernatant from Sf9 insect cells infected with one single plaque and grown in 3 ml of media in a 6-well plate. Those labelled with P2 are activity measured of supernatant from virus infection cells grown in 15 ml T75 flasks.

10

Table 3

GCB polypeptide	V <sub>max</sub>	K <sub>m</sub>
Wildtype	0.57	87.7
Cerezyme	0.52	91.9
pGC36	0.60	70.6
pGC38	0.48	44.0
pGC56	0.39	32.2
pGC60	0.57	79.1
pGC61	0.74	100.5
pGC62	0.86	110.8
pGC63	0.51	83.1

Table 3: Calculated V<sub>max</sub> and K<sub>m</sub> for uptake in the J774E macrophage cell line of the different GCB polypeptides. V<sub>max</sub> and K<sub>m</sub> was calculated from dosis response curve (See Fig. 1). The uptake of selected GCB polypeptides are shown in Figure 1

15 As can be seen from table 3, an increase in V<sub>max</sub> was observed for the N-terminally extended GCB polypeptides (pGC60, pGC61, and pGC62).

## EXAMPLE 3

*Glycosylation of GCB polypeptides of the invention expressed in insect cells*

MALDI-TOF mass spectrometry was used to investigate the amount of carbohydrate attached to GCB polypeptides expressed in Sf9 cells.

The 6 GCB polypeptide variants investigated all contained additional potential N-glycosylation sites compared to wtGCB.

WtGCB contains 5 potential N-glycosylation sites of which only 4 are used.

The 6 GCB polypeptide variants were:

- GC-36: ASPINATSPINAT-GCB,
- GC-38: ASPINAT-GCB(K194N,K321N),
- GC-60: ANNTNYTNWT-GCB,
- GC-61: ATNITLNYTANIT-GCB,
- GC-62: AANSTGNITINGT-GCB, and
- GC-63: AVNWTSNDTSNST-GCB.

**WtGCB:**

The theoretical peptide mass of wtGCB is 55 591 Da. WtGCB has 5 potential N-glycosylation sites of which only 4 are used. As the two most common N-glycan structures on recombinant proteins expressed in Sf9 cells are  $\text{Man}_3\text{GlcNAc}_2\text{Fuc}$  and  $\text{Man}_3\text{GlcNAc}_2$  having masses of 1038.38 Da and 892.31 Da, respectively, the expected mass of wtGCB carrying 4 N-glycans is between 59 159 Da and 59 743 Da.

MALDI-TOF mass spectrometry of wtGCB shows the broad peak typical of glycoproteins with a peak mass of 59.3 kDa in accordance with the expected mass of wtGCB carrying 4 N-glycans.

**GC-36 (ASPINATSPINAT-GCB):**

The theoretical peptide mass of GC-36 is 56 829 Da. The N-terminal extension contains two additional potential glycosylation sites at N5 and N11 compared to wtGCB. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 6 potential N-glycosylation sites.

As the two most common N-glycan structures on recombinant proteins expressed in Sf9 cells are  $\text{Man}_3\text{GlcNAc}_2\text{Fuc}$  and  $\text{Man}_3\text{GlcNAc}_2$  having masses of 1038.38 Da and 892.31 Da,

respectively, the expected mass of GC-36 carrying 4 N-glycans is between 60 397 Da and 60 981 Da, the expected mass of GC-36 carrying 5 N-glycans is between 61 289 Da and 62 019 Da, and the expected mass of GC-36 carrying 6 N-glycans is between 62 181 Da and 63 057 Da.

MALDI-TOF mass spectrometry of GC-36 shows a rather broad peak with a peak mass between 61.5 kDa and 62.9 kDa in accordance with the expected mass of GC-36 carrying either 5 or 6 N-glycans.

N-terminal amino acid sequence analysis of GC-36 showed that N5 is completely glycosylated while N11 is partially glycosylated in complete agreement with the result obtained using mass spectrometry.

**GC-38 (ASPINAT-GCB(K194N,K321N)):**

The theoretical peptide mass of GC-38 is 56 217 Da. The N-terminal extension contains one additional potential glycosylation sites at N5 compared to wtGCB. In addition, the substitutions of Lys194 and Lys321 with Asn-residues introduce two additional potential N-glycosylation sites. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 7 potential N-glycosylation sites.

Based on the same considerations as those used for GC-36, the expected mass of GC-38 carrying 4 N-glycans is between 59 785 Da and 60 369 Da, the expected mass of GC-38 carrying 5 N-glycans is between 60 677 Da and 61 407 Da, the expected mass of GC-38 carrying 6 N-glycans is between 61 569 Da and 62 445 Da, and the expected mass of GC-38 carrying 7 N-glycans is between 62 461 Da and 63 483 Da.

MALDI-TOF mass spectrometry of GC-38 shows a major peak with a peak mass of 63.1 kDa in accordance with the expected mass of GC-38 carrying 7 N-glycans. In addition, a minor peak with a peak mass of 62.3 kDa is seen which corresponds to GC-38 carrying 6 N-glycans.

N-terminal amino acid sequence analysis of GC-38 showed that N5 is completely glycosylated.

**GC-60 (ANNINYTNWT-GCB):**

The theoretical peptide mass of GC-60 is 56 770 Da. The N-terminal extension contains three additional potential glycosylation sites at N2, N5 and N8 compared to wtGCB. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 7 potential N-glycosylation sites.

Based on the same considerations as those used for GC-36 the expected mass of GC-60 carrying 4 N-glycans is between 60 338 Da and 60 922 Da, the expected mass of GC-60 carrying 5 N-glycans is between 61 230 Da and 61 960 Da, the expected mass of GC-60 carrying 6 N-glycans is between 62 122 Da and 62 998 Da, and the expected mass of GC-60 carrying 7 N-glycans is between 63 014 Da and 64 036 Da.

MALDI-TOF mass spectrometry of GC-60 shows two broad peaks with peak masses of 61.9 kDa and 62.8 kDa in accordance with the expected mass of GC-60 carrying either 5 or 6 N-glycans.

N-terminal amino acid sequence analysis of GC-60 showed that N2 is mainly glycosylated, N5 is completely glycosylated while N8 is only seldom glycosylated in acceptable agreement with the result obtained using mass spectrometry.

#### GC-61 (ATNTILNYTANTT-GCB):

The theoretical peptide mass of GC-61 is 56 970 Da. The N-terminal extension contains three additional potential glycosylation sites at N3, N7 and N11 compared to wtGCB. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 7 potential N-glycosylation sites.

Based on the same considerations as used for GC-36, the expected mass of GC-61 carrying 4 N-glycans is between 60 538 Da and 61 122 Da, the expected mass of GC-61 carrying 5 N-glycans is between 61 430 Da and 62 160 Da, the expected mass of GC-61 carrying 6 N-glycans is between 62 322 Da and 63 198 Da, and the expected mass of GC-61 carrying 7 N-glycans is between 63 214 Da and 64 236 Da.

MALDI-TOF mass spectrometry of GC-61 shows a very broad peak with peak mass between 61.5 kDa and 63.0 kDa in accordance with the expected mass of GC-61 carrying either 5 or 6 N-glycans.

N-terminal amino acid sequence analysis of GC-61 showed that N3 is completely glycosylated while N7 and N11 are partially glycosylated in acceptable agreement with the result obtained using mass spectrometry.

#### GC-62 (AANSTGNTINGT-GCB):

The theoretical peptide mass of GC-62 is 56 806 Da. The N-terminal extension contains three additional potential glycosylation sites at N3, N7 and N11 compared to wtGCB. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 7 potential N-glycosylation sites.



Based on the same considerations as those used for GC-36, the expected mass of GC-62 carrying 4 N-glycans is between 60 374 Da and 60 958 Da, the expected mass of GC-62 carrying 5 N-glycans is between 61 266 Da and 61 996 Da, the expected mass of GC-62 carrying 6 N-glycans is between 62 158 Da and 63 034 Da, and the expected mass of GC-62 carrying 7 N-glycans is between 63 050 Da and 64 072 Da.

MALDI-TOF mass spectrometry of GC-62 shows two broad peaks with peak masses of 61.6 kDa and 62.7 kDa in accordance with the expected mass of GC-62 carrying either 5 or 6 N-glycans.

N-terminal amino acid sequence analysis of GC-62 showed that N3 is completely glycosylated while N7 and N11 are partially glycosylated in acceptable agreement with the result obtained using mass spectrometry.

#### GC-63 (AVNWTSDNTSNGCB):

The theoretical peptide mass of GC-63 is 56 969 Da. The N-terminal extension contains three additional potential glycosylation sites at N3, N7 and N11 compared to wtGCB. Assuming that the wtGCB part of the variant is glycosylated like wtGCB, the variant has 7 potential N-glycosylation sites.

Based on the same considerations as those used for GC-36, the expected mass of GC-63 carrying 4 N-glycans is between 60 537 Da and 61 121 Da, the expected mass of GC-63 carrying 5 N-glycans is between 61 429 Da and 62 159 Da, the expected mass of GC-63 carrying 6 N-glycans is between 62 321 Da and 63 197 Da, and the expected mass of GC-63 carrying 7 N-glycans is between 63 213 Da and 64 235 Da.

MALDI-TOF mass spectrometry of GC-63 shows a major peak with a peak mass of 61.9 kDa in accordance with the expected mass of GC-63 carrying 5 N-glycans. In addition, a minor peak with a peak mass of 62.9 kDa is seen which corresponds to GC-63 carrying 6 N-glycans.

N-terminal amino acid sequence analysis of GC-63 showed that N3 and N7 are partially glycosylated. It was not possible to evaluate the glycosylation status of N11.

Furthermore, insect cell expressed N-terminally extended glycosylated polypeptide (GC-6 and GC-13) was subjected to N-terminal amino acid sequence analysis (using Procize from PE Biosystems, Foster City, CA). The sequencing cycle was blank for the Asn residue in both ANIT and ASPINAT N-terminal peptide additions, demonstrating that the introduced glycosylation site is glycosylated.

When subjecting GC-13 to mass spectrophotometry using the MALDI-TOF techniques on the Voyager DERP instrument (from PE-Biosystems, Foster City, CA) the following results were obtained:

The wildtype and ASPINAT-extended wildtype expressed in insect cells gave average masses very close to the calculated mass of 59,727 Da and 61,421 Da, respectively, assuming that four glycosylation sites were occupied by the carbohydrates FucGlcNAc<sub>2</sub>Man<sub>3</sub>.

#### EXAMPLE 4

##### Construction of plasmids for expression of FSH

5 A gene encoding the human FSH-alpha subunit was constructed by assembly of synthetic oligonucleotides by PCR using methods similar to the ones described in Stemmer et al. (1995) *Gene* 164, pp. 49-53. The native FSH-alpha signal sequence was maintained in order to allow secretion of the gene product. The codon usage of the gene was optimised for high expression in mammalian cells. Furthermore, in order to achieve high gene expression, an  
10 intron (from pCI-Neo (Promega)) was included in the 5' untranslated region of the gene. The synthetic gene was subcloned behind the CMV promoter in pcDNA3.1/Hygro (Invitrogen). The sequence of the resulting plasmid, termed pBvdH977, is given in SEQ ID NO:3 (FSH-alpha-coding sequence at position 1225 to 1570). Similarly, a synthetic gene encoding the wildtype human FSH-beta subunit was constructed. Also in this construct, the native signal  
15 sequence was maintained (except for a Lys to Glu mutation at position 2) in order to allow secretion, and the codon usage was optimised for high expression and an intron was included in the recipient vector (pcDNA3.1/Zeo (Invitrogen)). The sequence of the resulting FSH-beta - containing plasmid, termed pBvdH1022, is given in SEQ ID NO:4 (FSH-beta-coding sequence at position 1231 to 1617). A plasmid containing both the FSH-alpha and the FSH-beta  
20 encoding synthetic genes was generated by subcloning the FSH-alpha containing *NruI*-*PvuII* fragment from pBvdH977 into pBvdH1022 linearized with *NruI*. The resulting plasmid, in which the FSH-alpha and FSH-beta-expression cassettes are in direct orientation, was termed pBvdH1100.

##### 25 Expression of FSH in CHO cells

FSH was expressed in Chinese Hamster Ovary (CHO) K1 cells, obtained from the American Type Culture Collection (ATCC, CCL-61).

For transient expression of FSH, cells were grown to 95% confluency in serum-containing media (MEM $\alpha$  with ribonucleotides and deoxyribonucleotides (Life Technologies Cat # 32571-028) containing 1:10 FBS (BioWhittaker Cat # 02-701F) and 1:100 penicillin and streptomycin (BioWhittaker Cat # 17-602E), or Dulbecco's MEM/Nut.-mix F-12 (Ham) L-glutamine, 15 mM Hepes, pyridoxine-HCl (Life Technologies Cat # 31330-038) with the same additives. FSH-encoding plasmids were transfected into the cells using Lipofectamine 2000 (Life Technologies) according to the manufacturer's specifications. 24-48 hrs after transfection, culture media were collected, centrifuged and filtered through 0.22 micrometer filters to remove cells.

Stable clones expressing FSH were generated by transfection of CHO K1 cells with FSH-encoding plasmids followed by incubation of the cells in selective media (for instance one of the above media containing 0.5 mg/ml zeocin for cells transfected with plasmid pBvdHI100). Stably transfected cells were isolated and sub-cloned by limited dilution. Clones that produced high levels of FSH were identified by ELISA.

More specifically, the concentration of FSH in samples was quantified by use of a commercial immunoassay (DRG FSH EIA, DRG Instruments GmbH, Marburg, Germany). DRG FSH EIA is a solid phase immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a monoclonal antibody directed towards a unique antigenic site on the FSH- $\alpha$  subunit. An aliquot of FSH-containing sample (diluted in H<sub>2</sub>O with 0.1% BSA) and an anti-FSH antiserum conjugated with horseradish peroxidase are added to the coated wells. After incubation, unbound conjugate is washed off with water. The amount of bound peroxidase is proportional to the concentration of FSH in the sample. The intensity of colour developed upon addition of substrate solution is proportional to the concentration of FSH in the sample.

25

#### Large-scale production of FSH in CHO cells

The cell line CHO K1 1100-5, stably expressing human FSH, was passed 1:10 from a confluent culture and propagated as adherent cells in serum-containing medium Dulbecco's MEM/Nut.-mix F-12 (Ham) L-glutamine, 15 mM Hepes, pyridoxine-HCl (Life Technologies Cat # 31330-038), 1:10 FBS (BioWhittaker Cat # 02-701F), 1:100 penicillin and streptomycin (BioWhittaker Cat # 17-602E) until confluence in a 10 layer cell factory (NUNC #165250). The media was then changed to serum-free media: Dulbecco's MEM/Nut.-mix F-12 (Ham) L-glutamine, pyridoxine-HCl (Life Technologies Cat # 21041-025) with the addition of 1:500 ITS-A (Gibco/BRL # 51300-044), 1:500 EX-CYTE VLE (Serological Proteins Inc. # 81-129)

and 1:100 penicillin and streptomycin (BioWhittaker Cat # 17-602E). Subsequently, every 24 h, culture media were collected and replaced with 1 fresh liter of the same serum-free media. The collected media was filtered through 0.22  $\mu$ m filters to remove cells. Growth in cell factories was continued with daily harvests and replacements of the culture media until FSH yields dropped below one-fourth of the initial expression level (typically after 10-15 days).

## EXAMPLE 5

### 10 Purification of FSH wildtype and variants

Three chromatographic steps were employed to obtain highly purified FSH. First an anion exchanger step, then hydrophobic interaction chromatography (HIC) and finally an immunoaffinity step using an FSH- $\beta$  specific monoclonal antibody.

Culture supernatants were prepared as described in Example 4. Filtered culture  
15 supernatants were concentrated 10 to 20 times by ultrafiltration (10 kD cut-off membrane), pH was adjusted to 8.0 and conductivity to 10 - 15 mS/cm, before application on a DEAE Sepharose (Pharmacia) anion exchanger column, which had been equilibrated in ammonium acetate buffer (0.16 M, pH 8.0). Semipurified FSH was recovered both in the unbound flow-through fraction as well as in the wash fraction using 0.16 M ammonium acetate, pH 8.0. The  
20 flow through and wash fractions were pooled and ammonium sulfate was added from a stock solution (4.5 M) to obtain a final concentration of 1.5 M  $(\text{NH}_4)_2\text{SO}_4$ . The pH was adjusted to 7.0.

The partially purified FSH was subsequently applied on a 25 ml butyl Sepharose (Pharmacia) HIC column. After application, the column was washed with at least 3 column  
25 volumes of 1.5 M  $(\text{NH}_4)_2\text{SO}_4$ , 20 mM ammonium acetate, pH 7 (until the absorbance at 280 nm reached baseline level) and FSH was eluted with 4 column volumes of buffer B (20 mM ammonium acetate, pH 7). FSH enriched fractions from the HIC step were pooled, concentrated and diafiltrated using Vivaspin 20 modules, 10 kD cut-off membrane (Vivascience), to a 50 mM sodium phosphate, 150 mM NaCl, pH 7.2.

30 For the third chromatographic step, an anti-FSH- $\beta$  monoclonal antibody (RDI-FSH909, Research Diagnostics) was immobilized to CNBr-activated Sepharose (Pharmacia) using a standard procedure from the supplier. Approximately 1 mg antibody was coupled per ml resin.

The immunoaffinity resin was packed in plastic columns and equilibrated with 50 mM sodium phosphate, 150 mM NaCl, pH 7.2 before application.

The buffer exchanged eluate from the butyl HIC step was applied on the antibody column by use of gravity flow. This was followed by several washing steps in 50 mM sodium phosphate solutions (0.5 M NaCl and 1 M NaCl, both pH 7.2). Elution was performed using either 1 M  $\text{NH}_3$  or 0.6 M  $\text{NH}_3$ , 40% (v/v) isopropanol and the eluate was immediately neutralized with 1 M acetic acid to pH 6-8.

The purified FSH bulk product was concentrated and diafiltrated using Vivaspin 20 modules, 10 kD cut-off membrane (Vivascience), to a 50 mM sodium phosphate, 150 mM NaCl, pH 7.2. For subsequent storage, BSA was added to 0.1% (w/v) and the purified FSH was microfiltrated using a 0.22  $\mu\text{m}$  filter prior to storage at - 80°C.

SDS-PAGE, run under non-dissociating conditions (without boiling), showed wildtype FSH migrating as an apparent 42 $\pm$ 3 kDa band, slightly diffuse due to heterogeneity in the attached carbohydrates. The purity was about 80-90%. N-terminal sequencing showed that the  $\alpha$ -chain had the expected N-terminal sequence starting with residue 1 (SEQ ID NO:5) and the  $\beta$ -chain starting with residue 3 (SEQ ID NO:6). These N-terminal sequences have been found previously for recombinant FSH produced in CHO cells (Olijve, W. et al. (1996) *Mol. Hum. Reprod.* 2, 371-382).

## 20 EXAMPLE 6

### FSH in vitro activity assay

#### 6.1 FSH assay Outline

It has previously been published that activation of the FSH receptor by FSH leads to an increase in the intracellular concentration of cAMP. Consequently, transcription is activated at promoters containing multiple copies of the cAMP response element (CRE). It is thus possible to measure FSH activity by use of a CRE luciferase reporter gene introduced into CHO cells expressing the FSH receptor.

#### 6.2 Construction of a CHO FSH-R / CRE-luc cell line

30 Stable clones expressing the human FSH receptor were produced by transfection of CHO K1 cells with a plasmid containing the receptor cDNA inserted into pcDNA3 (Invitrogen) followed by selection in media containing 600 microg/ml G418. Using a

commercial cAMP-SPA RIA (Amersham), clones were screened for the ability to respond to FSH stimulation. On the basis of these results, an FSH receptor-expressing CHO clone was selected for further transfection with a CRE-luc reporter gene. A plasmid containing the reporter gene with 6 CRE elements in front of the Firefly luciferase gene was co-transfected with a plasmid conferring Hygromycin B resistance. Stable clones were selected in the presence of 600 microg/ml G418 and 400 microg/ml Hygromycin B. A clone yielding a robust luciferase signal upon stimulation with FSH ( $EC_{50} \sim 0.01$  IU/ml) was obtained. This CHO FSH-R / CRE-luc cell line was used to measure the activity of samples containing FSH.

#### 10 6.3 FSH luciferase assay

To perform activity assays, CHO FSH-R / CRE-luc cells were seeded in white 96 well culture plates at a density of about 15,000 cells/well. The cells were in 100  $\square$  DMEM/F-12 (without phenol red) with 1.25% FBS. After incubation overnight (at 37°C, 5% CO<sub>2</sub>), 25  $\mu$ l of sample or standard diluted in DMEM/F-12 (without phenol red) with 10% FBS was added to each well. The plates were further incubated for 3 hrs, followed by addition of 125  $\mu$ l LucLite substrate (Packard Bioscience). Subsequently, plates were sealed and luminescence was measured on a TopCount luminometer (Packard) in SPC (single photon counting) mode.

#### EXAMPLE 7

20

##### Construction and analysis of a variant form of FSH containing two N-linked glycosylations at the N-terminus of the alpha subunit

A construct encoding a modified form of FSH-alpha, having two additional sites for N-linked glycosylation at its N-terminus was generated by site-directed mutagenesis using standard DNA techniques known in the art. A DNA fragment encoding the sequence Ala-Asn-Ile-Thr-Val-Asn-Ile-Thr-Val was inserted immediately upstream of the mature FSH-alpha sequence in pBvdH977. The sequence of the resulting plasmid, termed pBvdH1163, is given in SEQ ID NO:7 (modified FSH-alpha-encoding sequence at position 1225 to 1599). A plasmid encoding both subunits was constructed by subcloning the FSH-containing *NruI-PvuII* fragment from pBvdH1163 into pBvdH1022 (Example 4), which had been linearized with *PvuII*. The resulting plasmid was termed pBvdH1208.

For expression of the variant form of FSH containing two N-linked glycosylations at the N-terminus of the alpha subunit (termed FSH1208), CHO K1 cells were transfected with

pBvdH1208 or co-transfected with a combination of pBvdH1163, encoding the modified alpha subunit and pBvdH1022, encoding the wildtype beta subunit. Transient expressions, isolation of stable expression clones, and large-scale production of FSH1208 were performed as described for wildtype FSH in Example 4.

5 The FSH content of samples was analysed by Western Blotting: Proteins were separated by SDS-PAGE and a standard Western blot was performed using rabbit anti human FSH (AHP519, Serotec) or mouse anti human FSH-alpha (MCA338, Serotec) as primary antibody, and an ImmunoPure Ultra Sensitive ABC Peroxidase Staining Kit (Pierce) for detection. Western blotting showed that FSH1208 had a larger molecular mass than wildtype  
10 FSH, indicating that the introduction of acceptor sites for N-linked glycosylation at the N-terminus of the alpha subunit indeed lead to hyperglycosylation of FSH. For analysis of pI, samples were separated on pH 3-7 IEF gels (NOVEX). After electrophoresis, proteins were blotted onto Immobilon-P (Millipore) membranes and a Western blot was performed as described above, using the same antibodies and detection kit. Isoelectric focusing demonstrated  
15 that the FSH forms in the FSH1208 samples were found in a lower pI range than wildtype FSH. Thus, the pH interval for FSH1208 isoforms was about 3.0-4.5 versus about 4.0-5.2 for wildtype FSH. This indicated that FSH1208 molecules are on average more negatively charged than the wild type, which is attributed to the presence of additional sialic acid residues.

FSH1208 was purified and characterized as described in Example 5. SDS-PAGE, run  
20 under non-dissociating conditions (without boiling), showed FSH1208 migrating as an apparent  $55 \pm 5$  kDa band, slightly diffuse due to heterogeneity in the attached carbohydrates. The purity was about 80-90%. N-terminal sequencing showed that while the  $\beta$ -chain had the same N-terminal sequence as wildtype FSH, the sequence of  $\alpha$ -chain was in agreement with this subunit carrying the expected N-terminal extension ANITVNTIV, in which both  
25 asparagines residues are glycosylated.

The specific activity of FSH1208 was determined by measurement of the *in vitro* bioactivity (FSH luciferase assay, Example 6) and the FSH content of the samples by ELISA. The specific activity of FSH1208 was found to be about one-third of that of the wildtype reference.

30 A pharmacokinetic study performed as follows:

Immature 26-27 days old female Sprague-Dawley rats were injected i.v. with 3-4 microg FSH, produced, purified and analyzed as described above. Subsequently, blood samples were taken at various time-points after injection. FSH concentrations in serum samples were determined by ELISA, as described above.

*In vivo* bioactivity of wildtype recombinant FSH and variant forms may be evaluated by the ovarian weight augmentation assay (Steelman and Pohley (1953) *Endocrinology* 53, 604-616). Furthermore, the ability of FSH and variant forms to stimulate maturation of follicles in laboratory animals may be detected with e.g. ultrasound equipment. The experiment showed

5 that 24 hours after injection of equal amounts of wildtype FSH and FSH1208, the sera of FSH1208-treated animals contained more than 10 fold more remaining immunoreactive material than the sera from animals treated with wildtype FSH.

#### EXAMPLE 8

##### 10 Construction and analysis of other FSH variants containing additional glycosylation sites

Plasmids encoding variant forms of FSH-alpha and FSH-beta containing additional sites for N-linked glycosylation were generated by site-directed mutagenesis using standard DNA techniques known in the art. The following amino acid substitutions and/or insertions were generated:

15 FSH1147: Amino acid Tyr58 of mature FSH-beta altered to Asn

FSH1349: N-terminus of mature FSH-alpha altered from APD QDC... to: APNDTVNFT QDC

...

FSH1354: N-terminus of mature FSH-beta altered from NS CEL ... to: NSNTVNVITV CEL ...

Plasmids encoding the variant forms were transiently expressed in CHO K1 cells as

20 described in Example 4. Plasmids encoding FSH-alpha variants were co-transfected with a plasmid encoding wild-type FSH-beta and vice versa.

Western and isoelectric focusing were performed on culture media samples as described above. The variant forms had higher molecular weights than the wild-type, indicating that the additional acceptor sites for N-linked glycosylation had indeed been glycosylated.

25 Furthermore, isoelectric focusing showed that the different isoforms of the three FSH variants were spread over a lower pI range than the wildtype. This strongly suggests that the variant forms had a higher sialic acid content than the wildtype.

*In vitro* FSH activities of the resulting media samples were analysed as described in Example 6.3. All three variant forms were able to stimulate the CHO FSH-R / CRE-luc cells,

30 indicating that these variant FSH forms have retained significant FSH activity.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that



various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques, methods, compositions, apparatus and systems described above may be used in various combinations. All publications, patents, patent applications, or other documents cited in this application are incorporated by reference in their  
5 entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document were individually indicated to be incorporated by reference for all purposes.

## CLAIMS

1. A glycosylated polypeptide comprising the primary structure

5  $\text{NH}_2\text{-X-Pp-COOH}$

wherein

X is a peptide addition comprising or contributing to a glycosylation site, and

Pp is a polypeptide of interest.

10 2. A glycosylated polypeptide comprising the primary structure  $\text{NH}_2\text{-P}_x\text{-X-P}_y\text{-COOH}$ ,  
wherein

$\text{P}_x$  is an N-terminal part of a polypeptide Pp of interest,

$\text{P}_y$  is a C-terminal part of said polypeptide Pp, and

X is a peptide addition comprising or contributing to a glycosylation site.

15 3. The polypeptide according to claim 1 or 2, wherein Pp is a mature polypeptide.

4. The polypeptide according to claim 2 or 3, wherein  $\text{P}_x$  is a non-structural N-terminal  
part of a mature polypeptide Pp, and  $\text{P}_y$  is a structural C-terminal part of said mature  
polypeptide.

5. The polypeptide according to any of claims 1-4, wherein Pp is a native polypeptide.

20 6. The polypeptide according to any of claims 1-5, wherein Pp is a variant of a native  
polypeptide.

7. The polypeptide according to claim 6, wherein Pp comprises at least one introduced  
and/or at least one removed glycosylation site for a non-peptide moiety as compared to the  
corresponding native polypeptide.

25 8. The polypeptide according to any of claims 1-7, wherein Pp is of mammalian origin.

9. The polypeptide according to claim 8, wherein Pp is of human origin.

10. The polypeptide according to any of claims 1-9, wherein Pp is a therapeutic  
polypeptide.

11. The polypeptide according to any of claims 1-10, wherein Pp is selected from the  
30 group consisting of an antibody or antibody fragment, a plasma protein, an erythrocyte or  
thrombocyte protein, a cytokine, a growth factor, a profibrinolytic protein, a protease inhibitor,  
an antigen, an enzyme, a ligand, a receptor, or a hormone.

12. The polypeptide according to any of claims 1-7, 10 or 11, wherein Pp is of  
microbial origin.

13. The polypeptide according to claim 12, wherein Pp is a microbial enzyme.

14. The polypeptide according to claim 13, wherein Pp is selected from the group consisting of protease, amylase, amyloglucosidase, pectinase, lipase and cutinase.

15. The polypeptide according to any of claims 1-14, wherein X comprises 1-500  
5 amino acid residues.

16. The polypeptide according to claim 15, wherein X comprises 2-50 amino acid residues, such as 3-20 amino acid residues.

17. The polypeptide according to any of claims 1-16, wherein X comprises 1-20, in particular 1-10 glycosylation sites.

10 18. The polypeptide according to any of the preceding claims, wherein X comprises at least one glycosylation site within a stretch of 30 amino acid residues, such as at least one within 20 amino acid residues, in particular at least one within 10 amino acid residues, in particular 1-3 glycosylation sites.

19. The polypeptide according to any of claims 1-18, wherein X comprises at least two  
15 glycosylation sites, wherein two of said sites are separated by at most 10 amino acid residues, none of which comprises a glycosylation site.

20. The polypeptide according to any of claims 6-19, wherein the polypeptide Pp is a variant of a native polypeptide which, as compared to said native polypeptide, comprises at least one introduced or at least one removed glycosylation site.

20 21. The polypeptide according to claim 20, wherein the polypeptide Pp comprises at least one introduced glycosylation site, in particular 1-5 introduced glycosylation sites.

22. The polypeptide according to any of claims 1-21, wherein X has an N residue in position -2 or -1, and Pp has a T or an S residue in position +1 or +2, respectively, the residue numbering being made relative to the N-terminal amino acid residue of Pp.

25 23. The polypeptide according to any of claims 1-22, wherein X has the structure  $X_1$ -N- $X_2$ -[T/S]-Z, wherein  $X_1$  is a peptide comprising at least one amino acid residue or is absent,  $X_2$  is any amino acid residue different from a proline residue, and Z is absent or a peptide comprising at least one amino acid residue, the N-terminal amino acid residue of which is different from a proline.

30 24. The polypeptide according to claim 23, wherein  $X_1$  is absent,  $X_2$  is an amino acid residue selected from the group consisting of I, A, G, V and S, and Z comprises at least one amino acid residue, the N-terminal amino acid residue of which is different from proline.

25. The polypeptide according to claim 24, wherein Z is a peptide comprising 1-50 amino acid residues, preferably comprising 1-10 glycosylation sites.

26. The polypeptide according to claim 25, wherein  $X_1$  comprises at least one amino acid residue,  $X_2$  is an amino acid residue selected from the group consisting of I, A, G, V and S, and Z is absent.

27. The polypeptide according to claim 26, wherein  $X_1$  is a peptide comprising 1-50 amino acid residues, preferably comprising 1-10 glycosylation sites.

28. The polypeptide according to any of claims 1-27, wherein X comprises a peptide sequence selected from the group consisting of INA[T/S], GNI[T/S], VNI[T/S], SNI[T/S], ASNI[T/S], NI[T/S], SPINA[T/S], ASPINA[T/S], ANI[T/S]ANI[T/S]ANI, ANI[T/S]GSNI[T/S]GSNI[T/S], FNI[T/S]VNI[T/S]V, YNI[T/S]VNI[T/S]V, AFNI[T/S]VNI[T/S]V, AYNI[T/S]VNI[T/S]V, APND[T/S]VNI[T/S]V, ANI[T/S], ASNS[T/S]NNG[T/S]LNA[T/S], ANH[T/S]NE[T/S]NA[T/S], GSPINA[T/S], ASPINA[T/S]SPINA[T/S], ANN[T/S]JNY[T/S]JNW[T/S], ATNI[T/S]JLNY[T/S]JAN[T/S]T, AANS[T/S]GNI[T/S]JNG[T/S], AVNW[T/S]JSDN[T/S]JSNS[T/S], GNA[T/S], AVNW[T/S]JSDN[T/S]JSNS[T/S], ANN[T/S]JNY[T/S]JNS[T/S], ANNTNYTNWT, ANI[T/S]VNI[T/S]V, ND[T/S]VNI[T/S]V and NI[T/S]VNI[T/S]V wherein [T/S] is either a T or an S residue, preferably a T residue.

29. The polypeptide according to any of claims 1-29, wherein the peptide addition X comprises the sequence NSTQNATA or ANLTVRNLTNRNVTV.

30. The polypeptide according to any of the preceding claims, further comprising an attachment group for a second non-peptide moiety, said attachment group being linked to the second non-peptide moiety.

31. The polypeptide according to claim 30, wherein the non-peptide moiety is selected from the group consisting of a polymer molecule, a lipophilic group and an organic derivatizing agent.

32. The polypeptide according to claim 30 or 31, wherein the attachment group for the non-peptide moiety is one present on an amino acid residue selected from the group consisting of the N-terminal amino acid residue, the C-terminal amino acid residue, lysine, cysteine, arginine, glutamine, aspartic acid, glutamic acid, serine, tyrosine, histidine, phenylalanine and tryptophan.

33. The polypeptide according to any of claims 30-32, wherein the polypeptide Pp is a variant of a native polypeptide, which as compared to said native polypeptide, comprises at least one introduced and/or at least one removed attachment group for the second non-peptide moiety.

34. The polypeptide according to claim 33, wherein the polypeptide Pp comprises at least one introduced attachment group, in particular 1-5 introduced attachment groups.

35. The polypeptide according to any of the preceding claims, which has a molecular weight of at least 67 kDa, in particular at least 70 kDa.

5 36. The polypeptide according to any of the preceding claims, which has at least one of the following properties relative to the polypeptide Pp, the properties being measured under comparable conditions:

*in vitro* bioactivity which is at least 25% of that of the polypeptide Pp as measured under comparable conditions, increased affinity for a mannose receptor or other carbohydrate  
10 receptors, increased serum half-life, increased functional *in vivo* half-life, reduced renal clearance, reduced immunogenicity, increased resistance to proteolytic cleavage, improved targeting to lysosomes, macrophages and/or other subpopulations of human cells, improved stability in production,  
improved shelf life, improved formulation, e.g. liquid formulation, improved purification,  
15 improved solubility, and/or improved expression.

37. A nucleotide sequence encoding the polypeptide according to any of claims 1-36.

38. A vector comprising the nucleotide sequence according to claim 37.

39. A host cell transformed or transfected with a nucleotide sequence according to claim 37, or a vector according to claim 38.

20 40. The host cell according to claim 39, which is a glycosylating host cell.

41. The host cell according to claim 40, which is a mammalian cell, an invertebrate cell such as an insect cell, a yeast cell or a plant cell, or a transgenic animal.

42. A method of producing the polypeptide according to any of claims 1-36, comprising culturing a host cells according to any of claims 39-41 under conditions permitting expression  
25 of the polypeptide and recovering the polypeptide from the culture.

43. A method of producing a polypeptide according to any of claims 30-36 attached to a second non-peptide moiety, which method comprises subjected the polypeptide to conjugation to the non-peptide moiety under conditions for the conjugation to take place.

44. The method according to claim 43, wherein the polypeptide is prepared by the  
30 method according to 42 or 43.

45. A method of preparing a nucleotide sequence according to claim 37, which method comprises

a) subjecting a nucleotide sequence encoding the polypeptide Pp to elongation mutagenesis,

- b) expressing the mutated nucleotide sequence obtained in step a) in a suitable host cell, optionally
- c) conjugating polypeptides expressed in step b) to a second non-peptide moiety,
- d) selecting polypeptides obtained in step b) or c) which comprises at least one oligosaccharide moiety and optionally a second non-peptide moiety attached to the peptide addition part of the polypeptide, and
- e) isolating a nucleotide sequence encoding the polypeptide selected in step d).

46. The method according to claim 45, which further comprises screening polypeptides resulting from step b) or c) for at least one improved property, and wherein the selection step d) further comprises selecting polypeptides having such improved property.

47. The method according to claim 45 or 46, wherein the elongation mutagenesis is conducted so as to enrich for codons encoding an amino acid residue comprising a glycosylation site.

48. The method according to claim 45 or 46, wherein the elongation mutagenesis is conducted so as to enrich for codons required for introduction of an attachment group for a second non-peptide moiety.


49. The method according to any of claims 44-48, which further comprises subjecting the part of the nucleotide sequence encoding Pp to mutagenesis to remove and/or introduce glycosylation sites and optionally amino acid residues comprising an attachment group for the second non-peptide moiety.

50. The method according to any of claims 45-49, wherein the selection in step d) is performed so as to select a conjugate having at least one of the properties defined in claim 36.

51. A method of producing a glycosylated polypeptide encoded by a nucleotide sequence prepared according to claims 45-50, wherein the nucleotide sequence encoding the polypeptide selected in step c) is expressed in a glycosylating host cell and the resulting glycosylated expressed polypeptide is recovered.

52. A method of improving one or more selected properties of a polypeptide Pp of interest, which method comprises

- a) preparing a nucleotide sequence encoding a polypeptide with the primary structure



wherein

X is a peptide addition comprising or contributing to a glycosylation site that is capable of conferring the selected improved property/ies to the polypeptide Pp,

b) expressing the nucleotide sequence of a) in an suitable host cell, optionally

c) conjugating the expressed polypeptide of b) to a second non-peptide moiety, and

5 d) recovering the polypeptide resulting from step c).

53. The method according to claim 52, wherein the polypeptide Pp and/or the peptide addition X is as defined in any of claims 1-40.

54. The method according to claim 52 or 53, wherein the nucleotide sequence of step a) is prepared by subjecting a nucleotide sequence encoding the polypeptide Pp to random  
10 elongation mutagenesis.


55. The method according to claim 54, wherein the random elongation mutagenesis is conducted so as to enrich for codons encoding an amino acid residue comprising or contributing to a glycosylation site and/or an attachment group for the second non-peptide moiety.

15 56. The method according to any of claims 52-55, wherein, in the preparation of the nucleotide sequence of a), the part of the nucleotide sequence encoding the polypeptide Pp is subjected to mutagenesis to remove and/or introduce a glycosylation site or to remove and/or introduce an attachment group for a second non-peptide moiety.

57. The method according to any of claims 52-56, wherein the property/ies to be  
20 improved is/are selected from the properties defined in claim 37.

1/2

Fig. 1





2/2




Fig. 2

## SEQUENCE LISTING

&lt;110&gt; MAXYGEN APS

&lt;120&gt; N-TERMINALLY EXTENDED POLYPEPTIDES

&lt;130&gt; 0217WO210

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 497

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (495)

&lt;223&gt; R or H

&lt;400&gt; 1

Ala	Arg	Pro	Cys	Ile	Pro	Lys	Ser	Phe	Gly	Tyr	Ser	Ser	Val	Val	Cys
1				5					10					15	
Val	Cys	Asn	Ala	Thr	Tyr	Cys	Asp	Ser	Phe	Asp	Pro	Pro	Thr	Phe	Pro
		20						25					30		
Ala	Leu	Gly	Thr	Phe	Ser	Arg	Tyr	Glu	Ser	Thr	Arg	Ser	Gly	Arg	Arg
		35					40					45			
Met	Glu	Leu	Ser	Met	Gly	Pro	Ile	Gln	Ala	Asn	His	Thr	Gly	Thr	Gly
	50					55					60				
Leu	Leu	Leu	Thr	Leu	Gln	Pro	Glu	Gln	Lys	Phe	Gln	Lys	Val	Lys	Gly
	65				70					75				80	
Phe	Gly	Gly	Ala	Met	Thr	Asp	Ala	Ala	Ala	Leu	Asn	Ile	Leu	Ala	Leu
			85					90						95	
Ser	Pro	Pro	Ala	Gln	Asn	Leu	Leu	Leu	Lys	Ser	Tyr	Phe	Ser	Glu	Glu
			100					105					110		
Gly	Ile	Gly	Tyr	Asn	Ile	Ile	Arg	Val	Pro	Met	Ala	Ser	Cys	Asp	Phe
		115				120						125			
Ser	Ile	Arg	Thr	Tyr	Thr	Ala	Asp	Thr	Pro	Asp	Asp	Phe	Gln	Leu	
	130					135				140					
His	Asn	Phe	Ser	Leu	Pro	Glu	Glu	Asp	Thr	Lys	Leu	Lys	Ile	Pro	Leu
	145				150					155				160	
Ile	His	Arg	Ala	Leu	Gln	Leu	Ala	Gln	Arg	Pro	Val	Ser	Leu	Leu	Ala
			165					170						175	
Ser	Pro	Trp	Thr	Ser	Pro	Thr	Trp	Leu	Lys	Thr	Asn	Gly	Ala	Val	Asn
			180					185					190		

Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly Asp Ile Tyr His Gln Thr  
 195 200 205  
 Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp Ala Tyr Ala Glu His Lys  
 210 215 220  
 Leu Gln Phe Trp Ala Val Thr Ala Glu Asn Glu Pro Ser Ala Gly Leu  
 225 230 235 240  
 Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly Phe Thr Pro Glu His Gln  
 245 250 255  
 Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro Thr Leu Ala Asn Ser Thr  
 260 265 270  
 His His Asn Val Arg Leu Leu Met Leu Asp Asp Gln Arg Leu Leu Leu  
 275 280 285  
 Pro His Trp Ala Lys Val Val Leu Thr Asp Pro Glu Ala Ala Lys Tyr  
 290 295 300  
 Val His Gly Ile Ala Val His Trp Tyr Leu Asp Phe Leu Ala Pro Ala  
 305 310 315 320  
 Lys Ala Thr Leu Gly Glu Thr His Arg Leu Phe Pro Asn Thr Met Leu  
 325 330 335  
 Phe Ala Ser Glu Ala Cys Val Gly Ser Lys Phe Trp Glu Gln Ser Val  
 340 345 350  
 Arg Leu Gly Ser Trp Asp Arg Gly Met Gln Tyr Ser His Ser Ile Ile  
 355 360 365  
 Thr Asn Leu Leu Tyr His Val Val Gly Trp Thr Asp Trp Asn Leu Ala  
 370 375 380  
 Leu Asn Pro Glu Gly Gly Pro Asn Trp Val Arg Asn Phe Val Asp Ser  
 385 390 395 400  
 Pro Ile Ile Val Asp Ile Thr Lys Asp Thr Phe Tyr Lys Gln Pro Met  
 405 410 415  
 Phe Tyr His Leu Gly His Phe Ser Lys Phe Ile Pro Glu Gly Ser Gln  
 420 425 430  
 Arg Val Gly Leu Val Ala Ser Gln Lys Asn Asp Leu Asp Ala Val Ala  
 435 440 445  
 Leu Met His Pro Asp Gly Ser Ala Val Val Val Val Leu Asn Arg Ser  
 450 455 460  
 Ser Lys Asp Val Pro Leu Thr Ile Lys Asp Pro Ala Val Gly Phe Leu  
 465 470 475 480  
 Glu Thr Ile Ser Pro Gly Tyr Ser Ile His Thr Tyr Leu Trp Xaa Arg  
 485 490 495

Gln

<210> 2  
<211> 1551  
<212> DNA  
<213> Homo sapiens

<400> 2  
atggctggcga gcctcacagg attgcttcta cttcaggcag tgcctgtggc atcagggtgc 60  
cgccctctgca tcctctaaag cttcggtclac agctcggtgg tgtgtgtc tg caatggccaa 120  
tactgtgact cctttgaccc ccgcaccttt cctgcctctg gtacctctca cgcctatgag 180  
agtcacacgca gggggcgacg gatggagctg agtatggggc ccctccaggc taatcacacg 240  
ggcacaggcc tgctactgac cctgcagcca gaacagaagt tccagaaagt gaagggtatt 300  
ggagggggcca tgacagatgc tgcctgtctc aacatccttg ccctgtcacc cctcgcccaa 360  
aatttgtctac ttaaatcgta ctctctgaa gaaggaatcg gatataacat catcggggta 420  
cccatgggcca gctgtgactt ctccatccgc acctacacct atgcagacac ccctgatgat 480  
ttccagttgc acaacttcag cctccagag gaagatacca agctcaagat acccctgatt 540  
caccgagcac tgcagttggc ccagcgtccc gtttctactc ttgccagccc ctggacatca 600  
cccaacttggc tcaagaccaa tggagcgggtg aatgggaagg ggttcaactca gggacagccc 660  
ggagacatct accaccagac ctggggccaga taacttbtga agtttcttga tgcctatgct 720  
gagcacaagt tcaagttctg ggacgtgaca gctgaaaatg agccttctcg tgggctgttg 780  
agtggtatacc ccttccagtg cctgggtctc acccctgaac atcagcgaga cttaattgac 840  
cgtgacctag gctctacct cgcacaacagt actcaacca atgtcgcctt actcatgtcg 900  
gatgaccaac gtttgtgtct gcccaactgg gcaaaaggtg tgcctgacaga cccagaagca 960  
gctaaatatg ttcattggcat tgcgtacatc tggtaacctg actttcttggc tccagccaaa 1020  
gcaacccctag gggagacaca ccgcctgttc cccaacacca tgcctcttgc ctacaggccc 1080  
tgtgtgggtc ccaagttctg ggagcagagt gtgcggctag gctcctggga tcgagggatg 1140  
cagtagacgc acagcatcat cagcaacctc ctgtaccatg tggctcggctg gaccagctgg 1200  
aaccttggcc tgaacccga aggaggaccc aattgggtgc gtaactttgt cgacagtcoc 1260  
atcattgtag acatcaccaa ggacacgttt tacaaacagc ccaatgttcta ccaccttggc 1320  
catttcagca agttcattcc tgaaggctcc cagagagtg ggcctgggttc cagtcagaag 1380  
aacgacctgg acgcagtgcc attgatgcac ccgagtgct ctgctgttgt ggtcgtgcta 1440  
aacctgctct ctaaggatgt gctcttacc atcaaggtc ctgctgtggg ctctctggag 1500  
acaatctcac ctggctactc cattcacacc tacctgtggc gtcgccagt g a 1551

<210> 3  
<211> 6186  
<212> DNA  
<213> Artificial sequence

<220>  
<221> exon  
<222> (1225)..(1572)  
<223> Coding sequence for human FSH-alpha

<400> 3  
gacggatcgg gagatctccc gatcccttat ggtcactct cagtacaatc tgcctgatg 60  
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120  
cgagcaaat ttaagctaca acaaggcaag gcttgacoga caattgcagc aagaatctgc 180  
ttagggttag gcgttttgcg ctgcttcgag atgtacgggc cagatatacg cgttgacatt 240





gagcgggttc ggcccatctog gaocgcagg aatcggtcaa tacactacat ggcgtgattt 3152  
 catatgcgcg attgctgac ccatgtgta tcactggcaa actgtgatgg acgacacgct 3212  
 cagtcgctcc gtgcgcagg ctctogatga gctgatgctt tgggcgagg actgcccgga 3272  
 agtcgggcac ctctgacag cggatttcgg ctccaacaat gtctgacgg acaatggcgg 3332  
 cataacagcg gtcaattgact ggagcgaggc gatgttgggg gattcccaat acgaggctgc 3392  
 caacatcttc ttctggaggc cgtggttggc ttgtatggag cagcagaogc gctaactcga 3452  
 goggaggcat ccggagcttg caggatcgcc ggggctccgg gcgtatatagc tccgcatggg 3512  
 tcttgaccaa ctctatcaga gcttggttga cggcaatttc gatgatgcag cttgggcgca 3572  
 gggctcagtc gacgaatcg tccgatccgg agccgggact gtccggcgta cacaatcgc 3632  
 ccgcagaagc cgggcgctct ggcacgatgg ctgtgtagaa gtactcgccg atagtgga 3692  
 ccgacgcccc agcactcgtc cggggcaca ggaatagcac gtgctacgag atttcgat 3752  
 ccgcgcgcgc ttctatgaaa ggttgggctt cggaaatcgt ttccgggacg ccggctggat 3812  
 gatctccagc cgcggggtac tcatgctgga gttcttcgoc caccocaaact tgtttattgc 3872  
 agcttataat ggttacaaat aaagcaatag catccaaat ttacaaata aagcattttt 3932  
 ttcaactgcat tctagtgtg gtttgcga actcatcat gtatcttct atgtctgtat 3992  
 acogtcgacc tctagctaga gcttggcgta atcatggta tagctgttc ctgtgtgaaa 4052  
 ttgttatcgc ctccaaatto cacaacaat acgagccgga agcataaagt gtaagccctg 4112  
 ggggtgcctaa tgagtgcgt aactcacatt aattgcgttg cgtcactgc ccgcttcca 4172  
 gtccgggaac ctgtgtgccc agctgcatta atgaatcgcc caacgoggg ggagaggcgg 4232  
 ttgtcgtatt gggcgctctt ccgcttcttc gctcaactgac tgcgtcgct ccgctgttcg 4292  
 gctgcggcga cgggtatcag ctcaactcaa ggggtaata cggttatcca cagaatcagg 4352  
 ggataacgca ggaagaaca tbtgagcaaa aggcacgcaa aaggccaggga accgtaaaaa 4412  
 ggccgcgttg ctggcgcttt tccataggct ccgccccct gacgagcacc acaaaaatcg 4472  
 acgtcaagt cagagggtgc gaaaaccgac aggaactaaa agataccagg cgtttccccc 4532  
 tggagctcc ctctgcgct ctctgttcc gaccctgcg cttaccggat acctgtccgc 4592  
 ctttctccct tcgggaagcg tggcgcttcc tcaatgctca cgtgtagggt atctcagttc 4652  
 ggtgtaggto gttcgtcca agctgggctg tgtgcacgaa ccccccgttc agcccgacgg 4712  
 ctgcgcctta tccggttaact atcgtcttga gtccaacccg gtaagacagc acttatcgcc 4772  
 actggaagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 4832

```

gttccttgag tgggtggccta actacggcta cactagaag acagtatttg gtatctgcgc 4892
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatocg gcaaacaaac 4952
cacogctggg agcgggtggt tttttgttg caagcagcag attacgcgca gaaaaaaagg 5012
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 5072
acgttaaggg attttgttca tgagattatc aaaaaggatc ttcacctaga tctttttaa 5132
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggg ctgacagtta 5192
ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt 5252
tgctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggcccccag 5312
tgctgcantg atacgcgag acccagctc accggctoca gatttatcag caataaacca 5372
gccagcggga agggccgagc gcagaagtgg tctgcgaact ttatccgctt ccattccagtc 5432
tattaattgt tgcggggaag ctgagtaga tagttcgcca gttaaatagt tgcgcaacgt 5492
tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg ttggtatgg cttcattcag 5552
ctcgggttcc caacgatcaa ggcaggttac atgaccccc atgttgtgca aaaaacgggt 5612
tagctccttc ggtcctcga tcgtgtcag aagtaagttg gccgcagtg taccactcat 5672
ggttatggca gcaactcata attctcttac tgcacgcca tccgtaagat gctttctgt 5732
gactggtgag tactcaacca agtcattctg agaatagtg atcgggcgac cgaagtgtctc 5792
ttgcocggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat 5852
cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 5912
ttcagtgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 5972
ttctgggtga gcaaaaacag gaagcaaaaa tgcgcgcaaa aagggaataa ggcgcacacg 6032
gaatgttga atactcatat tcttctttt tcaatattat tgaagcattt atcaggggtta 6092
ttgtctcatg agcggatata tatttgaatg tatttagaaa aataaacaaa taggggttcc 6152
ggcgacattt ccccgaaaaa tgcacactga cgtc 6186

```

```

<210> 4
<211> 5651
<212> DNA
<213> Artificial sequence

<220>
<221> exon
<222> (1231)..(1617)
<223> Coding sequence for human FSH-β

```



<400> 4  
gacggatcgg gagatctccc gatccccatc ggtcgactct cagtacaatc tgetctgatg 60  
ccgcatagtt aagccagatc ctgctccctg ctgtgtgttt ggaggtcgct gagtagtgcy 120  
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcacg aagaatctgc 180  
ttagggtagt gcgtttttgc ctgcttcgcy atgtacgggc cagatatacg cgttgacatt 240  
gattattgac tagttattaa tagtaataca ttacggggtc attagtccat agccatata 300  
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360  
cccgccattc gacgtcaata atgaogtatg ttcccatagt aacgccataa gggactttcc 420  
attgacgtca atgggtggac tatttacggt aaactgccca ctggcgagta catcaagtgt 480  
atcatatgcc aagtagcgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540  
atgccagcta catgacctta tgggaacttc ctacttggca gtacatctac gtattagtca 600  
tcgctattac catggtagtgc cgggttttggc agtacatcaa tggcggtgga tagcgggttg 660  
actcaogggg atttocaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720  
aaaatcaacg ggaactttcca aaatgtogta acaactccgc ccattgacg caaatgggcy 780  
gtaggogtgt acgggtgggag gtctatataa cgacagctct ctggctaact agagaaccca 840  
ctgcttactg ccttatcgaa attaatcga ctcaactatg ggagacccaa gctggctagc 900  
ttattcgggt agtttatcac agttaaattg ctacgcagtc cagtgccttc gacacaacag 960  
tctcgaactt aagctgcagt gactctctta aggtagcctt gcagaagttg gtcgtgaggc 1020  
actgggcagg taagtatcaa ggttacaaag caggtttaag gagaccaata gaaactgggc 1080  
ttgtcgagac agagaagact cttgcgttcc tgataggcac ctattggtct tactgacatc 1140  
caacttgctt ttctctccac aggtgtccac tccagttca attacagctc taaaagctt 1200  
ggtacogagc tcggtatctat cgtatgcacc atg gag acc ctg cag ttc ttc ttc 1254  
Met Glu Thr Leu Gln Phe Phe Phe  
1 5  
ctg ttc tgc tgc tgg aag gcc atc tgc tgc aac agc tgc gag ctg acc 1302  
Leu Phe Cys Cys Trp Lys Ala Ile Cys Cys Asn Ser Cys Glu Leu Thr  
10 15 20  
aac atc acc atc gcc atc gag aag gag gag tgc cgc ttc tgc atc agc 1350  
Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu Cys Arg Phe Cys Ile Ser  
25 30 35 40  
atc aac acc acc tgg tgc gcc ggc tac tgc tac acc cgc gac ctg gtg 1398  
Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys Tyr Thr Arg Asp Leu Val

	45	50	55	
tac aag gac ccc gcc cgc ccc aag atc cag aag acc tgc acc ttc aag				1446
Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln Lys Thr Cys Thr Phe Lys				
	60	65	70	
gag ctg gtg tac gag acg gtc cgg gtg ccc gcc tgc gcc cac cac gcc				1494
Glu Leu Val Tyr Glu Thr Val Arg Val Pro Gly Cys Ala His His Ala				
	75	80	85	
gac agc ctg tac acc tac ccc gtg gcc acc cag tgc cac tgc gcc aag				1542
Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr Gln Cys His Cys Gly Lys				
	90	95	100	
tgc gac agc gac agc acc gac tgc acc gtg cgc gcc ctg gcc ccc agc				1590
Cys Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser				
	105	110	115	120
tac tgc agc ttc gcc gag atg aag gag taactcgaga ctagagggcc				1637
Tyr Cys Ser Phe Gly Glu Met Lys Glu				
	125			
cgtttaaac ccgtgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg				1697
ccctccccc gtgccttctc tgaccctgga aggtgccact cccactgtcc ttctctaata				1757
aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt				1817
ggggcaggac agcaaggggg aggattggga agacaatagc aggcacgtcg gggatgcggc				1877
gggtctctat gcttctgagg cggaaagaac cagctggggc tctagggggg atccccacgc				1937
gccctgtagc ggcgcattaa gcgcggcggg tgtgtgtggt acgcgcagcg tgacgcctac				1997
acttgccagc gccctagcgc ccgctccctt cgtttttctc ccttccttcc tcgccacgtt				2057
cgccggcttt ccccgtaacg ctctaaatcg gggcatccct ttaggggtcc gatttagtgc				2117
tttaacggac ctgcacccca aaaaacttga ttaggggtgat ggttcacgta gtggggccac				2177
gccctgatag acggtttttc gccctttgac gttggagtc acgttcttta atagtggact				2237
cttgttccaa actggaacaa caactcaacc tatctcggtc tattcttttg atttataagg				2297
gattttgggg atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc				2357
gaattaatc tgtggaatgt gtgtcagtta ggggtgtgaa agtccccagg ctcccccaggc				2417
aggcagaagt atgcaaaagca tgcactctaa ttagtacgca accaggtgtg gaaagtcccc				2477
aggctcccca gcaggcagaa gtatgcaaa catgcatctc aattagttag caacatagct				2537
cccgccccca actccgccca tcccgccctt aactccggcc agttccggcc attctccgcc				2597
ccatggctga ctaatttttt ttatttatgc agaggccgag gccgcctctg cctctgagct				2657
attccagaag tagtgaggag gcttttttgg aggcctaggc ttttgcaaaa agctccgggg				2717

agcttggtata tccattttcg gatctgatca gcacgtgttg acaattaatc atcggcatag 2777  
tatatcggca tagtataata cgacaagggt aggaactaaa ccatggocaa gttgaccagt 2837  
gocgttcogg tgctoaaccg gcgcgacgtc gcgcgagcgg tcgagttctg gaccgaccgg 2897  
ctcgggttct cocgggaact cgtggaggac gaactcgcgg gtgtggtccg ggaacacgtg 2957  
acctgttca tcagcgcggt ccaggaccag gtggtgccgg acaacacctt ggootgggtg 3017  
tgggtgcgcg gcttggaaga gctgtacgoc gagtggtcgg aggtcgtgtc cactgaacttc 3077  
cgggagcgct cggggcgggc catgaaccag atcgcgagac agcgtggggg cgggaggttc 3137  
gcctgcgog acccgccggg caactgcgtg cacttcgtgg ccgaggagca ggactgacac 3197  
gtgtactag atttcgattc caccgcggcc ttctatgaag ggttgggctt cgggaatcgtt 3257  
ttcogggaag ccggctggat gatcctccag ogcggggatc tcatgctgga gttcttcgcc 3317  
cacccaact tgtttattgc agcttataat ggttacaagt aaagcaatag catcacaagt 3377  
ttcacaata aagcattttt ttcactgcac tctagtgttg gtttgtccaa actcatcaat 3437  
gtatcttacc atgtctgtat accgtcgacc tctagctaga gcttggcgta atcatggtca 3497  
tagctgtttc ctgtgtgaag ttgttatccg ctcaacaatc cacacaacat acgagccgga 3557  
agcataaagt gtaaagcctg gggcgccata tgagtgcgt aactcacatt aattgcgttg 3617  
cgctcactgc ccgctttcca gtccggaaac ctgtcgtgoc agctgcatta atgaatcggc 3677  
caaogcgcgg ggagaggcgg ttgcgtattt gggcgctctt ccgcttcctc ctccactgac 3737  
tcgctgcgct cggctgttcg gctgcggcga gcggtatcag ctcaactcaa ggcggtaata 3797  
cggttatcca cagaatcagg ggataacgca ggaagaaca tgtgagcaaa aggcacgcaa 3857  
aaggccagga accgtaaaaa ggcgcgcttg ctgvcgtttt tccatagcgt ccgccccct 3917  
gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggaactataa 3977  
agataccagg cgtttccccc tggaaagctc ctgctgcgct ctctgttcc gacctgcgcg 4037  
cttacgggat acctgtccgc cttctctcct tcgggaagcg tggcgcttcc tcaatgctca 4097  
cgctgtaggt atctcagttc ggtgtaggtc gttcgcacca agctgggctg tgtgcacgaa 4157  
cccccgctc agcccgaccg ctgcgcctta tccggttaac atcgttctga gtccaaacccg 4217  
gtaagacagc acttatcgcc actgacgca gccactggta acaggattag cagagcgagg 4277  
tatgtaggcg gtgctacaga gttcttgaag tgggtggccta actacggcta cactagaagg 4337  
acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc 4397

tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgttgy caagcagcag 4457  
 attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac 4517  
 gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc 4577  
 ttcaactaga tctctttaaa ttaaaaaatga agttttaaat caatctaaag tataatatgag 4637  
 taaacttggt ctgacagtta ccaatgctta atcagtgagg caoctatctc agcgatctgt 4697  
 ctatttcggt catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag 4757  
 ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccagctc accggctcca 4817  
 gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg tcttgcaact 4877  
 ttatccgcct ccatacagtc tattaattgt tgccgggaag cttagagtaag tagttcgcca 4937  
 gttaatagtt tgcccaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg 4997  
 ttggttatgg ctctattcag ctccgggttc caacgatcaa ggcgagttac atgatccccc 5057  
 atgttggtga aaaaagcggg tagctccttc ggtcctcoga tcgttgtagc aagtaagttg 5117  
 gcgcgagtggt tatcactcat ggttatggca gcactgcata attctcttac tgcatacgca 5177  
 tccgtaagat gctttttctgt gactgggtgag tactcaacca agtcaattctg agaatagttg 5237  
 atgcggcgac cgagttgctc ttgccggcgc toaatacggg ataatacgcg gccacatagc 5297  
 agaactttta aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc 5357  
 ttaccgctgt tgagatccag ttogatgtaa cccactcgtg caccacaactg atcttcagca 5417  
 tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgcgcgcaaa 5477  
 aagggaataa gggcgacacg gaaatgttga atactcatac tcttctcttt toaatattat 5537  
 tgaagcattt atcagggtta ttgtctcatg agcggatata tatttgaatg tatttagaaa 5597  
 aataacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga cgtc 5651

<210> 5  
 <211> 92  
 <212> PRT  
 <213> Homo sapiens

<400> 5

Ala	Pro	Asp	Val	Gln	Asp	Cys	Pro	Glu	Cys	Thr	Leu	Gln	Glu	Asn	Pro
1					5					10				15	
Phe	Phe	Ser	Gln	Pro	Gly	Ala	Pro	Ile	Leu	Gln	Cys	Met	Gly	Cys	Cys
			20					25					30		
Phe	Ser	Arg	Ala	Tyr	Pro	Thr	Pro	Leu	Arg	Ser	Iys	Iys	Thr	Met	Leu

35 40 45

Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser  
50 55 60

Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr  
65 70 75 80

Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser  
85 90

<210> 6  
<211> 111  
<212> FRT  
<213> Homo sapiens

<400> 6

Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu  
1 5 10 15

Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys  
20 25 30

Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln  
35 40 45

Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro  
50 55 60

Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr  
65 70 75 80

Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val  
85 90 95

Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met Lys Glu  
100 105 110

<210> 7  
<211> 6213  
<212> DNA  
<213> Artificial sequence

<220>  
<221> exon  
<222> (1225)..(1599)  
<223> Coding sequence for modified FSH-alpha

<400> 7  
gacggatcgg gagatctccc gatcccccatt ggtcgactct cagtacaatc tgctctgatg 60  
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120

cagagcaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttaaggtaa	atggcccgcc	tggctgacgc	ccccacgacc	360
cccgcccaatt	gacgtcaata	atgacgtatg	ttcccatatg	aacgcccaata	gggactttcc	420
attgacgtca	atgggtggac	tattttacgt	aaactgccca	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgaog	tcaatgacgy	taaatggccc	gccttggcaatt	540
atgcocagta	catgaacctta	tgggacatttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtaacataa	tgggcgtgga	tagcggtttg	660
actcaccggg	atttccaagt	ctccaccoca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccatgacg	caaatggggc	780
gtaggcggtg	acgggtggag	gtctatatata	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacocaa	gctggcttagc	900
ttattgcggt	agtttatcac	agttaaattg	ctaacgoagt	cagtgcttct	gacacaacag	960
tctogaanaat	aagctgcagt	gactctctta	agytgacctt	gcagaagttg	gtcgtgaggc	1020
actgggcag	taagtatcaa	ggttacaaga	cagggttaag	gagaccaata	gaaactggggc	1080
ttgtcgagac	agagaagact	cttgcggttc	tgataggcac	ctattgggtct	tactgacatc	1140
cactttgect	ttctctccac	agggtgtccac	tccacgttca	attacagctc	ttanaagctt	1200
ggtacccgagc	tcggatccgc	cacc	atg gac tac tac	cgc aag tac gcc gcc		1251
		Met Asp Tyr Tyr	Arg Lys Tyr Ala Ala			
		1	5			
atc ttc ctg gtg acc ctg agc gtg ttc ctg cac gtg ctg cac agc gcc	1299					
Ile Phe Leu Val Thr Leu Ser Val Phe Leu His Val Leu His Ser Ala						
10 15 20 25						
aac atc acc gtt aac atc acc gtg gcc ccc gac gtg cag gac tgc ccc	1347					
Asn Ile Thr Val Asn Ile Thr Val Ala Pro Asp Val Gln Asp Cys Pro						
30 35 40						
gag tgc acc ctg cag gag aac ccc ttc ttc agc cag ccc gcc gcc ccc	1395					
Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro						
45 50 55						
atc ctg cag tgc atg gcc tgc tgc ttc agc cgc gcc tac ccc acc ccc	1443					
Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro						
60 65 70						
ctg cgc agc aag aag acc atg ctg gtg cag aag aac gtg acc agc gag	1491					

Leu	Arg	Ser	Lys	Lys	Thr	Met	Leu	Val	Gln	Lys	Asn	Val	Thr	Ser	Glu			
						75												
agc	acc	tgc	tgc	gtg	gcc	aag	agc	tac	aac	cgc	gtg	acc	gtg	atg	ggc			
Ser	Thr	Cys	Cys	Val	Ala	Lys	Ser	Tyr	Asn	Arg	Val	Thr	Val	Met	Gly			
90							95									100	105	1539
ggc	ttc	aag	gtg	gag	aac	cac	acc	gcc	tgc	cac	tgc	agc	acc	tgc	tac			
Gly	Phe	Lys	Val	Glu	Asn	His	Thr	Ala	Cys	His	Cys	Ser	Thr	Cys	Tyr			
						110										115	120	1587
tac	cac	aag	agc	taactctagag	ggcccggttta	aaccocgtga	tcagcctoga									1639		
Tyr	His	Lys	Ser	125														
ctgtgccttc	tagttgccag	coactctgttg	tttgcacctc	ccccgtgect	tccctgacct											1699		
tggaaaggtc	caotcccact	gtcctttcct	aataaaaatga	ggaaatttga	tcgcatttgt											1759		
tgatagtgg	tcattctatt	ctgggggggtg	gggtggggca	ggacagcaag	ggggaggatt											1819		
gggaagacaa	tagcaggcat	gctggggatg	cggctgggtc	tatggcttct	gaggcggaaa											1879		
gaaccagctg	gggctctagg	gggtatcccc	acgcgcacctg	tagcggcgca	ttaaagcogg											1939		
cgggtgtggt	ggttacgcgc	agcgtgaccg	ctacacttgc	cagcgccta	gcgcccgcctc											1999		
ctttogcttt	cttcccttcc	ttctctogcca	cgcttcgcgg	ctttccccgt	caagctctaa											2059		
atcggggcat	ccctttaggg	ttcogattta	gtcttttaacg	gcacctcyac	ccccaaaaac											2119		
ttgattagg	tgatgttca	cgtagtgggc	catcgccctg	atagacggtt	tttcgcocct											2179		
tgaogttgga	gtccacgttc	tttaaatagt	gactcttggt	ccaaacttga	acaacactca											2239		
accctatctc	ggctctattct	tttgatttat	aagggtat	ggggatttgc	gcctatttgt											2299		
taaaaaatga	gctgatttaa	caaaaattta	acgcgaatta	attctgttga	atgtgtgtca											2359		
gttaggggt	ggaaagtccc	caggctcccc	aggcaggcag	aagtatgcaa	agcatgcctc											2419		
tcaattatgc	agcaaccagg	tgtggaaagt	ccccaggctc	ccagcaggc	agaagtatgc											2479		
aaagcatgca	tctcaattag	tcagcaacca	tagtcccgcc	cctaactcgg	cccactccgc											2539		
ccctaactcc	gcccagttcc	gcccatcttc	cgccccatgy	ctgactaatt	ttttttat											2599		
atgcagaggc	cagggccccc	tctgcctctg	agctattcca	gaagtatgta	ggaggctttt											2659		
ttggaggcct	aggcttttgc	aaaaagctcc	cgggagcttg	tatatccatt	ttcggatctg											2719		
atcagcacgt	gatgaaaaag	cctgaactca	cgcgcagctc	tgtctagaag	ttctgtatgc											2779		
aaaagtctga	cagcgtctcc	gacctgatgc	agctctcgga	ggcgagaaga	tctcgtgctt											2839		
tcagctctga	tgtaggaggg	cgtgatgatg	tctcgcgggt	aaatagctgc	gocgatgggt											2899		

tctacaaga tcgttatgtt tatcggcaact ttgcacggc cgcgtcccg attccggaag 2959  
 tgcttgacat tggggaattc agcagagagc tgacctattg catctcccg cgtgcacagg 3019  
 gtgtcacggt gcaagaactg cotgaaacg aactgcccg tgttctgcag cgggtgcgg 3079  
 aggcocatgga tgcgatcgct gcggcogato ttagccagac gagcgggttc ggcocattcg 3139  
 gaccgcaagg aatcgggtcaa taaactacat ggcgtgattt catatgcgcg attgctgac 3199  
 cccatgtgta tcaatggcaa actgtgatgg acgacacgt cagtgcgtcc gtgcgcagg 3259  
 ctctcgatga gctgatgctt tgggcgcagg actgcccgga agtcgggac ctgcgtcacg 3319  
 cggatttcgg ctccaacaat gtctcgacgg acaatggccg cataacagcg gtcattgact 3379  
 ggagcgaggc gatgttcggg gattccaat acgaggtgc caacatcttc ttctggaggc 3439  
 cgtgggtggc ttgtatggag cagcagagcg gctacttoga cgggaggcat cgggagcttg 3499  
 caggatcgcc gcggctccgg gcgtatatgc tcgcattgg tcttgaccaa ctctatcaga 3559  
 gcttggttga cggcaatttc gatgatgcag cttgggcga ggttcgatgc gaagcaatcg 3619  
 tcgatccgg agccgggact gtccggcgta cacaatgcg ccgcagaagc gcggccgtct 3679  
 ggaccgatgg ctgtgtagaa gtactcgccg atagtggaaa ccgaagcccc agcactcgtc 3739  
 cgagggcгаа ggaatagcac gtgctacgag atttcgattc caccgcgcc ttctatgaaa 3799  
 ggttgggctt cggatcgctt ttccgggagc cggctggat gatccacag cgcggggatc 3859  
 tcatgtcgga gttcttcgac caaccacact tgtttattgc agcttataat ggttacaaat 3919  
 aaagcaatag catoacaat ttcaacaata aagcattttt ttaactgcac tctagtgtg 3979  
 gtttgtcaa actcatcaat gtatcttata atgtctgtat accgtgcac tctagctaga 4039  
 gcttgcgcta atoatgtca tagctgttcc ctgtgtgaaa ttgttatccg ctcaaatc 4099  
 cacacaacat acgagccgga agcataaagt gtaaagcctg ggtgcctaa tgaagtgcct 4159  
 aactcacatt aattgcgttg cgtcactgc ccgctttcca gtccggaac ctgtcgtgc 4219  
 agctgcatta atgaatcgcc caacgcgcgg ggagagcggt tttgcgtatt gggcgtctt 4279  
 ccgcttcttc gctcactgac tcgctgcgct cggctgttcg gctgcggcga gcggtatcag 4339  
 ctcaactcaa ggcgttaata cggttatcca cagaatcagg ggataacgca ggaagaaca 4399  
 tbtgagcaaa aggcagcaa aaggccagga accgtaaaaa ggcgcgtgt ctgcgtttt 4459  
 tcatatggct ccgccccct gacgagcaco acaaaatcg acgtcaagt cagaggtggc 4519  
 gaaaccogac aggactataa agatacagc cgtttccccc tgggaagctcc ctgcgtgcct 4579  
 ctctcgttcc gaacctgcgc cttacgggat acctgtccgc cttctccct tcgggaagcg 4639



tggegetttc tcaatgetca cgctgtagggt atctcagttc ggtgtaggtc gttcgetcca 4699  
agctgggctg tgtgcaacgaa ccccccttc agcccgaccg ctgcgcctta tccggttaact 4759  
atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta 4819  
acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tgggtggcta 4879  
actacggcta cactagaagg acagtatttg gtatctgogc tctgctgaag ccagttacct 4939  
tcggaaaaag agttggtagc tcttgatcog gcaaaaaaac caccgctggt agcgggtggt 4999  
tttttgttg caagcgcag attacgcgca gaaaaaagg atctcaagaa gatcctttga 5059  
tctttctac ggggtctgac gctcagtgga acgaaaactc aogttaaggg attttggta 5119  
tgagattatc aaaaaggatc ttcaactaga tcttttaaa ttaaaatga agttttaaat 5179  
caatctaag tatatatgag taaacttgggt ctgacagtta ccaatgctta atcagtggg 5239  
cacctatctc agcgatctgt ctatttogg tcatccatagt tgctgactc cccgtcgtgt 5299  
agataactac gatacgggag ggcttaccat ctggcccgag tgctgcaatg ataccgcgag 5359  
acccaogctc accggctcca gatttatcag caataaacca gccagccgga agggccgagc 5419  
gcagaagtgg tcttgcaact ttatccgcct ccatacagtc tattaatgtg tgccgggaag 5479  
ctagagtaag tagttcgcca gttaatagtt tgccgaacgt tgttgccatt gctacaggca 5539  
tcgtggtgtc acgctcgteg ttgggtatgg ctccattcag ctccggttcc caacgatcaa 5599  
ggcgagttaac atgatcccc atgttgtgca aaaaagcgggt tagctccttc ggtcctccga 5659  
tcgttgtcag aagtaagttg gccgcagtggt tatcactcat ggttatggca gcaactgcata 5719  
attctcttac tgcctatgca tccgtaagat gctttctgtg gactgggtgag tactcaacca 5779  
agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccgcg tcaatacggg 5839  
ataataccgc gccacatagc agaactttaa aagtgtctat cattggaaaa cgttcttcgg 5899  
ggcgaaaact ctcaaggatc ttacgcgtgt tgagatccag ttcgatgtaa cccactcgtg 5959  
caccocactg atcttcagca tcttttactt tcaccagcgt tcttgggtga gcaaaaacag 6019  
gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatatc 6079  
tcttcttttt tcaatattat tgaagcattt atcagggtta ttgtctcatg agcggataca 6139  
tatttgaatg tatttagaaa aataacaaa taggggttcc gcgaacattt ccccgaaaag 6199  
tgccaactga cgtc 6213

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (5)  
<223> T or S

<400> 8  
Ala Ser Asn Ile Xaa  
1 5

<210> 9  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (6)  
<223> T or S

<400> 9  
Ser Pro Ile Asn Ala Xaa  
1 5

<210> 10  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (7)  
<223> T or S

<400> 10  
Ala Ser Pro Ile Asn Ala Xaa  
1 5

<210> 11  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (4)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (8)  
<223> T or S

<400> 11  
Ala Asn Ile Xaa Ala Asn Ile Xaa Ala Asn Ile  
1 5 10

<210> 12  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (4)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (9)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (14)  
<223> T or S

<400> 12  
Ala Asn Ile Xaa Gly Ser Asn Ile Xaa Gly Ser Asn Ile Xaa  
1 5 10

<210> 13  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (5)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (9)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (13)  
<223> T or S

<400> 13  
Ala Ser Asn Ser Xaa Asn Asn Gly Xaa Leu Asn Ala Xaa  
1 5 10

<210> 14  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<220>  
<221> MOD\_RES  
<222> (4)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (7)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (10)  
<223> T or S

<400> 14  
Ala Asn His Xaa Asn Glu Xaa Asn Ala Xaa  
1 5 10

<210> 15  
<211> 7  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (7)

<223> T or S

<400> 15

Gly Ser Pro Ile Asn Ala Xaa

1

5

<210> 16

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (7)

<223> T or S

<220>

<221> MOD\_RES

<222> (13)

<223> T or S

<400> 16

Ala Ser Pro Ile Asn Ala Xaa Ser Pro Ile Asn Ala Xaa

1

5

10

<210> 17

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (4)

<223> T or S

<220>

<221> MOD\_RES

<222> (7)

<223> T or S

<220>

<221> MOD\_RES

<222> (10)

<223> T or S

<400> 17

Ala Asn Asn Xaa Asn Tyr Xaa Asn Trp Xaa

1

5

10

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (5)

<223> T or S

<220>

<221> MOD\_RES

<222> (9)

<223> T or S

<220>

<221> MOD\_RES

<222> (12)

<223> T or S

<400> 18

Ala Thr Asn Ile Xaa Leu Asn Tyr Xaa Ala Asn Xaa Thr

1

5

10

<210> 19

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (5)

<223> T or S

<220>

<221> MOD\_RES

<222> (9)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (13)  
<223> T or S

<400> 19  
Ala Ala Asn Ser Xaa Gly Asn Ile Xaa Ile Asn Gly Xaa  
1 5 10

<210> 20  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (5)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (9)  
<223> T or S

<220>  
<221> MOD\_RES  
<222> (13)  
<223> T or S

<400> 20  
Ala Val Asn Trp Xaa Ser Asn Asp Xaa Ser Asn Ser Xaa  
1 5 10

<210> 21  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (5)  
<223> T or S

<220>

<221> MOD\_RES

<222> (9)

<223> T or S

<220>

<221> MOD\_RES

<222> (13)

<223> T or S

<400> 21

Ala Val Asn Trp Xaa Ser Asn Asp Xaa Ser Asn Ser Xaa  
1 5 10

<210> 22

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<220>

<221> MOD\_RES

<222> (4)

<223> T or S

<220>

<221> MOD\_RES

<222> (7)

<223> T or S

<220>

<221> MOD\_RES

<222> (10)

<223> T or S

<400> 22

Ala Asn Asn Xaa Asn Tyr Xaa Asn Ser Xaa  
1 5 10

<210> 23

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 23

Ala Asn Asn Thr Asn Tyr Thr Asn Trp Thr  
1 5 10



<210> 24  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Linker

<400> 24  
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
1 5 10 15

<210> 25  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 25  
cgcagatctg atggctggca gcctcacag attgc 35

<210> 26  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 26  
cgggaattcc catcactggc gacgccacag gtaggtg 37

<210> 27  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 27  
acgcgagctc gcccttgcat ccctaaaagc ttccg 35

<210> 28  
<211> 54  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 28  
gcgttgacgg cagtcagagt tgacagaagg gccagccagc aaaggatagt catg 54

<210> 29  
<211> 62  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 29  
ctagcatgac tatcctttgc tggctgcccc ttctgtcaac tctgactgcc gtcaacgcag 60  
ct 62

<210> 30  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 30  
cctgtctactg ctcccagcag cagtgaaga gtccaaagtg gcagcatg 48

<210> 31  
<211> 56  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 31  
ctagcatgct gccactttgg actctttcac tggctgtggg agcagtagca ggagct 56

<210> 32  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 32  
cagctggcca tgggtaccgg g 21

<210> 33  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: N-terminal  
peptide addition

<400> 33  
Ala Asn Ile Thr  
1

<210> 34  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: N-terminal  
peptide addition

<400> 34  
Ala Ser.Pro Ile Asn Ala Thr  
1 5

<210> 35  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 35  
tgggcatcag gtgccaacat tacagccgc cctgcaccc ctaaaagc

48

<210> 36  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 36  
tttactgttt tcgtaacagt ttg

24

<210> 37  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 37

gcagggcggt gctgtaatgt tggcacctga tgcccacgac actgcctg

48

<210> 38

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (1)..(13)

<223> "Xaa" represents a variable amino acid

<400> 38

Ala Xaa Asn Xaa Thr Xaa Asn Xaa Thr Xaa Asn Xaa Thr  
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (1)..(10)

<223> "Xaa" represents a variable amino acid

<400> 39

Ala Asn Xaa Thr Asn Xaa Thr Asn Xaa Thr  
1 5 10

<210> 40

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<221> modified\_base

<222> (1)..(81)

<223> "n" represents a, t, c, g, other or unknown

<220>

<223> Description of Artificial Sequence: Primer

<400> 40

gtgtgtgtgtgt catcagggtc cnnsaaydns achdnsaayd nsachdnsaa ydnsachgcc 60  
cgccctgtgca tccctaaag c 81

<210> 41  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 42  
ggcacctgat gccacgaca ctgcctg

27

<210> 43  
<211> 68  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<220>  
<221> modified\_base  
<222> (1)..(68)  
<223> "nnn" is a mixture of trinucleotide codons for all  
natural amino acid residues, except proline

<400> 43  
cgtgggcac acagtgccaac nnnachaaayn nnachaaayn nachgcccgc cctgcacac 60  
ctaaaagc 68

<210> 44  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 44  
gttggcacct gatgccacg acactgectg

30

<210> 45  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (4)

<223> variable amino acid

<220>

<221> MOD\_RES

<222> (12)

<223> F or L

<400> 45

Ala Phe Asn Xaa Thr Leu Asn Lys Thr Trp Asn Xaa Thr  
1 5 10

<210> 46

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 46

Thr Met Asn Asn Thr Trp Asn Trp Thr Trp Asn Trp Thr  
1 5 10

<210> 47

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 47

Ala Leu Asn Ser Thr Gly Asn Leu Thr Val Asp Gly Thr  
1 5 10

<210> 48

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 48

Ala Ser Asn Ser Thr Phe Asn Leu Thr Glu Asn Leu Thr  
1 5 10

<210> 49

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 49

Thr Arg Asn Val Thr Ile Asn Cys Thr Asn Ser Thr  
1 5 10

<210> 50

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 50

Ala Leu Asn Trp Thr Tyr Asn Gly Thr Lys Asn Val Thr  
1 5 10

<210> 51

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 51

Ala Ala Asn Trp Thr Val Asn Phe Thr Gly Asn Phe Thr  
1 5 10

<210> 52

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (2)

<223> variable amino acid

<220>

<221> MOD\_RES

<222> (4)

<223> variable amino acid

&lt;400&gt; 52

Ala Xaa Asn Xaa Thr Val Asn Ser Thr Asn Val Thr  
1 5 10

&lt;210&gt; 53

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 53

Ala Asn Asn Phe Thr Phe Asn Gly Thr Leu Asn Leu Thr  
1 5 10

&lt;210&gt; 54

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 54

Ala Gly Asn Trp Thr Ala Asn Val Thr Val Asn Val Thr  
1 5 10

&lt;210&gt; 55

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 55

Ala Gly Asn Ser Thr Ser Asn Val Thr Gly Asn Trp Thr  
1 5 10

&lt;210&gt; 56

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide



<400> 56  
Ala Val Asn Ser Thr Met Asn Ile His Ala Ile Pro Pro  
1 5 10

<210> 57  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 57  
Ala Gly Asn Gly Thr Val Asn Gly Thr Ile Asn Gly Thr  
1 5 10

<210> 58  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (8)  
<223> variable amino acid

<400> 58  
Ala Val Asn Ser Thr Gly Asn Xaa Thr Gly Asn Trp Thr  
1 5 10

<210> 59  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 59  
Ala Gly Asn Gly Thr Asn Gly Thr Ser Asn Leu Thr  
1 5 10

<210> 60  
<211> 13  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 60

Ala Met Asn Ser Thr Lys Asn Ser Thr Leu Asn Ile Thr  
1 5 10

&lt;210&gt; 61

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 61

Ala Phe Asn Tyr Thr Ser Lys Asn Ser Thr  
1 5 10

&lt;210&gt; 62

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 62

Ala Val Asn Ala Thr Met Asn Trp Thr Ala Asn Gly Thr  
1 5 10

&lt;210&gt; 63

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 63

Ala Ser Asn Ser Thr Asn Asn Gly Thr Leu Asn Ala Thr  
1 5 10

&lt;210&gt; 64

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic peptide

<400> 64

Ala Arg Asn Lys Thr Lys Asn Phe Thr Ile Asn Leu Thr  
1 5 10

<210> 65

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 65

Ala Pro Asn Ile Thr Asn Asp Thr Val Asn Met Thr  
1 5 10

<210> 66

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 66

Ala Gln Asn Lys Thr Phe Asn Phe Thr Met Asn Cys Thr  
1 5 10

<210> 67

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 67

Ala Leu Asn Val Thr Trp Asn Cys Thr Leu Asn Leu Thr  
1 5 10

<210> 68

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

## peptide

&lt;400&gt; 68

Ala Leu Asn Thr Thr Trp Thr Asn Leu Thr  
1 5 10

&lt;210&gt; 69

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 69

Ala Asn Thr Thr Asn Phe Thr Asn Glu Thr  
1 5 10

&lt;210&gt; 70

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 70

Ala Asn Trp Thr Asn Arg Thr Asn Cys Thr  
1 5 10

&lt;210&gt; 71

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 71

Ala Asn Trp Thr Asn Phe Thr Asn Trp Thr  
1 5 10

&lt;210&gt; 72

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 72

Pro	Thr	Gly	Leu	Ile	Gly	Thr	Asn	Phe	Thr
1				5					10

&lt;210&gt; 73

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 73

Ala	Asn	Trp	Thr	Asn	Lys	Thr	Asn	Phe	Thr
1				5					10

&lt;210&gt; 74

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 74

Ala	Asn	Asn	Thr	Asn	Leu	Thr	Asn	Ala	Thr
1				5					10

&lt;210&gt; 75

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 75

Ala	Asn	Tyr	Thr	Asn	Trp	Thr	Asn	Phe	Thr
1				5					10

&lt;210&gt; 76

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 76

Ala Asn Thr Thr Asn Gln Thr Asn Asp Thr  
1 5 10

&lt;210&gt; 77

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 77

Ala Asn Arg Thr Asn Trp Thr Asn Thr Thr  
1 5 10

&lt;210&gt; 78

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 78

Pro Thr Ala Thr Asn His Thr Asn Ser Thr  
1 5 10

&lt;210&gt; 79

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 79

Ala Asn Trp Thr Asn Gln Thr Asn Gln Thr  
1 5 10

&lt;210&gt; 80

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 80

Ala Asn Trp Thr Asn Trp Thr Asn Ala Thr  
1 5 10

<210> 81  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 82  
Ala Asn Phe Thr Asn Lys Thr Asn Met Thr  
1 5 10

<210> 83  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 83  
Ala Asn His Thr Asn Glu Thr Asn Ala Thr  
1 5 10

<210> 84  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (3)  
<223> C or W

<400> 84  
Ala Asn Xaa Thr Asn Phe Thr Asn Glu Thr  
1 5 10

<210> 85  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 85

Ala Asn Leu Asp Lys Leu His Lys His  
1 5

<210> 86

<211> 11

<212> FRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 86

Ala Asn Cys Phe Thr Asn Gln Thr Asn Phe Thr  
1 5 10

<210> 87

<211> 11

<212> FRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 87

Ala Asn Trp Thr Asn Trp Thr Asn Glu Trp Thr  
1 5 10

<210> 88

<211> 10

<212> FRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 88

Ala Asn Cys Thr Asn Trp Thr Asn Cys Thr  
1 5 10

<210> 89

<211> 10

<212> FRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic



## peptide

&lt;400&gt; 89

Cys His Pro Tyr Asn Trp Thr Asn Trp Thr  
1 5 10

&lt;210&gt; 90

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 90

Ala Asn Glu Thr Asn Tyr Thr Asn Glu Thr  
1 5 10

&lt;210&gt; 91

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 91

Ala Asn Trp Thr Asn Trp Thr  
1 5

&lt;210&gt; 92

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 92

Ala Lys Pro Tyr Lys Ser Tyr Lys Phe Tyr  
1 5 10

&lt;210&gt; 93

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 93

Ala Asn Ile Thr Asn Lys Thr Asn Trp Thr  
1 5 10

&lt;210&gt; 94

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 94

Ala Asn Trp Thr Asn Met Thr Asn Ile Thr  
1 5 10

&lt;210&gt; 95

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 95

Ala Asn Asn Thr Asn Arg Thr Asn Phe Thr  
1 5 10

&lt;210&gt; 96

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 96

Ala Asn Trp Thr Asn Trp Thr Asn Trp Thr  
1 5 10

&lt;210&gt; 97

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 97

Ala Asn Trp Arg Thr Asn His Thr Asn Lys Thr  
1 5 10

&lt;210&gt; 98

&lt;211&gt; 10

&lt;212&gt; FRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 98

Ala Asn Gln Thr Asn Ile Thr Asn Trp Thr  
1 5 10

&lt;210&gt; 99

&lt;211&gt; 11

&lt;212&gt; FRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;400&gt; 99

Ala Asn Phe Thr Asn Val Ala Thr Asn Gln Thr  
1 5 10

&lt;210&gt; 100

&lt;211&gt; 10

&lt;212&gt; FRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Synthetic peptide

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)

&lt;223&gt; most probable amino acid

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (2)

&lt;223&gt; most probable amino acid

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (5)

&lt;223&gt; variable amino acid

<220>  
<221> MOD\_RES  
<222> (9)  
<223> most probable amino acid

<400> 100  
Ala Asn Thr Thr Xaa Leu Thr Asn Lys Thr  
1 5 10

<210> 101  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (6)  
<223> S or C

<400> 101  
Ala Asn Lys Thr Asn Xaa Thr Asn Ile Thr  
1 5 10

<210> 102  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (9)  
<223> most probable amino acid

<400> 102  
Ala Asn Trp Thr Asn Cys Thr Asn Ile Thr  
1 5 10

<210> 103  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<221> MOD\_RES  
<222> (6)  
<223> F or L

<400> 103  
Ala Asn Trp Thr Asn Xaa Thr Asn Trp Thr  
1 5 10

<210> 104  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 104  
Cys Gln Leu Asp Arg Ser Thr Asn Glu Thr  
1 5 10

<210> 105  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 105  
Ala Asn Asn Thr Asn Tyr Thr Asn Trp Thr  
1 5 10

<210> 106  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 106  
Ala Asn Asn Thr Asn Tyr Thr Asn Trp Thr  
1 5 10

<210> 107  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 107  
Ala Ala Asn Asp Thr Asn Trp Thr Val Asn Cys Thr  
1 5 10

<210> 108  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 108  
Ala Thr Asn Ile Thr Leu Asn Tyr Thr Ala Asn Thr Thr  
1 5 10

<210> 109  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 109  
Ala Ala Asn Ser Thr Gly Asn Ile Thr Ile Asn Gly Thr  
1 5 10

<210> 110  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 110  
Ala Val Asn Trp Thr Ser Asn Asp Thr Ser Asn Ser Thr  
1 5 10

<210> 111  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 111

Ala Ser Pro Ile Asn Ala Thr Ser Pro Ile Asn Ala Thr  
1 5 10

<210> 112

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Linker

<400> 112

Gly Gly Gly Gly  
1

<210> 113

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Linker

<400> 113

Gly Asn Ala Thr

<210> 114

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 114

Asn Ser Thr Gln Asn Ala Thr Ala  
1 5

<210> 115

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 115

Ala Asn Leu Thr Val Arg Asn Leu Thr Arg Asn Val Thr Val

WC 00002597

PCT/DK01/00459

1

5

10

47